FINAL PROGRAMME

WFSBP Congress 2017

13th World Congress of Biological Psychiatry

18 – 22 June 2017
Copenhagen, Denmark
Bella Center Copenhagen

www.wfsbp-congress.org

Organised by: World Federation of Societies of Biological Psychiatry

Hosted by the Danish Society of Biological Psychiatry

CONGRESS APP

Get the free congress App for your smartphone

Quickly find your way through the most up-to-date congress schedule of scientific sessions.

- Mark your favorite sessions and personalise your experience.
- Find information on sponsors and exhibitors involved in the WFSBP Congress 2017.
- Access vital information around the congress.

Download on the App Store

GET IT ON Google Play

The WFSBP 2017 App is powered by GLOBIT GmbH in cooperation with esanum GmbH.

Further information is given at www.wfsbp-congress.org/app.

Table of Contents

Page

4 **Welcome to the 13th World Congress of Biological Psychiatry**

5 **About WFSBP**

About the WFSBP Congress 2017
6 Congress Administration
6 WFSBP Executive Committee
6 Honorary Committee
6 International Scientific Programme Committee
7 National Presidents
8 Chairs of the Local Organising Committee
8 Congress Ambassadors
8 Administrative Meetings
9 Task Force Meetings

11 **Floor Plan**

12 **WFSBP Awards**

13 **Format Descriptions**

Scientific Information
14 Topics
15 Opening Ceremony
16 CME Accreditation
16 Colour Legend
17 Scientific Programme Schedules

Page

Scientific Programme
22 Sunday, 18 June 2017
27 Monday, 19 June 2017
38 Tuesday, 20 June 2017
50 Wednesday, 21 June 2017
63 Thursday, 22 June 2017

72 **Congress Information**

76 **List of Exhibitors / Exhibition Floor Plan**

77 **Acknowledgements**

78 **Industry Sessions**

79 **List of Chairpersons, Authors and Co-Authors**

WFSBP GLOBAL HEADQUARTERS
Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49–40–670 882 90
Fax: +49–40–670 882 91
Email: info@wfsbp.org
www.wfsbp-congress.org

CONGRESS VENUE
Bella Center Copenhagen
Conference Entrance
Center Boulevard 5
2300 Copenhagen S, Denmark
www.bellacentercopenhagen.dk

CONGRESS AND EXHIBITION OFFICE
CPO HANSER SERVICE
Phone: +49–30–300 669-0
Email: wfsbp2017@cpo-hanser.de

Welcome to the 13th World Congress of Biological Psychiatry

Masatoshi Takeda



Constantin R. Soldatos

Gregers Wegener

Dear Colleagues,

It is both an honor and a privilege to welcome all of you to the 13th World Congress of Biological Psychiatry in Copenhagen, 18–22 June 2017, which will be an excellent setting to discuss the current progress in molecular biology, the development of novel drugs based upon new concepts, and the advances in modern neuroscience that will change our approach to psychiatric disorders and our attitudes towards mental health care. It is the time for biological psychiatry to be developed into the new stage where biopsycho-socio-spiritual aspects are integrated for the betterment of patients and families with mental and psychiatric disorders. The field of biological psychiatry is expanding by the development of bioinformatics (genomics, transcriptomics, proteomics) identifying importance of glycome, lipidome, metabolome, and brain activity mapping methodology.

Looking back at a few examples of previous world congress of biological psychiatry in Paris (2009), Prague (2011), Kyoto (2013), and Athens (2015), it is remarkable to have witnessed significant contribution of biological psychiatry research into the diagnosis, treatment, care, and even prevention of psychiatric and mental disorders.

The field of biological psychiatry is rapidly developing, reaching a new stage of clinical application. Genetic engineering, iPS cells, brain mapping, and other new technologies have been integrated into the translational research in the field. Modified electroconvulsive therapy (mECT), repetitive trans-cranial stimulation (rTMS), near-infrared spectroscopy (NIRS), and decoded neurofeedback (DecNef) are examples of recent application in biological psychiatry. Considering the impact of most CNS disorders, biological psychiatry is expected to fill in the unmet need for CNS drugs including new generation antipsychotics, anti-depressants, anti-epileptics, anxiolytics, and sleep inducers, and others. Biological psychiatry is the field where academia and industry should proceed together aiming for the developing of new methods of diagnosis and treatment of CNS disorders.

We are confident that the 13th World Congress of Biological Psychiatry in Copenhagen will be a superb setting for presentation and discussion of recent findings in biological psychiatry. To this end, 5 Lectures, 3 Debates, 12 Task Force Symposia/Workshops and 83 independent Symposia/Workshops are forming the core scientific programme; all of them on very interesting topics to be presented by prominent researchers-scientists in their respective fields.

We are looking forward to meeting you in Copenhagen and interacting with you both socially and professionally.

With our best wishes

Prof. Masatoshi Takeda
Congress President

Prof. Constantin R. Soldatos
Chair of the International Scientific Programme Committee

Prof. Gregers Wegener
Chair of the Local Organising Committee

About WFSBP

Founded in 1974 in Buenos Aires, Argentina, the World Federation of Societies of Biological Psychiatry is a non-profit world wide organization composed of 63 National Societies of Biological Psychiatry and Individual Members representing professionals from over 70 countries.

With this multitude of countries represented in its worldwide community, the World Federation has built an international network of over 4,500 opinion leaders, the majority of which are key opinion-leaders in the practice of Biological Psychiatry.

WFSBP members by continent



As of May 2017

- Europe
- Asia
- South America
- Africa
- North America
- Oceania

The principle objectives of WFSBP are:

- To foster and encourage scientific research and advancement in the field of Biological Psychiatry
- To improve the quality of training spanning all the biological psychiatry sciences
- To promote education and achieve the highest level of knowledge and understanding within the field
- To provide information and guidance to all institutions, societies or individuals with an interest in biological psychiatry
- To establish, build, and maintain solid collaboration with international and national organisations related to biological psychiatry

Educational activities, regional, international and world congresses, the interactive website **www.wfsbp.org**, and The World Journal of Biological Psychiatry build the World Federation's portfolio and insure its worldwide influence. The development of worldwide treatment guidelines is one of WFSBP's main areas of international leadership.

Year after year, more and more professionals choose to join the World Federation's Biological Psychiatry arena and enjoy its exclusive educational and networking opportunities.

WFSBP members by field of activity:



About the WFSBP Congress 2017

CONGRESS ADMINISTRATION

The 13th World Congress of Biological Psychiatry is organised by the World Federation of Societies of Biological Psychiatry (WFSBP).

WFSBP EXECUTIVE COMMITTEE

President (2015–2019)
Masatoshi Takeda, Japan

Vice President (2013–2017)
Tudor Udristoiu, Romania

Past President (2015–2017)
Constantin R. Soldatos, Greece

Secretary (2013–2017)
Lakshmi N. Yatham, Canada

Treasurer (2013–2017)
Martin Hatzinger, Switzerland

Vice Secretary (2013–2017)
Ladislav Hosak,
Czech Republic

Vice Treasurer (2013–2017)
Victoria Valdez, Ecuador

HONORARY COMMITTEE (HC)

Jules Angst, Switzerland
Jose Luis Ayuso, Spain
Jorge Ciprian-Ollivier, Argentina
Jorge Alberto Costa e Silva, Brazil
Tetsuo Fukuda, Japan
Gerardo Heinze, Mexico
Carlos Roberto Hojaij, Brazil
Florian Holsboer, Germany
Siegfried Kasper, Austria
Jeffrey Lieberman, USA
Julien Mendlewicz, Belgium
Hans-Jürgen Möller, Germany
Robin Murray, UK
Ahmed Okasha, Egypt
Mitsumoto Sato, Japan
Norman Sartorius, Switzerland
Göran Sedvall, Sweden
Costas Stefanis, Greece
Florence Thibaut, France
Michael Trimble, UK

INTERNATIONAL SCIENTIFIC PROGRAMME COMMITTEE (ISPC)

Chair
Constantin R. Soldatos, Greece

Vice Chairs
Peter Falkai, Germany
Lakshmi Yatham, Canada

Deputy Chairs
Dimitris Dikeos, Greece
Yoshio Hirayasu, Japan
Tudor Udristoiu, Romania

Secretary
Georgios Kiosterakis, Greece

Members of ISPC
G. Alexopoulos, USA*
C. A. Altamura, Italy*
C. Arango, Spain
E. Baca Garcia, Spain
M. Bauer, Germany*
E. Belfort, Venezuela
A. Benyamina, France
M. Berk, Australia*
J. Bobes, Spain
A. Bozkurt, Cyprus
N. Boutros, USA
C. L. Bowden, USA
P. Boyer, France
J. Bradford, Canada
P. Brambilla, Italy
M. Bras, Croatia
M. S. Buchsbaum, USA
A. Burns, UK
R. Castilla-Puentes, USA*
D. Castle, Australia*
E. Ceskova, Czech Republic*
M. Cetkovich-Bakmas, Argentina
Y. Hwa Chou, Taiwan*
H. Correa, Brazil*
P. Cosyns, Belgium
P. Courtet, France*
B. Dean, Australia*
J. de Buitelaar, The Netherlands
M. Dierick, Belgium
B. Dubois, France
K. Fountoulakis, Greece*
S. Frangou, UK
W. Gaebel, Germany
F. D. Garcia, Brazil*
W. F. Gattaz, Brazil
P. Gejman, USA
A. Germanavicious, Lithuania
M. George, USA*
A. H. Glassman, USA
B. Glenthoj, Denmark
G. M. Goodwin, UK
D. Gorelick, USA
P. Gorwood, France*
A. Grace, USA*
H. Grunze, UK*
G. Hajak, Germany
A. Halaris, USA*
A. Hasan, Germany
S. Heckers, USA
C. Hiemke, Germany
E. Hollander, USA
E. Holsboer-Trachsler, Switzerland*
W. G. Honer, Canada
J. Horacek, Czech Republic
A. Jablensky, Australia
R. Kahn, The Netherlands
J. Kane, USA
S. Kanba, Japan*
T. Kato, Japan
C. Katona, UK
W. Kaye, USA
J. Kennedy, Canada*
L. Konopka, USA
H. R. Kranzler, USA*
C. Krieg, Germany
T. Kudo, Japan
J. Soo Kwon, Korea
S. Lamy, France
R. Lanzenberger, Austria*
V. Larach, Chile

* Special correspondents of ISC Core Group

About the WFSBP Congress 2017

M. Leboyer, France
M.S. Lee, Korea*
M. Lejoyeux, France
B. Leonard, Ireland*
Y. Levkovitz, Israel
A. Lopez Mato, Argentina*
C. Lyketsos, USA
R. McCarley, USA
P. Mc Gorry, Australia
P. Mc Guire, UK
M. Maes, Belgium*
J.-L. Martinot, France
V. Matei, Romania*
H. Mayberg, USA
H. Y. Meltzer, USA
A. Meyer-Lindenberg, Germany
A. Kant Mital, India
E. Mohan Das, India
N. Müller, Germany
T. Murai, Japan*
Z. Nahas, Lebanon
D. Nutt, UK
J. Ospina-Duque, Colombia*
N. Ozaki, Japan
C. Pantelis, Australia*
G. Papadimitriou, Greece
T. Paparrigopoulos, Greece*
G. Parker, Australia
L. Pezewas, Austria
O. Pogarell, Gemany
S. G. Potkin, USA
R. Post, USA*
M. Rapaport, USA
M.S. Reddy, India*
E. Richelson, USA
P. Riederer, Germany
D. Rujescu, Germany
R. Rupprecht, Germany
J. Rybakowski, Poland
H. Sackeim, USA
T. Saito, Japan
P. Salgado Pineda, Spain
M. Sarchiapone, Italy
T. Schlaepfer, Germany*
A. Schmitt, Germany
L. Schneider, USA
C. Schulz, USA
T. G. Schulze, Germany*
S. Seedat, South Africa*
E. Seifritz, Switzerland
A. Serretti, Italy*
E. Serfaty, Argentina
W. W. Shen, Taiwan
L. Siever, USA
D. St. Clair, UK
N. Stefanis, Greece*
J. Steiner, Germany
T. Suhara, Japan
M. Taleb, France/Algeria
T. Taneli, USA
J. Tellez-Vargas, Colombia
J. Treasure, UK
N. A. Uranova, Russia
P. Udomratn, Thailand*
I. Udristoiu, Romania*
W. van den Brink, The Netherlands*
J. van Os, The Netherlands
D. Velakoulis, Australia*
N. Venizelos, Sweden*
E. Vieta, Spain*
J. Waddington, Ireland
A. Weinstein Israel
P. Whybrow, USA
X. Yu, China
M. Zanarini, USA
Y. Zervas, Greece*
J. Zohar, Israel

NATIONAL PRESIDENTS

A. Corrales, Argentina
A. Boyajyan, Armenia
D. Eyles, Australia
C. Geretsegger, Austria
S. Claes, Belgium
N. D. Noya-Tapia, Bolivia
A. B. Mehmedbašič, Bosnia-Herzegovina
A. Marcolin, Brazil
O. A. Mikova-Demireva, Bulgaria
R. W. Lam, Canada
E. Olea, Chile
C. Gutierrez, Columbia
R. Castro, Costa Rica
M. Jakovljevic, Croatia
Ladislav Hosak, Czech Republic
G. Wegener, Denmark
F. Solis de Mendez, Dominican Republic
M. L. Meneses, Ecuador
A. Okasha, Egypt
M. Meija Pena, El Salvador
J. Harro, Estonia
P. Courtet, France
S. Herpertz, Germany
C. Soldatos, Greece
H. S. Chavez, Guatemala
M. Aguilar Lopez, Honduras
M. Wong Ming Cheuk, Hong Kong
C. Banki, Hungary
R. Nagpal, India
A. J. Tanra, Indonesia
D. Gothelf, Israel
M. Maj, Italy
T. Nishikawa, Japan
M. Assimov, Kazakhstan
Y.-K. Kim, Republic of Korea
B. Kupca, Latvia
C. Baddoura, Libanon
J. Neverauskas, Lithuania
B. Stefanovski, Macedonia
S. Krishnaswamy, Malaysia
D. Moussaoui, Morocco
G. Villanueva Colín, Mexico
H. Lovdahl, Norway
M. Amin Pakistan
G. Da Costa, Panama
L. Villalba, Paraguay
E. Galli, Peru
P. Mierzejewski, Poland
J. Marques Teixeira, Portugal
T. Udristoiu, Romania
S. Mosolov, Russia
N. Maric Bojovic, Serbia
L. Vavrusova, Slovakia
S. Seedat, South Africa
A. González-Pinto Arrillaga, Spain
M. Ramklint, Sweden
M. Hatzinger, Switzerland
S.-K. Lin, Taiwan
P. Udomratn, Thailand
B. Taneli, Turkey
A. V. Kalueff, Ukraine
G. B. Raggio de Suaya, Uruguay
J. Ibáñez-Domínguez, Venezuela

* Special correspondents of ISC Core Group

About the WFSBP Congress 2017

CHAIRS OF THE LOCAL ORGANISING COMMITTEE (LOC)

Chair
Gregers Wegener, Denmark

Deputy Chairs
Ida Hageman Pedersen, Denmark
Søren Dinesen Østergaard, Denmark

Members of LOC
Kjeld Andersen, Denmark
Ole A. Andreassen, Norway
Lone Baandrup, Denmark
Per Bech, Denmark
Nils Bilenberg, Denmark
Bjørn Ebdrup, Denmark
Jesper Ekelund, Finland
Anders Fink-Jensen, Denmark
Birte Glenthøj, Denmark
Simon Glerup, Denmark
Jaanus Harro, Estonia
Torsten Bjørn Jacobsen, Denmark
Martin Balslev Jørgensen, Denmark
Olli Kampman, Finland
Lars Kessing, Denmark
Gitte Moos Knudsen, Denmark
Rasmus Licht, Denmark
Pall Mathiasson, Iceland
Tanja Michel, Denmark
Thomas Middelboe, Denmark
Ole Mors, Denmark
Merete Nordentoft, Denmark
Kerstin Plessen, Denmark
Andreas Reif, Germany
Dan Rujescu, Germany
Bo Söderpalm, Sweden
Per Hove Thomsen, Denmark
Jari Tiihonen, Sweden
Anders Tingström, Sweden
Poul Videbech, Denmark
Thomas Werge, Denmark

CONGRESS AMBASSADORS

Carlo Altamura, Italy
Ajit Avasthi, India
Charles Baddoura, Libanon
Robert Belmaker, Israel
Michael Berk, Australia
István Bitter, Hungary
David Castle, Australia
Enrique Galli, Peru
Peter Gaszner, Hungary
Bai Han, China
Gerhard Heinze, Mexico
Daniela Jezova, Slovakia
Nick Kates, Canada
Valery Krasnov, Russia
Donatella Marazziti, Italy
Giorgio Racagni, Italy
M.S. Reddy, India
Pedro Ruiz, USA
Dan Rujescu, Germany
Janusz Rybakowski, Poland
Dan Stein, South Africa
Andi J. Tanra, Indonesia
Si Tian-Mei, China
Nikolaos Venizelos, Sweden
Eduard Vieta, Spain
Shigeto Yamawaki, Japan
Yukio Yoneda, Japan
Allan Young, UK

ADMINISTRATIVE MEETINGS

By invitation only

WFSBP Individual Membership Section Meeting
Wednesday, 21 June 2017
10:15 – 10:45, Room B3 M3-M4

WFSBP Council Meeting
Wednesday, 21 June 2017
11:00 – 12:30, Room B3 M3-M4

WFSBP General Assembly
Wednesday, 21 June 2017
13:00 – 15:00, Auditorium 11

TASK FORCE MEETINGS (by invitation only)

Conference Room 6

▶ Sunday, 18 June 2017

Addiction Disorders (Guidelines)
08:00 – 09:30

Child and Adolescence Psychiatry
09:45 – 11:15

Dementia (Guidelines)
11:30 – 13:00

Nosology and Psychopathology (Consensus Paper)
13:15 – 14:45

Pain Management
15:00 – 16:30

Biological Markers (Consensus Paper)
16:45 – 18:15

▶ Monday, 19 June 2017

Meeting of the Task Force Chairs
09:00 – 10:30

Anxiety Disorders and OCD (Guidelines)
10:45 – 12:15

Eating Disorders (Guidelines)
12:30 – 14:00

Schizophrenia (Guidelines)
14:15 – 15:45

Electroconvulsive Therapy (ECT)
16:00 – 17:30

Bipolar Affective Disorders (Guidelines)
17:45 – 19:15

▶ Tuesday, 20 June 2017

Neuroimaging
08:00 – 09:30

Women´s Mental Health
09:45 – 11:15

Brain Pathology
11:30 – 13:00

Tools for Optimising Pharmacotherapy in Psychiatry
13:15 – 14:45

Personality Disorders (Guidelines)
15:00 – 16:30

Brain Stimulation (Guidelines)
16:45 – 18:15

▶ Wednesday, 21 June 2017

Genetics
08:00 – 09:30

Men´s Mental Health
09:45 – 11:15

Sexual Disorders (Guidelines)
11:30 – 13:00

Unipolar Depressive Disorders (Guidelines)
15:00 – 16:30

Sleep Disorders
16:45 – 18:15

▶ Thursday, 22 June 2017

Collaborative Mental Health Care
13:00 – 14:30

Suicide: Biological Markers
14:45 – 16:15

Meeting dates and times are subject to change (please check with the staff at the registration counter).

We organize your success

CPO HANSER SERVICE is specialist in the field of Conference, Event and Destination Management organizing events of any size throughout Germany and also abroad for more than 35 years.

CPO HANSER® SERVICE

CONFERENCE – EVENT – DESTINATION – ASSOCIATION MANAGEMENT

We offer you:

- the best congress organization
- state-of-the-art online solutions
- electronic abstract handling
- CME accreditation handling
- effective congress technology
- sponsoring and exhibition acquisition and management
- finance management
- professional tax solutions
- creative event programs
- inhouse graphic design

BERLIN
Paulsborner Str. 44
14193 Berlin, Germany
Phone: +49–(0)30–30 06 69-0
Fax: +49–(0)30–30 57 39-1
Email: berlin@cpo-hanser.de

HAMBURG
Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49–(0)40–67 08 82-0
Fax: +49–(0)40–67 03 28-3
Email: hamburg@cpo-hanser.de

www.cpo-hanser.de

ICCA Member · GCB Meetings made in Germany Member · IAPCO ACCREDITED · site · DRV · INCON

Floor Plan

Ground Floor

Session Rooms

Hall B3
M1 M3
M2 M4

Cloakroom

Hall A3

Congress Hall A1
Poster, Exhibition, Catering

Auditorium 15

Registration

AC Hotel Bella Sky

Auditorium Foyer

Conference Entrance

First Floor

Conference Room 6

Congress Hall A

Auditorium 15

Auditorium
10 11 12

Foyer

WFSBP Awards

The following WFSBP Awards will be delivered and presented during the 13th World Congress of Biological Psychiatry 2017 in Copenhagen.

WFSBP AWARD FOR SCIENTIFIC EXCELLENCE OF THE WFSBP HOST

The WFSBP Award for Scientific Excellence of the WFSBP Host is dedicated to an outstanding researcher in the field of Biological Psychiatry originating from the host country of the World Congress of Biological Psychiatry. This award consists of a monetary award of EUR 1,000.

Awardee 2017:
Per Bech, Denmark

WFSBP RESEARCH AWARD

The WFSBP Research Award is intended for WFSBP members (MD, PhD or equivalent) whose current scientific work has had an important impact in the field of clinical and/or basic research in the area of biological psychiatry. This award consists of a monetary award of EUR 1,000.

Awardee 2017:
Eduard Vieta, Spain

WFSBP AWARD FOR EXCELLENCE IN EDUCATION

The WFSBP Award for Excellence in Education is to acknowledge outstanding and innovative education in biological psychiatry including the implementation of new interactive media. The WFSBP Education prize is open to all WFSBP members who have improved the education in all fields of Psychiatry. This award consists of a monetary award of EUR 1,000.

Awardee 2017:
Florence Thibaut, France

WFSBP YOUNG INVESTIGATOR AWARDS FOR THE 8 BEST POSTERS (UNDER 40 YEAR-OLD)

All posters will be evaluated at the congress. The awards will go to those presentations that not only provide evidence of innovative research, but which are also well presented.

WFSBP YOUNG INVESTIGATOR AWARDS

WFSBP provides Educational Grants for young investigators to attend the WFSBP biennial congress and the special educational sessions. These sessions are especially designed for young researchers (under 40 year-old) which have been pre-selected via an application process. The grant includes a travel grant of EUR 400 plus free registration to the WFSBP Congress.

Awardees 2017:
Melanie Ashton, Australia
Sofi Atshemyan, Armenia
Lucie Bartova, Austria
Chiara Cristina Bortolasci, Australia
Julius Burkauskas, Lithuania
Trisha Chakrabarty, Canada
Michaela Filiou, Germany
Firoz Kazhungil, India
Srisaiyini Kidnapillai, Australia
Bruno Kluwe-Schiavon, Switzerland
Karishma Kulkarni, India
Sagar Lavania, India
Chieh-Hsin Lin, Taiwan
Amanda Lyall, USA
Eleonora Maggioni, Italy
Maddalena Mauri, Italy
Ahmed Mhalla, Tunisia
Blazej Misiak, Poland
Narayan R. Mutalik, India
Pradip Paul, India
Alessandro Pigoni, Italy
Gopinath Sathyanarayanan, India
André Schmidt, Switzerland
Leigh van den Heuvel, South Africa
Nora S. Vyas, United Kingdom
Gwyneth Zai, Canada
Clement Zai, Canada
Roksana Zakharyan, Armenia
Mikhail Zastrozhin, Russia
Julia Zaytseva, Czech Republic

Format Descriptions

OPENING LECTURE

The Opening Lecture will be held during the Opening Ceremony on 18 June 2017.

PLENARY LECTURES

Plenary Lectures are 45-minute sessions held by renowned experts. The speakers have been chosen among the most prominent researchers in the respective field.

DEBATES

Debates are intended to offer a platform for a lively, yet balanced discussion on controversial issues. A moderator (chairperson) and two speakers (one proponent and one opponent) will state their opinions on different subjects.

WFSBP TASK FORCE SYMPOSIA

A good number of WFSBP Task Forces have submitted Symposia organised by their key members on issues related to their field of special expertise. All of them have been included in the scientific programme and pertain to Treatment Guidelines, Consensus Statements and other hot topics in their respective thematic areas.

WFSBP TASK FORCE WORKSHOPS

A good number of WFSBP Task Forces have submitted Workshops organised by their key members on issues related to their field of special expertise. All of them have been included in the scientific programme and pertain to Treatment Guidelines, Consensus Statements and other hot topics in their respective thematic areas.

SYMPOSIA

Symposia are selected, covering basic, clinical, interface, and conceptual topics of Biological Psychiatry. Symposia are 90-minute sessions and will be organised and chaired by the experts whose proposals are accepted by the International Scientific Programme Committee.

WORKSHOPS

Workshops are 90-minute highly interactive sessions with an educational focus. This format is designed to give specific regions a platform for presentation and networking.

FREE COMMUNICATIONS

Authors were invited to submit abstracts on their latest research findings. All submitted abstracts were reviewed and the best were selected and allocated to Free Communication Sessions.

GUIDED POSTER TOURS

Poster Exhibition

The poster exhibition is located in Congress Hall A1. Posters will be changed daily and are on display for the entire day of the respective poster tour. They will be sorted by topics and will be numbered within those topics. The poster exhibition is open to all registered delegates:

Poster exhibition times for P-01 to P-05

Monday, 19 June 2017	09:00 – 17:00
Guided Poster Tours	13:00 – 14:30

Poster exhibition times for P-06 to P-10

Tuesday, 20 June 2017	09:00 – 17:00
Guided Poster Tours	13:00 – 14:30

Poster exhibition times for P-11 to P-17

Wednesday, 21 June 2017	09:00 – 17:00
Guided Poster Tours	13:00 – 14:30

Poster exhibition times for P-18 to P-22

Thursday, 22 June 2017	09:00 – 17:00
Guided Poster Tours	13:00 – 14:30

BEST POSTER AWARDS (SEE YOUNG INVESTIGATOR AWARDS)

All posters will be evaluated on site by the WFSBP Prize Committee. The WFSBP Prize Committee will shortlist 5 posters per day that will be exhibited at a Best Poster area in Congress Hall A1 in the afternoon. Two of these will win a Best Poster Award which will be announced on the day of the session. A total of 8 Best Poster Awards for young investigators under 40 years will be presented. All Best Poster Award winners will also be mentioned during the Closing Ceremony on Thursday, 22 June 2017.

EDUCATIONAL SESSIONS

These sessions are dedicated to young researchers up to 40 years of age which will be preselected via an application process. Herewith the WFSBP is promoting education for talented young researchers. Interactional and practical learning is in the focus of these sessions. The educational grant sessions are open to all congress delegates.

INDUSTRY SPONSORED SATELLITE SYMPOSIA

These 90-minute sessions are fully integrated into the congress. The sessions are organised and executed by the pharmaceutical industry by unrestricted educational grants.

Topics

The scientific programme of the WFSBP 2017 Congress will cover the following topics.
Within each topic the track may be basic, clinical, interface or conceptual:

T1 Addictive Disorders
T2 Antidepressants: Basic/Clinical
T3 Antipsychotics: Basic/Clinical
T4 Anxiety Disorders: Basic/Clinical
T5 Anxiolytics: Basic/Clinical
T6 Bipolar Disorders: Basic/Clinical
T7 Childhood & Adolescent Disorders: Basic/Clinical
T8 Chronobiology and Psychiatry
T9 Cognitive Neuroscience
T10 Dementia: Basic/Clinical
T11 Depression: Basic/Clinical
T12 Eating Disorders: Basic/Clinical
T13 Emergency Psychiatry
T14 Epidemiology
T15 Ethics in Biological Psychiatry
T16 Forensic Psychiatry
T17 Genetics
T18 Hypnotics: Basic/Clinical
T19 Inflammation Psychiatry
T20 Liaison Psychiatry
T21 Mental Retardation or Chromosomal Aberrations: Basic/Clinical
T22 Molecular Neurobiology
T23 Mood Stabilisers: Basic/Clinical
T24 Neuropathology
T25 Neuroimaging: Genetic, Functional, Structural
T26 Neurophysiology
T27 Obsessive-Compulsive Disorders: Basic/Clinical
T28 Pain: Basic/Clinical
T29 Panic Disorders: Basic/Clinical
T30 Personality Disorders: Basic/Clinical
T31 Pharmacoeconomics
T32 Pharmacogenetics
T33 Pharmacology
T34 Phototherapy
T35 Posttraumatic Stress: Basic/Clinical
T36 Pregnancy, post partum and new born: Basic/Clinical
T37 Premenstrual Syndrome: Basic/Clinical
T38 Psychogeriatrics
T39 Psychoneuroimmunology
T40 Psychopathology
T41 Psychosurgery
T42 Psycho-Oncology
T43 Schizophrenia: Basic/Clinical
T44 Sexual Disorders: Basic/Clinical
T45 Sleep Disorders: Basic/Clinical
T46 Somatoform Disorders: Basic/Clinical
T47 Stimulation Methods (ECT, TMS, VNS, DBS)
T48 Stress: Basic/Clinical
T49 Suicide: Basic/Clinical
T50 Violence: Basic/Clinical
T51 Miscellaneous

Copenhagen, Nyhavn harbor @ tanya/fotolia.com

Opening Ceremony

Sunday, 18 June 2017
18:00 – 19:15

Master of Ceremony
Dr. Søren Dinesen Østergaard, Denmark, Local Organising Committee Deputy Chair

WELCOME ADDRESSES
Prof. Gregers Wegener, Denmark, Local Organising Committee Chair
Prof. Ralf Hemmingsen, Denmark, Immediate Past Rector of the University of Copenhagen

OPENING ADDRESS
Prof. Masatoshi Takeda, Japan, WFSBP President

SCIENTIFIC PROGRAMME COMMITTEE CHAIR ADDRESS
Prof. Constantin R. Soldatos, Greece, WFSBP Immediate Past President

PRESENTATION OF AWARDS AND DISTINCTIONS

Awards presented by Prof. Constantin R. Soldatos
Prof. Eduard Vieta, Spain, WFSBP Research Award
Prof. Florence Thibaut, France, WFSBP Award for Excellence in Education
Prof. Per Bech, Denmark, WFSBP Award for Scientific Excellence of the WFSBP Host

Distinctions presented by Prof. Masatoshi Takeda
Prof. Peter Riederer, Germany, being presented with Presidential Commendation
Prof. Constantin R. Soldatos, Greece, being pronounced WFSBP Honorary President

OPENING LECTURE
"The microbiome-gut-brain axis: A key regulator of brain & behaviour across the lifespan"
Speaker: Prof. John F. Cryan, Ireland
Chair: Prof. Masatoshi Takeda, Japan

Culture Programme by Chris Minh Doky, Denmark, Bass Player

The Opening Ceremony is followed by a Networking Reception in the Auditorium Foyer.

CME Accreditation / Colour Legend

CME ACCREDITATION

The '13th World Congress of Biological Psychiatry' is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), **www.uems.net**

The '13th World Congress of Biological Psychiatry' is designated for a maximum of 29 hours of European external CME credits. Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at **www.ama-assn.org/go/internationalcme**

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EACCME credits

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

COLOUR CODES OF SESSIONS (SCIENTIFIC PROGRAMME)

OP	Opening Lecture	TFW	Task Force Workshops	ES	Educational Sessions
PL	Plenary Lectures	S	Symposia	P	Guided Poster Tours
D	Debates	WS	Workshops	SA	Satellite Symposia
TFS	Task Force Symposia	FC	Free Communications	GA	General Assembly

Sunday, 18 June 2017 / Scientific Programme Schedule

	Auditorium 10–12	Auditorium 15	Congress Hall A3	B3 M1–M2	B3 M3–M4		
8:30	**S-01** Towards novel rapid-acting antidepressants	**S-02** Psychiatric services in emergency departments: Challenges and solutions	**S-03** Dissecting the role of the neurotrophin Brain Derived Neurotrophic Factor in cocaine addiction: Clues from clinical and preclinical studies	**WS-01** Initiatives from the Spanish Society of Biological Psychiatry: From evidence to experience	**FC-01** Treatment of depression		
9:00							
9:30							
10:00							
10:30	**S-04** Pathways of neuroprogression in Bipolar Disorder (BP)	**S-05** Extracellular vesicles in neuropsychiatric diseases: Basic mechanisms and biomarkers	**S-06** Drug addiction and GPCR heteroreceptor complexes: What goes wrong in receptor plasticity as addiction develops?	**WS-02** New investigations on the relationship between working memory and ADHD	**FC-02** Molecular neurobiology		
11:00							
11:30							
12:00	**Coffee Break**						
12:30	**S-07** Social cognition and neuronal correlates in patients with schizophrenia		**S-08** Inflammation markers of peripherial blood in depression spectrum	**FC-03** Schizophrenia & dementia			
13:00							
13:30							
14:00					**ES-01** How to build an academic career		
14:30	**S-09** Mechanisms contributing to neuroprogression in psychiatric disorders and promising interventions	**S-10** Effects and side effects of electroconvulsive therapy	**S-11** Abnormal neurogenesis in schizophrenia	**S-12** New approaches into diagnosis and treatment of psychotic Bipolar Disorder (BP)			
15:00							
15:30							
16:00	**Coffee Break**						
16:30				**S-13** Biomarkers for early diagnosis of Alzheimer's Disease (AD) and other neurodegenerating diseases: Advantages and limitations			
17:00							
17:30							
18:00	**Opening Ceremony** 18:00 – 19:00 (Auditorium 10–12) (incl. **OP-01** The microbiome-gut-brain axis: A key regulator of brain & behaviour across the lifespan) **Networking Reception** 19:00 – 20:00 (Auditorium Foyer)						
18:30							
	Registration Counter 07:30–19:00						

Scientific Programme Schedule / Monday, 19 June 2017

	Auditorium 15	Congress Hall A3	Auditorium 12	Auditorium 10	Auditorium 11	B3 M1 – M2	B3 M3 – M4	Congress Hall A1
8:30	**S-14** Problematic sexual behaviors: Diagnostic, categorical, epidemiological, imaging, psychopathological and treatment considerations	**S-15** Posttraumatic Stress Disorder (PTSD) and gender	**S-16** The elephant in the room: The role of glial cells in psychiatric disorders	**S-17** Psychosis is disrespectful to diagnostic boundaries	**S-18** Epigenetic modification, effect of early life stress, and signaling mechanisms in suicide	**S-19** Psychedelics: Mechanisms and applications in psychiatry	**S-20** Affective and psychotic psychopathology from pregnancy to early adulthood	
9:00								
9:30								
10:00	**Coffee Break**							
10:30	**PL-01** Drug discovery in neuroscience							
11:00								
11:30	**D-01** Antidepressants are effective for treating acute bipolar depression	**TFS-01** Therapeutic drug monitoring, pharmacogenetics and brain imaging methods as tools for optimizing pharmacotherapy in psychiatry	**S-21** Measurement-based psychiatry: Toward rating scale-based assessments in the real world	**S-22** Dissecting the shared and non-shared biological features in schizophrenia and autism spectrum disorder	**S-23** Combining cognitive remediation with brain imaging techniques: Evidence for neural changes or neuroplasticity?	**WS-03** Current status of electroconvulsive therapy in the treatment of major psychiatric disorders	**S-24** Serotonin and anxiety disorders: Recent evidences from neuroimaging studies	
12:00								
12:30								
13:00			**SA-01** Sunovion Satellite Symposium					**Guided Poster Tours** P-01 – P-05
13:30								
14:00								
14:30								
15:00	**S-25** tDCS: From research to clinical practice	**TFS-02** Post-mortem findings across psychiatric disorders and their association with cognitive symptoms	**TFW-01** Workshop of the WFSBP Task Force on Genetics: Focus on pharmacogenomics	**S-26** Into novel drugs for depression	**S-27** Beyond unitary models of psychosis: Confronting complex etiology and dimensionality	**WS-04** Rethinking depression in the Century XXI: Where are we now in biological psychiatry?	**S-28** Wake and sleep electroencephalogramm provide biomarkers of depression	
15:30								
16:00								
16:30	**Coffee Break**							
17:00		**TFS-03** Update biomarkers in psychiatry	**S-29** Autism spectrum disorders in adults – from the clinical phenotype to the underlying neurobiology			**FC-04** Neuroimaging 1	**FC-05** Psychoneuroimmunology	
17:30								
18:00								
18:30								
	Registration Counter 08:00 – 18:30			**Poster Exhibition** 09:00 – 17:00			**Technical Exhibition** 09:00 – 17:00	

Tuesday, 20 June 2017 / Scientific Programme Schedule

	Auditorium 15	Congress Hall A3	Auditorium 12	Auditorium 10	Auditorium 11	B3 M1 – M2	B3 M3 – M4	Congress Hall A1
8:30	**S-30** Recent insights in schizophrenia physiopathology and treatments	**S-31** Duration of untreated psychosis: From neuroimaging to clinical trials	**S-32** New perspectives on transcranial magnetic stimulation in psychiatric disorders	**S-33** Epigenetic biomarkers for the diagnosis of mood disorders	**S-34** Sex hormones and their wide-ranging effects on psychopathology	**WS-05** Gesture as window to psychosis pathobiology: From aberrant body experience to social interaction	**S-35** New insights into the neurobiology and treatment aspects of OCD comorbid with schizophrenia and bipolar disorder	
9:00								
9:30								
10:00	Coffee Break							
10:30	**PL-02** Ketamine in mood disorders							
11:00								
11:30	**D-02** The Research Domain Criteria (RDoC) can create a new kind of taxonomy holding greater promise compared to the traditional ...	**TFS-04** Sleep in depression and cognition – from research to clinical practice	**S-36** The role of the nucleus accumbens in psychiatry	**S-37** Neurobiologic imaging studies of mood disorders, neurogenetics and antidepressant action with positron emission tomography	**S-38** Treatment resistant schizophrenia: Definitions, psychobiology and clinical treatment	**WS-06** Neurobiology of suicidal behaviour	**WS-08** Functional neuroanatomy of hallucinations	
12:00								
12:30								
13:00								**Guided Poster Tours** P-06 – P-10
13:30			**SA-02** Actelion Satellite Symposium					
14:00						**ES-02** Pharmacological treatment and non-invasive brain stimulation		
14:30								
15:00	**WS-07** Merging evidence and clinical practice in management of depression: The CANMAT experience	**TFS-05** Biomarkers for schizophrenia: From molecules to brain function. A consensus of the WFSBP Task Force on biological markers	**TFW-02** WFSBP Consensus on the management of agitation in psychiatry	**S-39** Current research on the use of cannabinoids	**S-40** Alzheimer's Disease (AD) pathophysiology, prevention and treatment strategies: Where we stand and where we go?		**S-41** Electroconvulsive therapy for depression – optimising treatment and maintaining recovery	
15:30								
16:00								
16:30	Coffee Break							
17:00	**S-66** NMDA receptor antagonists in psychiatry	**S-42** Neuroepigenetic approaches to assess disease risk, mechanism and treatment	**TFS-06** Electroconvulsive therapy: Beyond depression	**FC-06** Antipsychotics 1	**FC-07** Anxiety & PTSD		**FC-08** Depression 2	
17:30								
18:00								
18:30								
	Registration Counter 08:00 – 18:30			**Poster Exhibition** 09:00 – 17:00			**Technical Exhibition** 09:00 – 17:00	

Scientific Programme Schedule / Wednesday, 21 June 2017

	Auditorium 15	Congress Hall A3	Auditorium 12	Auditorium 10	Auditorium 11	B3 M1 – M2	B3 M3 – M4	Congress Hall A1
8:30	**S-43** Novel approaches in mechanisms of action of antidepressant treatment	**S-44** Cannabinoid Receptor (CBR) gene variations in neuropsychiatric disorders	**FC-09** Depression 1	**S-45** Behavioral Addictions: Diagnosis, co-morbidity and neurobiology	**S-46** Neurobiology and psychopharmacology of aggressive behaviour: Where are we?	**S-47** Catecolamines, anhedonia and depression	**FC-10** Antipsychotics 2	
9:00								
9:30								
10:00	**Coffee Break**							
10:30	**PL-03** Epigenetic consequences of early adversity							
11:00								
11:30	**D-03** Deep brain stimulation is a worthwhile treatment method in psychiatry	**TFS-07** Enhancing the role of primary care in looking after people with mental health problems	**S-48** Pharmacogenetics of drug defense and neuroprotection: From the Neandertal to the modern humans	**S-49** Evidence-based guidelines for treatment of major depressive disorder: Contrasting views across the world	**S-50** Real time assessment of psychopathology and behavior in Bipolar Disorder (BP) using e-mental health technologies	**WS-09** Schizophrenia research in Chile		
12:00								
12:30								
13:00					**WFSBP** General Assembly			**Guided Poster Tours** P-11 – P-17
13:30								
14:00								
14:30								
15:00	**S-51** Advances in biomarker development for neurostimulation	**TFS-08** Men's mental health: Contemporary aspects	**TFW-03** WFSBP Treatment Guideline Session: Do bipolar mixed states merit a treatment guideline on its own?	**S-52** The G protein coupled receptors as a target for psychotropic drugs	**S-55** Rediscovering Lithium	**WS-10** Evidence for brain stimulation methods in schizophrenia	**S-53** Suicidal behavior: Neurobiological and genetic determinants	
15:30								
16:00								
16:30	**Coffee Break**							
17:00	**FC-12** Schizophrenia	**TFS-09** Providing acute inpatient care for children, adolescents and young adults from a men's mental health perspective	**S-54** Lithium as a neuroprotective agent: When and how?	**FC-13** Genetics	**FC-11** Inflammation	**FC-14** Neuroimaging 2	**FC-15** Addictive disorders	
17:30								
18:00								
18:30								
	Registration Counter 08:00 – 18:30			**Poster Exhibition** 09:00 – 17:00			**Technical Exhibition** 09:00 – 17:00	

Thursday, 22 June 2017 / Scientific Programme Schedule

	Auditorium 15	Congress Hall A3	Auditorium 12	Auditorium 10	Auditorium 11	B3 M1 – M2	B3 M3 – M4	Congress Hall A1
8:30	**S-56** Clinical effects and neural mechanisms of electro-convulsive therapy in major depression and schizophrenia	**S-57** Causes and consequences of inflammation in Bipolar Disorder (BP)	**S-58** Novel thera-peutics for neu-rodegenerative disorders	**S-59** The relevance of Neuregulin1–ErbB4 signaling for neuropsy-chiatric patho-mechanisms	**S-60** Multi-omics and psychiatry: The missing molecu-lar link	**S-61** Suicide: Aspects that burn		
9:00							**ES-03** Update on research	
9:30								
10:00	Coffee Break							
10:30	**PL-04** Lithium in mood disorders: a Danish homage							
11:00	**S-62** Innovative approaches in suicide research	**S-63** Atypical neu-rotransmitters in psychiatry: Rele-vance for future therapeutics	**S-64** Operational-izing the dysconnection syndrome: Translational ap-proaches reveal brain network dysfunction in schizophrenia	**S-65** Cell-type spe-cific epigenetic, proteomic and gene expression signatures in schizophrenia: New findings		**S-67** Spectrum of Mood Disorders (MD): Where is the place for mixed states?		
11:30								
12:00								
12:30								
13:00								**Guided Poster Tours** P-18 – P-22
13:30								
14:00								
14:30	Coffee Break							
15:00	**S-68** Dynamical brain: How brain complexi-ty changes with aging and mental illness?	**S-69** Increased intes-tinal permeabili-ty and bacterial translocation in neuro-psychia-tric disorders	**S-70** Current use of EEG-based techniques in psychiatry	**S-71** Sex-specific neuroendo-crinological findings in conduct disorder	**S-72** Socio-demo-graphic and clinical differ-ences between Bipolar I and II Disorder (BP) and implications for treatment	**S73** Neuropatholo-gic implication of abnormal cortico-basal ganglia connec-tivity in schizo-phrenia hallu-cination and its models	**FC-16** Childhood & adolescent disorders	
15:30								
16:00								
16:30	**Closing Ceremony**							
17:00								
17:30								
18:00								
18:30								
	Registration Counter 08:00 – 17:30			**Poster Exhibition** 09:00 – 17:00				

Scientific Programme / Sunday, 18 June 2017

▶ Sunday, 18 June 2017

T2: ANTIDEPRESSANTS: BASIC / CLINICAL

S-01 **SYMPOSIUM**

08:30–10:00 Auditorium 10+11+12

Towards novel rapid-acting antidepressants

Chair: *Tomi Rantamäki, Finland*

Co-Chair: *Gregers Wegener, Denmark*

001 **Rapid acting antidepressants in chronic pain**
Ipek Yalcin, France

002 **Morphological and structural alterations following rapid acting antidepressants**
Gregers Wegener, Denmark

003 **Antidepressant potential of cannabidiol: Preclinical evidence**
Sâmia Joca, Brazil

004 **Anesthetics as rapid-acting antidepressants**
Tomi Rantamäki, Finland

T20: LIAISON PSYCHIATRY

S-02 **SYMPOSIUM**

08:30–10:00 Auditorium 15

Psychiatric services in emergency departments: Challenges and solutions

Chair: *Ruby Castilla-Puentes, USA*

Co-Chair: *Tatiana Falcone, USA*

001 **Psychiatric consultations in rural general hospitals – Latinos vs. Anglos**
Bernardo Ng, USA

002 **A study of insomnia and cormobid psychiatric conditions in rehabilitation clinics**
Franklin Escobar, Colombia

003 **Depression and medical comorbidity in emergency departments in Mexico**
Ricardo Secin, Mexico

004 **Self-inflicted injuri in children and adolescents: A study in a tertiary care hospital in Santiago de Chile**
Arturo Grau, Chile

T1: ADDICTIVE DISORDERS

S-03 **SYMPOSIUM**

08:30–10:00 Congress Hall A 3

Dissecting the role of the neurotrophin Brain Derived Neurotrophic Factor in cocaine addiction: Clues from clinical and preclinical studies

Chair: *Fabio Fumagalli, Italy*

001 **Acute exposure to cocaine during brain development evokes depressive-like behaviors via downregulation of Brain Derived Neurotrophic Factor signaling**
Fabio Fumagalli, Italy

002 **Cocaine and orbitofrontal cortical Brain Derived Neurotrophic Factor deficiency induce habit-based decision-making: Blockade by trkB stimulation**
Shannon Gourley, USA

003 **Systemic administration of the brain-penetrant TrkB antagonist cyclotraxin-b reduces short and long access cocaine intake**
Michel Verheij, The Netherlands

004 **Brain Derived Neurotrophic Factor and cocaine in clinical samples: A useful biomarker for treatment?**
Lisia von Diemen, Brazil

T51: MISCELLANEOUS

WS-01 **WORKSHOP**

08:30–10:00 B3 M1-M2

Initiatives from the Spanish Society of Biological Psychiatry: From evidence to experience

Chair: *Miquel Bernardo, Spain*

Co-Chair: *Ana Gonzalez Pinto, Spain*

001 **Agitation consensus**
Eduard Vieta, Spain

002 **ECT consensus**
Mikel Urretavizcaya, Spain

003 **Clinical guidelines for adult patients with a severe mental disorder and a comorbid substance use**
Luis San, Spain

FC-01 **FREE COMMUNICATION SESSION**

08:30–10:00 B3 M3-M4

Treatment of depression

Chair: *Tom Bolwig, Denmark*

Co-Chair: *Eva Ceskova, Czech Republic*

001 **Optimization of therapy with antidepressants**
Eva Ceskova, Czech Republic
P. Silhán

002 **The efficacy of minocycline as an adjunctive treatment for major depressive disorder: A double blind, randomised, placebo controlled trial**
Olivia Dean, Australia
B. Kanchanatawan, M. Ashton, M. Maes, L. Berk, A. Sughondhabirom, S. Tangwongchai, C. Ng, K. Hasebe, C. Bortolasci, K. Walder, M. Berk

003 **Expression and subcellular localization of serotonin transporter in LCLs as putative biomarker for antidepressant response**
Abdul-Karim Barakat, Germany
C. Scholl, S. Lucae, M. Ising, A. Kalayda, U. Jaehde, J. Stingl

004 **The place of Electroconvulsive Therapy in the treatment of depression in France: A comparison of practices with international recommendations**
Pierre-Michel Llorca, France
T. Charpeaud, A. Tremey, B. Aouizerate, P. Courtet

005 **Prediction of electroconvulsive therapy response and remission in major depression: A meta-analysis**
Linda van Diermen, Belgium
S. Van Den Ameele, A. M. Kamperman, B. C. G. Sabbe, V. Tom, D. Schrijvers, T. K. Birkenhäger

006 **rTMS long-term prevention of depressive relapse / recurrence does not increase risk of switching to mania even in patients with first depressive episode: A randomised controlled trial**
Zhang-Jin Zhang, Hong Kong
H.-N. Wang, X.-X. Wang, Q.-R. Tan

T6: BIPOLAR DISORDERS: BASIC / CLINICAL

S-04 **SYMPOSIUM**
10:15 – 11:45 Auditorium 10+11+12
Pathways of neuroprogression in Bipolar Disorder (BP)
Chair: *Benicio Frey, Canada*
Co-Chair: *Flavio Kapczinski, Brazil*

001 **Indicators or risk and resilience in the high-risk offspring of bipolar parents**
Anne Duffy, Canada

002 **Lithium compared to quetiapine in the maintenance phase after a first episode of mania**
Michael Berk, Australia

003 **Biological rhythms and illness progression in Bipolar Disorder (BP)**
Benicio Frey, Canada

004 **Illness trajectories and neuroprogression in Bipolar Disorder (BP)**
Flavio Kapczinski, Brazil

T22: MOLECULAR NEUROBIOLOGY

S-05 **SYMPOSIUM**
10:15 – 11:45 Auditorium 15
Extracellular vesicles in neuropsychiatric diseases: Basic mechanisms and biomarkers
Chair: *Takashi Kudo, Japan*
Co-Chair: *Dimitrios Kapogiannis, USA*

001 **Extracellular vesicles as a source of biomarkers for Alzheimer's Disease**
Dimitrios Kapogiannis, USA

002 **Tau inside neutrally-derived exosome**
Dominic Walsh, USA

003 **Mechanisms of exosome involvement in neurodegerative diseases**
Andrew Hill, Australia

004 **Changes in exosomes proteins by the degree of stress**
Takashi Kudo, Japan

T22: MOLECULAR NEUROBIOLOGY

S-06 **SYMPOSIUM**
10:15 – 11:45 Congress Hall A 3
Drug addiction and GPCR heteroreceptor complexes: What goes wrong in receptor plasticity as addiction develops?
Chair: *Kjell Fuxe, Sweden*
Co-Chair: *Anita Hansson, Germany*

001 **Neurochemical mechanisms underlying goal-directed and habitual drug seeking and how these mechanisms produce compulsions: Focus on Gq-coupled glutamate receptors**
Kjell Fuxe, Sweden

002 **Homo and heteroreceptor complexes participate in learning and memory and as an emerging target for treatment of cocaine addiction**
Dasiel Borroto-Escuela, Sweden

003 **Evidence for a role of A2A-D2 heteroreceptor complexes in cocaine addiction**
Malgorzata Filip, Poland

004 **Dopamine D4-MOR interactions prevent nigrostriatal dopamine pathway activation by morphine: Relevance for drug addiction**
Alicia Rivera, Spain

Scientific Programme / Sunday, 18 June 2017

T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC / CLINICAL

WS-02 **WORKSHOP**

10:15–11:45 B3 M1-M2

New investigations on the relationship between working memory and ADHD

Chair: Joseph Biederman, USA

001 **Clinical correlates of working memory deficits in youth with and without ADHD**
Ronna Fried, USA

002 **Are working memory deficits and ADHD dissociable?: An fMRI study**
Joseph Biederman, USA

003 **Reduced prefrontal efficiency for visuospatial working memory in attention-deficit / hyperactivity disorder**
Jeffrey Newcorn, USA

004 **Working memory deficits in a prenatal nicotine exposure mouse model**
Pradeep Bhide, USA

FC-02 **FREE COMMUNICATION SESSION**

10:15–11:45 B3 M3-M4

Molecular neurobiology

Chair: Sagar Lavania, India

001 **Anxiety is triggered by elevated levels of the GDNF sorting receptor SorLA**
Camilla Gustafsen, Denmark
D. Demontis, J. Lundhede, M. Kaas, H. Buttenschøn, S. Mølgaard, C. M. Petersen, A. Nykjær, S. Glerup

002 **Does mitochondrial function underpin the efficacy of polypharmacy for Bipolar Disorder (BP)?**
Chiara Bortolasci, Australia
B. Spolding, E. Callaly, S. Martin, B. Panizzutti, S. Kidnapillai, T. Connor, K. Hasebe, S. McGee, S. Dodd, L. Gray, M. Berk, K. Walder

003 **Proteome-wide study of cerebrospinal fluid biomarkers for Bipolar Disorder and other neuropsychiatric disorders**
Jessica Holmén Larsson, Sweden
M. Hölttä, C. Sellgren, H. Zetterberg, K. Blennow, M. Landén, J. Gobom

004 **Caudate neurochemistry in unmedicated OCD (obsessive compulsive disorder) patients: A 3 Tesla 1H-MRS study**
Arpit Parmar, India
A. Parmar, P. Sharan, S. Khandelwal, U. Sharma, N. Jagannathan

005 **Plasma Oxytocin in OCD**
Donatella Marazziti, Italy
F. Mucci, S. Baroni, A. Piccinni

006 **Plasma lipid peroxides level in schizophrenia patients**
Sagar Lavania, India
A. Pattojoshi, A. H. Khan

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-07 **SYMPOSIUM**

12:30–14:00 Auditorium 10+11+12

Social cognition and neuronal correlates in patients with schizophrenia

Chair: Gabriele Sachs, Austria
Co-Chair: Armida Mucci, Italy

001 **Neurocognitive predictors of social cognition**
Vijaya Lakshmi Valaparla, India

002 **Emotional intelligence in patients suffering from schizophrenia and unaffected siblings**
Alex Hofer, Austria

003 **Social cognition and negative symptoms in schizophrenia: Constructs, assessment and relationships with functional outcome**
Armida Mucci, Italy
S. Galderisi, A. Rossi, P. Rocca, A. Bertolino, M. Maj

004 **Neurobiological correlates of the treatment of emotion processing in schizophrenia**
Gabriele Sachs, Austria

T19: INFLAMMATION PSYCHIATRY

S-08 **SYMPOSIUM**

12:30–14:00 Congress Hall A 3

Inflammation markers of peripherial blood in depression spectrum

Chair: Piotr Galecki, Poland
Co-Chair: Angelos Halaris, USA

001 **(Auto)immune biomarkers of depression and subtypes**
Michael Maes, Thailand

002 **Targeting inflammation to prevent depression**
Michael Berk, Australia

003 **Stratification of depressed patients by means of blood markers of inflammation, growth factors and kynurenine metabolites**
Angelos Halaris, USA

004 **Omega-3 fatty acids, inflammation and depression: From biological mechanisms to clinical application**
Kuan-Pin Su, Taiwan

FC-03 FREE COMMUNICATION SESSION
12:30–14:00 B3 M1-M2
Schizophrenia & dementia
Chair: Alessandro Serretti, Italy
Co-Chair: Do-Hoon Kim, Republic of Korea

001 **Clinical usefulness of the Screen for Cognitive Impairment in Psychiatry (SCIP) in patients with schizophrenia and affective disorder before and after cognitive remediation**
Andreas Erfurth, Austria
E. Maihofer, M. Neuwirth, H. Swoboda, G. Sachs

002 **Association of plasma brain-derived neurotrophic factor level with neurocognitive functions in patients with at-risk mental state and first-episode psychosis**
Kenji Sanada, Japan
S. Ruiz de Azúa, S. Mesa, S. Matsuzaki, A. Takahashi, K. Saito, M. Martínez-Cengotitabengoa, A. Iwanami, A. Gonzalez Pinto

003 **The effects of Donepezil on Alzheimer's Diseased (AD) rats' model with intestinal endotoxemia**
Bai Han, People's Republic of China
F. Wu, C. Li, X. Shan, Q. Sun, K. Liu

004 **Differential association of depression level with cognitive function according to cognitive domains of mild cognitve impairment and Alzheimer's Disease**
Do-Hoon Kim, Republic of Korea
C. H. Lee, Y.-S. Moon

005 **D-amino acid oxidase level in the peripheral blood is higher in patients with age-related cognitive decline**
Chieh-Hsin Lin, Taiwan
H.-Y. Lane

ES-01 EDUCATIONAL SESSION
14:00–17:00 B3 M3-M4
How to build an academic career
Chair: Ida Hageman Pedersen, Denmark

001 **How to get published**
Gregers Wegener, Denmark
Søren Dinesen Østergaard, Denmark

002 **How to combine research and clinical work**
Klaus Munkholm, Denmark

003 **How to combine research and clinical work**
David Erritzoe, United Kingdom

004 **How to get funded**
Michael Berk, Australia

T39: PSYCHONEUROIMMUNOLOGY

S-09 SYMPOSIUM
14:30–16:00 Auditorium 10+11+12
Mechanisms contributing to neuroprogression in psychiatric disorders and promising interventions
Chair: Angelos Halaris, USA

001 **Inflammatory and innate immune markers of neuroprogression in depressed and teenage suicide brain**
Ghanshyam Pandey, USA

002 **Major depression as a prelude to dementia: What is the evidence?**
Brian Leonard, Ireland

003 **Neuroimaging of microglia activation in major depression**
Jeffrey Meyer, Canada

004 **Promising neuroprotective and anti-inflammatory interventions to arrest neuroprogression**
Angelos Halaris, USA

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-10 SYMPOSIUM
14:30–16:00 Auditorium 15
Effects and side effects of electroconvulsive therapy
Chair: Michael Grözinger, Germany
Co-Chair: Helge Frieling, Germany

001 **Effects of ECT on the oxygen saturation in the frontal brain**
Michael Grözinger, Germany

002 **DNA methylation of P11 / S100A10: A putative marker of response to ECT?**
Helge Frieling, Germany

003 **Electroconvulsive therapy enhances amyloid ß 1-42 in the cerebrospinal fluid of patients with major depression**
Alexander Sartorius, Germany

004 **The EFFECT-Dep Trial (ISRCTN23577151): Immediate and long-term cognitive outcomes**
Declan McLoughlin, Ireland

Scientific Programme / Sunday, 18 June 2017

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-11 **SYMPOSIUM**

14:30–16:00 Congress Hall A 3

Abnormal neurogenesis in schizophrenia

Chair: *Dragos Inta, Germany*
Co-Chair: *Guo-Li Ming, USA*

001 **Modeling predisposition to schizophrenia using hiPSCs**
Kristen Brennand, USA

002 **Neurogenesis and psychiatric neurodevelopmental disorders**
Guo-Li Ming, USA

003 **Precise activation of the Reelin pathway controls dendritic maturation, synapse formation and glial ensheathment of adult-generated granule cells**
Eduardo Soriano, Spain

004 **Adult neurogenesis in the striatum: Effect of psychiatric treatment**
Dragos Inta, Germany

T6: BIPOLAR DISORDERS: BASIC / CLINICAL

S-12 **SYMPOSIUM**

14:30–16:00 B3 M1-M2

New approaches into diagnosis and treatment of psychotic Bipolar Disorder (BP)

Chair: *Carlo Altamura, Italy*
Co-Chair: *Allan Young, United Kingdom*

001 **Neuroimaging aspects of psychotic Bipolar Disorder (BP)**
Paolo Brambilla, Italy

002 **Candidate biomarkers for psychotic Bipolar Disorder (BP): The role of neuroinflammation and hormones**
Massimiliano Buoli, Italy

003 **The role of dopamine in psychotic bipolar disorder and treatment implications**
Oliver Howes, United Kingdom

T10: DEMENTIA: BASIC / CLINICAL

S-13 **SYMPOSIUM**

16:30–18:00 B3 M1-M2

Biomarkers for early diagnosis of Alzheimer's Disease (AD) and other neurodegenerating diseases: Advantages and limitations

Chair: *Piotr Lewczuk, Germany*
Co-Chair: *Henrik Zetterberg, Sweden*

001 **New developments in the biomarkers for Alzheimer's Disease (AD)**
Kaj Blennow, Sweden

002 **Amyloid beta 42 / 40 Ratio in diagnosis of AD: Do we need it?**
Piotr Lewczuk, Germany

003 **Sensitive technologies for blood biomarkers in neurodegeneration**
Henrik Zetterberg, Sweden

004 **Current diagnostic approaches in frontotemporal lobar degeneration**
Markus Otto, Germany

OPENING SESSION

18:00–19:00 Auditorium 10+11+12

Opening Ceremony

Chair: *Masatoshi Takeda, Japan*

001 **The microbiome-gut-brain axis: A key regulator of brain & behaviour across the lifespan**
John F. Cryan, Ireland

Please see page 15.

▶ Monday, 19 June 2017

T1: ADDICTIVE DISORDERS

S-14 **SYMPOSIUM**

08:30–10:00 Auditorium 15

Problematic sexual behaviors: Diagnostic, categorical, epidemiological, imaging, psychopathological and treatment considerations

Chair: *Marc Potenza, USA*
Co-Chair: *Florence Thibaut, France*

001 **Classification and clinical issues relating to hypersexuality**
Marc Potenza, USA
S. Kraus

002 **Sexual impulsivity, psychopathology and trauma: Gender-related differences**
Galit Erez, Israel

003 **Advances in pharmacological treatments for sex offenders**
Florence Thibaut, France

004 **Neurobiology of compulsive sexual behaviors**
Valerie Voon, United Kingdom

T35: POSTTRAUMATIC STRESS: BASIC / CLINICAL

S-15 **SYMPOSIUM**

08:30–10:00 Congress Hall A 3

Posttraumatic Stress Disorder (PTSD) and gender

Chair: *Hans-Jürgen Möller, Germany*
Co-Chair: *Victoria Valdez, Ecuador*

001 **Clinical issues: PTSD and gender violence**
Victoria Valdez, Ecuador

002 **Course and prognosis PTSD**
Kayihan Oguz Karamustafa, Turkey

003 **Biological aspects and PTSD**
Soraya Seedat, South Africa

004 **Genetics and PTSD**
Sian Hermann, South Africa

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-16 **SYMPOSIUM**

08:30–10:00 Auditorium 12

The elephant in the room: The role of glial cells in psychiatric disorders

Chair: *Sabina Berretta, USA*
Co-Chair: *Mikhail Pletnikov, USA*

001 **Psychiatric genetic risk factors in healthy and diseased astrocytes**
Mikhail Pletnikov, USA

002 **Glia-extracellular matrix interactions in the pathophysiology of schizophrenia and Bipolar Disorder (BD)**
Sabina Berretta, USA

003 **Abnormalities of glutamate transporter localization in severe mental illness**
Robert McCullumsmith, USA

004 **Evidence for neuroinflammation, gliosis and leaky brain in people with schizophrenia**
Cyndi Shannon Weickert, Australia

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-17 **SYMPOSIUM**

08:30–10:00 Auditorium 10

Psychosis is disrespectful to diagnostic boundaries: Nosological and pathobiological implications of psychoses beyond the schizophrenia spectrum

Chair: *John Waddington, Ireland*
Co-Chair: *Sidney Kennedy, Canada*

001 **Reconciling the diversity of psychotic illness and dimensional concepts with current diagnostic algorithms**
Rajiv Tandon, USA

002 **Psychosis in major depressive disorder: Systematic comparisons with and beyond the schizophrenia spectrum**
John Waddington, Ireland

003 **Psychosis in Bipolar Disorder (BP): Genetics and relationships to paternal age**
Sidney Kennedy, Canada

004 **Post-stroke psychosis: Pathobiology and behavioral susceptibility**
Eileen Joyce, United Kingdom
P. Malhotra, M. Devine

Scientific Programme / Monday, 19 June 2017

T49: SUICIDE: BASIC / CLINICAL

S-18 **SYMPOSIUM**

08:30–10:00 Auditorium 11

Epigenetic modification, effect of early life stress, and signaling mechanisms in suicide

Chair: *Ghanshyam Pandey, USA*
Co-Chair: *Victoria Arango, USA*

001 **Impact of the early-life environment on the epigenetic regulation of the anterior cingulate gyrus**
Gustavo Turecki, Canada

002 **Expression and methylation of glucocorticoid receptors and FKBP5 in teenage and adult suicide**
Ghanshyam Pandey, USA

003 **Genome-wide epigenetic changes in suicide attempters**
Jussi Jokinen, Sweden

004 **5-HT1A receptor anti-apoptotic transduction pathways in suicide**
Victoria Arango, USA

T11: DEPRESSION: BASIC / CLINICAL

S-19 **SYMPOSIUM**

08:30–10:00 B3 M1-M2

Psychedelics: Mechanisms and applications in psychiatry

Chair: *Tomas Palenicek, Czech Republic*
Co-Chair: *Katrin Preller, Switzerland*

001 **Role of 5-HT2A receptors in the mechanism of action of psilocybin and LSD and the treatment of affective disorders**
Katrin Preller, Switzerland

002 **The effect of psilocybin on brain connectivity and emotional processing in healthy volunteers**
Tomas Palenicek, Czech Republic

003 **Psilocybin for the treatment of depression**
Robin Carhart-Harris, United Kingdom

004 **Exploring the therapeutic potential of ayahuasca in the treatment of psychiatric disorders**
Jordi Riba, Spain

T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC / CLINICAL

S-20 **SYMPOSIUM**

08:30–10:00 B3 M3-M4

Affective and psychotic psychopathology from pregnancy to early adulthood: The dynamic developmental interplay between genes, structures and functions

Chair: *Paolo Brambilla, Italy*
Co-Chair: *Michael Kaess, Germany*

001 **Can personality and parental care impact on brain development?**
Paolo Brambilla, Italy

002 **Neurodevelopmental trajectories and psychopathology in adults who were born very preterm**
Chiara Nosarti, United Kingdom

003 **Grin2b mediates susceptibility to affective problems in children and adolescents**
Maria Nobile, Italy

004 **Corollary discharge auditory hallucinations and schizophrenia: A structural network analysis**
Romy Hemze, Germany

PL-01 **PLENARY SESSION**

10:15–11:00 Auditorium 15

Drug discovery in neuroscience: Promises, barriers and opportunities

Chair: *Lakshmi Yatham, Canada*
Speaker: *Husseini Manji, USA*

D-01 **DEBATE**

11:15–12:45 Auditorium 15

Antidepressants are effective for treating acute bipolar depression

Chair: *Lakshmi Yatham, Canada*
Proponent: *Glenda MacQueen, Canada*
Opponent: *Robert Post, USA*

T51: MISCELLANEOUS

TFS-01 WFSBP TASK FORCE SYMPOSIUM

11:15–12:45 Congress Hall A 3

Therapeutic drug monitoring, pharmacogenetics and brain imaging methods as tools for optimizing pharmacotherapy in psychiatry

Chair: Chin B. Eap, Switzerland
Co-Chair: Christoph Hiemke, Germany

001 **Pharmacogenetics in psychiatry**
Chin B. Eap, Switzerland

002 **Therapeutic drug monitoring in psychiatry**
Christoph Hiemke, Germany

003 **Brain imaging in psychiatry**
Gerhard Gründer, Germany

004 **Strategies for the implementation of genetic biomarkers in clinical practice**
Daniel Müller, Canada

T11: DEPRESSION: BASIC / CLINICAL

S-21 SYMPOSIUM

11:15–12:45 Auditorium 12

Measurement-based psychiatry: Toward rating scale-based assessments in the real world

Chair: Christoph U. Correll, USA
Co-Chair: Søren Dinesen Østergaard, Denmark

001 **Measurement-based care psychiatry: Where are we at and where should we head?**
Andrew A. Nierenberg, USA

002 **Measurement-based care versus standard care for major depression: Conducting a successful randomized controlled trial with blind raters**
Christoph U. Correll, USA

003 **The role for measurement-based care for Bipolar Disorder (BP) in current and future clinical practice**
Eduard Vieta, Spain

004 **PANSS-6: A new rating scale for both research and clinical care in schizophrenia**
Søren Dinesen Østergaard, Denmark

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-22 SYMPOSIUM

11:15–12:45 Auditorium 10

Dissecting the shared and non-shared biological features in schizophrenia and autism spectrum disorder

Chair: Kenji Tsuchiya, Japan
Co-Chair: Manabu Makinodan, Japan

001 **Comparative genetic analysis of autism spectrum disorder and schizophrenia: Focus on rare variants**
Branko Aleksic, Japan

002 **The genetic overlap between autism and schizophrenia: Focus on common variation**
Jakob Grove, Denmark

003 **Neurobiological findings in schizophrenia and autism spectrum disorder**
Manabu Makinodan, Japan

004 **Advanced paternal age at birth is associated with autism and schizophrenia**
Kenji Tsuchiya, Japan

T9: COGNITIVE NEUROSCIENCE

S-23 SYMPOSIUM

11:15–12:45 Auditorium 11

Combining cognitive remediation with brain imaging techniques: Evidence for neural changes or neuroplasticity?

Chair: Martin Lepage, Canada
Co-Chair: Kamilla Miskowiak, Denmark

001 **Neural markers and predictors of therapeutic change with cognitive enhancement therapy**
Matcheri Keshavan, USA

002 **Short-term working memory training for individuals with psychosis: Cognitive and neurophysiological effects**
Christopher Bowie, Canada

003 **Randomised trial of low support cognitive training for schizophrenia: Cortical and behavioural outcomes**
Gary Donohoe, Ireland

004 **SESAME: A brief intervention for memory in schizophrenia. Behavioral and imaging data**
Martin Lepage, Canada

Scientific Programme / Monday, 19 June 2017

T4: ANXIETY DISORDERS: BASIC / CLINICAL

S-24 **SYMPOSIUM**
11:15–12:45 B3 M3-M4
Serotonin and anxiety disorders: Recent evidences from neuroimaging studies
Chair: *Eduard Maron, Estonia*
Co-Chair: *Tomas Furmark, Sweden*

001 **Serotonin system and panic disorder**
Eduard Maron, Estonia

002 **Serotonin system and social anxiety disorder**
Tomas Furmark, Sweden

003 **Serotonin system and obsessive-compulsive disorder**
Oliver Pogarell, Germany

004 **Serotonin regulation of anxiety neuronal network**
Andreas Frick, Sweden

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

WS-03 **WORKSHOP**
11:15–12:45 B3 M1-M2
Current status of electroconvulsive therapy in the treatment of major psychiatric disorders
Chair: *Yong-Sik Kim, Republic of Korea*
Co-Chair: *Pascal Sienaert, Belgium*

001 **Current status on efficacy of ECT**
Hans Mørch Jensen, Denmark

002 **Mechanism of ECT focused on psychosis**
Ung-Gu Kang, Republic of Korea

003 **ECT for the treatment resistant psychosis**
In-Won Chung, Republic of Korea

004 **ECT in catatonia**
Pascal Sienaert, Belgium

P-01 **POSTER TOUR**
13:00–14:30 Congress Hall A 1
Addictive disorders
Chair: *Fabricio Moreira, Brazil*

001 **Investigating the role of one-carbon metabolism pathway in complicated alcohol withdrawal states**
Karishma Kulkarni, India
M. Purushottam, P. Sharma, B. Viswanath, P. Chand, S. Jain, P. Murthy

002 **Binge drinking, mood and psychological well being in university students**
Thomas Heffernan, United Kingdom

003 **Brain activation patterns associated with cue reactivity in Internet gaming disorder**
Dai Jin Kim, Republic of Korea
J.-E. Jeong, J.-W. Chun, H. Cho

006 **The study on antidepressant-like effect of Acamprosate for depression with alcohol use disorder**
Masaya Tayama, Japan
T. Saito

010 **Study of dopamine transporter gene DAT1 / SLC6A3 Variable Number of Tandem Repeats (VNTR) polymorphism in complicated alcohol withdrawal and alcohol dependence syndrome in South Indian population: Case-control Genetic Association study**
Brij Kishore, Australia
P. Murthy, S. Jain, V. Benegal, M. Purushottam, K. Thennarasu, S. Devasenapathy, B. Shankarappa, A. Dahale

011 **DNA methylation signatures of chronic alcohol dependence in purified CD3+ T cells of patients undergoing alcohol treatment**
Vanessa Nieratschker, Germany
C. Brückmann, S. Islam, A. Batra, M. Kobor

014 **Reduced amplitude of executive control and front parietal networks reflects duration of illness in gambling disorder patients**
Kosuke Tsurumi, Japan
R. Kawada, J. Miyata, T. Murai, H. Takahashi

015 **Prescription opioid abuse disorder, comparing outcomes of different approaches**
Susana Patricia Gomes da Costa, Spain
G. Anmella, A. Giménez, J. E. Pinzón, C. Oliveras, P. Bruguera, P. Barrio, A. López, S. Mondon, M. Balcells, A. Lligoña

017 **A new vaccine for cocaine addiction: Preliminary results of the UFMG-VAC4N2 molecule**
Frederico Garcia, Brazil
P. Augusto, Â. de Fátima, L. Silva Neto, A. Godin, A. Freitas

020 **Hair cortisol concentration as risk marker for increased alcohol use following traumatic experiences**
Sebastian Trautmann, Germany
M. Muehlhan, S. Steudte-Schmiedgen

023 **Poor sleep quality and suicide attempt among adults with internet addiction: A nationwide community sample of Korea**
Eun-Jin Na, Republic of Korea
K. Kim, H. Lee, H.-J. Jeon

P-02 **POSTER TOUR**

13:00–14:30 Congress Hall A 1

Antipsychotics

Chair: Ofer Agid, Canada

001 **Weight gain and gut hormones in patients initiating clozapine**
Marina Garriga, Spain
A. Mallorqui, L. Serrano, C. Oliveira, M. Salamero, E. Vieta, M. Bernardo, C. García Rizo

002 **Cost- efficacy study in patients with psychotic disorder treated with an atypical depot antipsychotic**
Aida Alvarez Pedrero, Spain
B. Bote, C. Marin, R. De Alarcón, C. Lorenzo, J. Matías

003 **Toxicity after paliperidone overdose in an Asian patient: A case report**
Maria Marta Jalon Urbina, Spain
L. Gómez de Segura Iriarte, C. M. Rodriguez Mercado, L. Perez Gomez, L. Garcia Gonzalez, Emeterio Delgado , A. González Fernández

004 **Frequency of NMS diagnosis in calls to a National Telephone Information Service**
Ronald Gurrera, USA
G. Mortillaro, V. Velamoor, S. Caroff

006 **DECIDE Study: Effectiveness of shared decision making in treatment planning at discharge of inpatient with schizophrenia: 3 years of recruitment, full sample preliminary analysis**
Jose Maria Villagran Moreno, Spain
J. I. Pérez Revuelta, J. M. Mongil San Juan, J. Mestre Morales, F. González Sáiz

007 **DECIDE Study: Influence of share decisions making strategy on the antipsychotic treatment profile. Comparison of antipsychotic polytherapy in patients discharged after acute episode – UHSM, after one year follow up**
Jose Maria Villagran Moreno, Spain
F. González Sáiz, J. I. Pérez Revuelta, J. Mestre Morales, J. M. Pascual Paño

008 **Patient perceived participation in decision-making on their antipsychotic treatment: Evidence of validity and reliability of the Spanish version of COMRADE scale in a sample of schizophrenia spectrum disorder patients**
Jose Ildefonso Pérez Revuelta, Spain
C. Gutiérrez Santaló, G. Vaz Domínguez, J. M. Mongil San Juan, J. M. Villagran Moreno

009 **Satisfaction with antipsychotic as a medication: The role of the therapeutic alliance and patient perceived participation in decision making in a sample of schizophrenia spectrum disorder patients**
Jose Ildefonso Pérez Revuelta, Spain
M. L. Moreno Sánchez, F. J. Puerto Garrido, J. M. Pascual Paño, J. M. Villagran Moreno

010 **Assessment of the evidences regarding predictive biomarkers in clozapine-treated patients: A focus on research methodology**
Ferdinando Cerrato, Italy
L. Guizzaro, P. Scudellari, D. De Ronchi, M. Fabrazzo, A. R. Atti

011 **Genetic polymorphisms associated with constipation and anticholinergic symptoms in clozapine-treated patients**
Anssi Solismaa, Finland
O. Kampman, L.-P. Lyytikäinen, N. Seppälä, M. Viikki, N. Mononen, T. Lehtimäki, E. Leinonen

013 **How to combine risperidone with low-potency First Generation Antipsychotics (FGA): Decision making based on pharmacokinetic considerations**
Georgios Schoretsanitis, Switzerland
E. Haen, B. Stegmann, C. Hiemke, G. Gründer, M. Paulzen

014 **A case presentation of the reintroduction of clozapine in a patient who developed neutropenia: Taking risks for a greater benefit**
Jose Maria Villagran Moreno, Spain
J. I. Pérez Revuelta, C. Rodríguez Gómez

015 **Detoxifying enzymes are increased in aripiprazole-treated PC12 cells**
Miyuki Ota, Japan
G. Takami, Y. Kaneko, H. Nagasaki, Y. Kodani, A. Nakashima, K. Mori, A. Ota

016 **Control of symptoms and safety with the administration of paliperidone palmitate 3-month formulation**
José Ángel Alcalá Partera, Spain
A. B. Rico del Viejo, J. L. Prados Ojeda

018 **Efficacy of Lurasidone in schizophrenia: A systematic review and meta-analysis of RCTs with active comparators**
Tadashi Nosaka, Japan
K. Hagi, K. Hagi, A. Pikalov, A. Loebel, J. Kane

019 **Safety of Lurasidone in schizophrenia: A systematic review and meta-analysis of RCTs with active comparators**
Katsuhiko Hagi, Japan
T. Nosaka, A. Pikalov, A. Loebel, J. Kane

Scientific Programme / Monday, 19 June 2017

P-03 **POSTER TOUR**

13:00–14:30 Congress Hall A 1

Molecular Neurobiology

Chair: Simon Glerup, Denmark

001 **In vivo mitochondrial targeting exerts anxiolytic effects**
Michaela Filiou, Germany
M. Nussbaumer, J. Asara, L. Teplytska, M. Murphy, A. Chen, C. Turck

002 **Prenatal androgen exposure, OPRM1, and alcohol dependence in adulthood**
Jordan Gegenhuber, Germany
C. Mühle, J. Kornhuber, B. Lenz

003 **Binge drinking: A consequence of increased prenatal androgen exposure?**
Christiane Mühle, Germany
P. Bouna-Pyrrou, J. Kornhuber, B. Lenz

004 **Estradiol levels and variants in the estrogen receptor 1 gene in alcohol dependence**
Christiane Mühle, Germany
B. Barry, C. Weinland, B. Braun, J. Kornhuber, B. Lenz

007 **Seasonality-resilient individuals downregulate their cerebral serotonin transporter binding in winter while 5-HT levels appear unchanged: A longitudinal combined 11C-DASB and 11C-SB207145 PET study**
Brenda Elvira Munk McMahon, Denmark
M. Nørgaard, C. Svarer, S. Andersen, M. Madsen, W. Baaré, J. Madsen, V. G. Frokjaer, G. Knudsen

008 **No evidence for a role of the serotonin 4 receptor in normal personality traits: A positron emission tomography study**
Vibeke Høyrup Dam, Denmark
D. S. Stenbæk, P. Fisher, N. Hansen, L. V. Hjordt, V. G. Frokjaer

009 **Sex-related changes of plasma oxytocin levels in humans**
Donatella Marazziti, Italy
S. Baroni, F. Mucci, I. Moroni, A. Piccinni, V. Falaschi

011 **Hippocampal gene expression profiling of a transgenic mice model of Alzheimer Disease (3xTg APP/Bin1/COPS5)**
Iván Carrera, Spain
L. Fernandez Novoa, S. Seoane, C. Sampedro, M. Lackshmana, R. Cacabelos

012 **Effects of chronic ethanol abuse on endogenous retinoid homeostasis**
Vera Clemens, Germany
F. Regen, I. Heuser, J. Hellmann-Regen

014 **Evaluation of animals induced by prenatal exposure to valproic acid in behaviour and neurogenesis**
Tomoya Kinjo, Japan
M. Ito, K. Bolati, T. Suzuki, H. Arai

P-04 **POSTER TOUR**

13:00–14:30 Congress Hall A 1

Childhood & adolescent disorders

Chair: Pradeep Rao, Australia

001 **The effect of a behavioral level reward system on rates of agitation pro re nata medication administration, seclusion and restraints on an acute inpatient psychiatric unit for children and adolescents**
Timothy Rice, USA
Y. Kufert, E. Feldman, A. Walther, U. Anagboso, A. Kolevzon

003 **Pre- and perinatal complications in relation to oppositional-defiant and conduct disorder symptoms in the Avon Longitudinal Study of parents and children**
Hyun Ruisch, The Netherlands
A. Dietrich, J. Glennon, J. Buitelaar, P. Hoekstra

004 **Collecting youths' drawings as a diagnostic aid in acute care demonstrates feasibility**
Timothy Rice, USA
S. Berkson, E. Feldman, Y. Kufert, A. Walther, M. Hubert, A. Sterchele, A. Cohen, M. Abroms, J. Goltz

006 **Impulsivity in adult ADHD patients across schizophrenia and substance use disorders groups: A cross-sectional analysis**
Srinivas Kandrakonda, India
S. K. Jaiswal

007 **Grand rounds and professional development in adult psychiatry residency training: Illustration concerning a presentation of an adolescent with gender dysphoria and severe nonsuicidal self-injury**
Timothy Rice, USA
Y. Kufert, E. Feldman, P. Rosenfield

008 **Factors affecting psychiatric disorders in offspring of parents with Bipolar Disorder (BP) in South Korea**
Se-Hoon Shim, Republic of Korea
S.-W. Hahn

010 **Gender dysphoria and Autism spectrum disorder: A literature review**
Gabriela Safyer, USA
M. P. Trelles, T. Rice

011 **SorcS2 transduces Gaba(A) receptor subunit identity of inhibitory synapses**
Simon Mølgaard, Denmark
S. Boggild, S. Skeldahl, M. Ulrichsen, U. Bølcho, P. Madsen, A. Nykjær, J. Nyengaard, S. Glerup

012 **fNIRS and emotional dysregulation: Effect of Methylphenidate in children with Attention-Deficit Hyperactivity Disorder (ADHD)**
Maddalena Mauri, Italy
E. Maggioni, C. Sacchi, A. Crippa, E. Gatti, P. Brambilla, M. Molteni, M. Nobile

014 **Neuronal networks underlying emotional processing in children with Attention Deficit Hyperactivity Disorder (ADHD): An EEG study**
Eleonora Maggioni, Italy
M. Mauri, A. Crippa, C. Sacchi, E. Gatti, M. Molteni, M. Nobile, P. Brambilla

016 **The Comparison of Methylphenidate and Psychotherapy in Adult ADHD Study (COMPAS): How safe is methylphenidate or psychotherapy? Analysis of the adverse event data**
Bernhard Kis, Germany
M. Abdel-Hamid, E. Graf, M. Berger, L. Tebartz van Elst, H. Müller, A. Philipsen

017 **The relationship between symptomatic and functional changes of Korean children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) treated with OROS methylphenidate**
Dong-Ho Song, Republic of Korea
S.-B. Lee

019 **Sensory modulation and behavioral phenotypes observed in individuals with Williams syndrome in Japan**
Tomonari Awaya, Japan
R. Kimura, T. Kato, M. Nakata, K. Matsushima, T. Kato, K. Tomiwa, T. Heike, M. Hagiwara

020 **The Michigan peer-to-peer depression awareness campaign: School-based prevention to reduce the impact of depression among teens**
Sagar Parikh, USA
D. Taubman, L. Salazar, S. Salazar

021 **Altered fetal steroidgenesis and dysregulated placental immune response in a developmental vitamin D deficient rat model of autism**
Asad Ali, Australia
X. Cui, D. Eyles

P-05	POSTER TOUR
13:00–14:30	Congress Hall A 1
Depression 1	
Chair: *Paolo Brambilla, Italy*	

001 **Serum angiotensin-converting enzyme level is associated with multiple relapses in major depression: Preliminary study**
Ho-Young Sohn, Republic of Korea
M.-S. Kwon, B.-R. Kim

002 **Mental health coordination in Treatment-Resistant Depression (TRD): Two years of experience in Ciudad Real, Spain**
Carlos Rodriguez Gomez-Carreño, Spain
L. Beato, E. Segura

003 **Frontal brain asymmetry moderated by suicidal ideation in patients with major depressive disorder**
Seung-Hwan Lee, Republic of Korea
S.-C. Roh, S.-K. Kim, Y.-S. Park

004 **Neurofeedback of frontal response to emotional sentence in healthy subjects: A functional near-infrared spectroscopy study**
Toshio Matsubara, Japan

005 **Reduced fronto-subcortical white matter connectivity in association with suicidal ideation in major depressive disorder**
Hong-Jin Jeon, Republic of Korea
B.-Y. Lee, H.-K. Lee, H.-W. Kim, H.-U. Chi, J.-H. Lee, Y.-J. Chang

006 **Evaluating anhedonia as a potential endophenotype for major depressive disorder**
Harish Musaliarveettil Tharayil, India
M. Sidharthan

007 **Behavioural and hippocampal changes across the pre- to postpartum transition in rats**
Agnete Overgaard, Denmark
S. E. Lieblich, S. Wong, L. A. M. Galea, V. G. Frokjaer

009 **Serotonin receptor composition across the rat peripartum in a postpartum depression model**
Beatriche Henriksen, Denmark
A. Overgaard, V. G. Froekjaer

012 **How does affective cognition influence maternal sensitivity? A systematic review**
Ipshita Mukherjee, United Kingdom
M. Ramachandran, R. Elliott, K. Abel

Scientific Programme / Monday, 19 June 2017

013 **Effective antidepressant treatment with alternating intravenous racemic ketamine and electroconvulsive therapy in treatment resistant depression: A case report**
Lucie Bartova, Austria
A. Weidenauer, M. Dold, A. Naderi-Heiden, S. Kasper, M. Willeit, N. Praschak-Rieder

014 **The use of psychopharmacological augmentations and combination strategies in depressive patients treated in tertiary psychiatric centers: A systematic evaluation among 8 European countries**
Markus Dold, Austria
A. Kautzky, L. Bartova, U. Rabl, D. Souery, J. Mendlewicz, A. Serretti, S. Porcelli, J. Zohar, S. Montgomery, S. Kasper

015 **The efficacy, safety and tolerability of probiotics on depressive symptoms: Pilot study results**
Caroline Wallace, Canada
J. Foster, S. Kennedy, R. Milev

016 **A systematic review of the clinimetric properties of the 6-item version of the Hamilton Depression Rating Scale (HAM-D6)**
Nina Timmerby, Denmark
J. Husted Andersen, S. Søndergaard, S. Dinesen Østergaard, P. Bech

017 **Relationship between rapheal hypoechogenicity and personality as possible markers of a disposition to develop depressive and anxiety disorders**
Petr Silhán, Czech Republic
L. Hosák, M. Hýža, D. Pernicková, J. Vantuch, M. Jelínková, D. Skoloudík

019 **Aerobic exercise as add-on treatment in depressed inpatients improves cognitive domains but has no additional effect on emotional symptoms**
Christian Imboden, Switzerland
M. Gerber, J. Beck, U. Pühse, M. Hatzinger, E. Holsboer-Trachsler

020 **Cognitive complaints and predictors of perceived cognitive dysfunction in adults with major depressive disorder: Findings from the Cognitive Dysfunction in Asians with Depression (CogDAD) study**
Manit Srisurapanont, Thailand
Y. K. Yang, N. Z. Zainal, S. Jambunathan, Y. M. Mok, H.-N. Chan, C. D., Della, N. Amir, P. Kalita

021 **Discrepancy between objective and subjective cognition in adults with major depressive disorders**
Manit Srisurapanont, Thailand
S. Suttajit, K. Eurviriyanukul, P. Varnado

022 **Increased blood BDNF in healthy individuals with a family history of depression**
Ulla Knorr, Denmark
M. Greisen Søndergaard, P. Koefoed, A. Jørgensen, M. Fauerholt-Jepsen, M. Vinberg, L. Kessing

023 **Interaction of genetic risk and early life stress on risk of depression investigated in a nationwide, Danish case-cohort study**
Nis Palm Suppli, Denmark
E. Agerbo, K. K. Andersen, V. Manikandan, M. E. Benros, W. Thompson, T. Munk-Olsen, M. Nordentoft, P. B. Mortensen, K. L. Musliner

SA-01 INDUSTRY SPONSORED SATELLITE SYMPOSIUM

13:15–14:45 Auditorium 12

Sunovion Satellite Symposium

Please see page 78

T24: NEUROPATHOLOGY

TFS-02 WFSBP TASK FORCE SYMPOSIUM

15:00–16:30 Congress Hall A 3

Post-mortem findings across psychiatric disorders and their association with cognitive symptoms

Chair: *Andrea Schmitt, Germany*
Co-Chair: *Johann Steiner, Germany*

001 **Alterations in hippocampal oligodendrocyte and neuron number in patients with schizophrenia, Bipolar Disorder (BP) and major depression**
Peter Falkai, Germany

002 **GABAergic system impairment in the hippocampus and superior temporal gyrus of patients with paranoid schizophrenia**
Johann Steiner, Germany

003 **Presynaptic contributions to cognitive reserve**
William Honer, Canada

004 **Different changes in cortical muscarinic receptors in psychiatric and neurological disorders**
Andrew Gibbons, Australia

T32: PHARMACOGENETICS

TFW-01 **WFSBP TASK FORCE WORKSHOP**

15:00–16:30 Auditorium 12

Workshop of the WFSBP Task Force on genetics: Focus on pharmacogenomics

Chair: *Dan Rujescu, Germany*
Co-Chair: *Jim Kennedy, Canada*

001 **Pharmacogenetics in schizophrenia**
Rainald Mössner, Germany

002 **Largest genome wide association study on agranulocytosis under Clozapine**
Dan Rujescu, Germany

003 **Whole exom sequencing reveals risk factors in treatment resistant depression**
Alessandro Serretti, Italy

004 **Pharmacogenetic discoveries and applications in psychiatric populations**
Jim Kennedy, Canada

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-25 **SYMPOSIUM**

15:00–16:30 Auditorium 15

tDCS: From research to clinical practice

Chair: *Jerome Brunelin, France*

001 **Translational research on tDCS: Data from a German multisite project**
Frank Padberg, Germany

002 **Combining tDCS with neuroimaging**
Shirley Fecteau, Canada

003 **Effects of tDCS on biological reactivity to stress and decision making**
Jerome Brunelin, France

004 **Improvement of cognitive control with anodal tDCS: Translational perspectives for the treatment of depression**
Christian Plewnia, Germany

T33: PHARMACOLOGY

S-26 **SYMPOSIUM**

15:00–16:30 Auditorium 10

Into novel drugs for depression

Chair: *Erich Seifritz, Switzerland*

001 **Conceptual strategies of Big Pharma into innovation in psychiatric therapies: Future leads**
Siegfried Kasper, Austria

002 **Personalizing psychiatry treatment**
Florian Holsboer, Germany

003 **Psychedelic drugs and clinical markers as innovation road to psychopharmacotherapy**
Katrin Preller, Switzerland

004 **Gamma-hydroxybutyrate: neuropharmacology and implications for depression treatment**
Oliver G. Bosch, Switzerland

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-27 **SYMPOSIUM**

15:00–16:30 Auditorium 11

Beyond unitary models of psychosis: Confronting complex etiology and dimensionality

Chair: *Mikhail Pletnikov, USA*
Co-Chair: *John Waddington, Ireland*

001 **Recognising the dimensionality of psychotic illness: Broadening the phenotype to the affective domain**
Catherine Belzung, France

002 **Addressing the translational challenge of etiological diversity: Complex gene-environment interactions in risk for psychosis**
Mikhail Pletnikov, USA

003 **Closing the translational gap between heritability and genetics: Complex gene-gene interactions in risk for psychosis**
John Waddington, Ireland

004 **Extending the strategy for translation: Human induced pluripotent stem cells**
Kristen Brennand, USA

T11: DEPRESSION: BASIC / CLINICAL

S-28 **SYMPOSIUM**

15:00–16:30 B3 M3-M4

Wake and sleep electroencephalogramm provide biomarkers of depression

Chair: *Axel Steiger, Germany*
Co-Chair: *Thorsten Mikoteit, Switzerland*

001 **Central and autonomous nervous system activity in the prediction of antidepressant treatment**
Sebastian Olbrich, Switzerland

002 **The value of prefrontal theta cordance of resting EEG in the prediction of antidepressant response**
Martin Brunovsky, Czech Republic

003 **Novel REM-sleep derived biomarkers of depression**
Thorsten Mikoteit, Switzerland

Scientific Programme / Monday, 19 June 2017

004 **sLORETA derived from REM sleep EEG as biomarkers for treatment response in depression after antidepressant medication**
Marcel Pawlowski, Germany

T11: DEPRESSION: BASIC / CLINICAL

WS-04 **WORKSHOP**
15:00–16:30 B3 M1-M2
Rethinking depression in the Century XXI: Where are we now in biological psychiatry?
Chair: Victoria Valdez, Ecuador
Co-Chair: Adriana Rivetti, Argentina

001 **Genetics risk variants for major depressive disorder**
Alejo Corrales, Argentina

002 **Serotonergic hypothesis of depression: Is still up-to-date?**
Adriana Rivetti, Argentina

T22: MOLECULAR NEUROBIOLOGY

TFS-03 **WFSBP TASK FORCE SYMPOSIUM**
17:00–18:30 Congress Hall A 3
Update biomarkers in psychiatry
Chair: Peter Riederer, Germany
Co-Chair: Peter Falkai, Germany

001 **Biomarkers for schizophrenia**
Florence Thibaut, France

002 **Biological marker in alcoholism**
Toshikazu Saito, Japan

003 **Specifity of biomarkers for OCD / ADHD**
Edna Grünblatt, Switzerland

004 **Specifity of biomarkers for anxiety**
Borwin Bandelow, Germany

T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC / CLINICAL

S-29 **SYMPOSIUM**
17:00–18:30 Auditorium 12
Autism spectrum disorders in adults – from the clinical phenotype to the underlying neurobiology – novell technics such as phenotype-based genetic variants association studies, high field magnet resonance imaging and 3d brain organoids
Chair: Tanja Michel, Denmark
Co-Chair: Sophia Frangou, USA

001 **On the outcome, time course and clinical presentation of autism in adults: A longitudinal study of clinical trajectories**
Marlene Briciet Lauritsen, Denmark

002 **Accumulated common variants in the broader fragile X gene family modulate autistic phenotypes**
Hannelore Ehrenreich, Germany

003 **New insights from proteomics and nanotechnology- 3 D brain organoids: A promising new tool for an vitro model for ASD**
Tanja Michel, Denmark

004 **The role of myelination in neurodevelopmental disorders**
Sophia Frangou, USA

FC-04 **FREE COMMUNICATION SESSION**
17:00–18:30 B3 M1-M2
Neuroimaging 1
Chair: Glenda MacQueen, Canada
Co-Chair: Andreas J. Fallgatter, Germany

001 **Cortical excitability in a healthy human cohort of mutation carriers in Plasticity Related Gene 1**
Johann-Philipp Horstmann, Germany
S. Groppa, M. Muthuraman, A. Stroh, R. Nitsch, K. Lieb, H. J. Grabe, M. Lotze, J. Vogt, O. Tuescher

002 **Near-infrared Sprectoscopy (NIRS) neurofeedback in ADHD**
Andreas J. Fallgatter, Germany
B. Barth, J. Hudak, A.-C. Ehlis

003 **Child maltreatment is associated with altered NAA / Cr concentration at the anterior cingulate gyrus in children and adolescents**
Andrea Parolin Jackowski, Brazil
A. C. Milani, B. Foester, M. Feijó de Mello

004 **Dynamic response to 12 week antidepressant treatment follows a sigmoid function and is negatively correlated with anterior cingulate and prefrontal activation in major depression**
Christoph Kraus, Austria
M. Klöbl, B. Auer, M. Tik, I.-L. Stürkat, N. Geissberger, D. Pfabigan, M. Woletz, S. Kasper, C. Lamm, C. Windischberger, R. Lanzenberger

FC-05 FREE COMMUNICATION SESSION
17:00–18:30 B3 M3-M4
Psychoneuroimmunology
Chair: Brian Leonard, Ireland
Co-Chair: Frederico Garcia, Brazil

001 **Resting state dynamics during systemic inflammation in healthy men: Neural correlates of state anxiety in the variability of low frequency oscillations**
Franziska Labrenz, Germany
S. Benson, F. Ferri, M. Schedlowski, H. Engler, S. Elsenbruch, M. Costantini

002 **Autoantibodies against NMDAR1: Pathogenic potential despite diversity**
Bárbara Oliveira, Germany
E. Castillo-Gómez, M. Mitjans, D. Tapken, S. Bertrand, H. Pan, J. Steiner, R. Trippe, H. Prüss, W.-H. Zimmermann, D. Bertrand, M. Hollmann, H. Ehrenreich

003 **Autoantibodies reacting with oxytocin are associated with antenatal depression**
Frederico Garcia, Brazil
T. Castro e Couto, M. Brancaglion, R. Pereira, S. Caligiorne, M. Neves, H. Corrêa

004 **Elevated levels of Insulin-like Growth Factor-1 (IGF-1) in drug-naïve patients with psychosis**
Petros Petrikis, Greece
V. Boumba, A. Tzallas, P. Voulgari, P. Skapinakis, V. Mavreas

005 **C-Reactive Protein as a marker of inflammation in acute psychosis and schizophrenia**
Thomas Weickert, Australia
I. Jacomb, C. Stanton, R. Vasudevan, H. Powell, D. Liu, C. Galletly, R. Lenroot, M. O'Donnell, C. Weickert

ADVERT



Scientific Programme / Tuesday, 20 June 2017

▶ Tuesday, 20 June 2017

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-30 **SYMPOSIUM**
08:30–10:00 Auditorium 15
Recent insights in schizophrenia physiopathology and treatments
Chair: *Pierre-Michel Llorca, France*
Co-Chair: *Fabrice Berna, France*

001 **Bridging the gap between research and clinical practice: The development of a national network of schizophrenia expert centers**
Fabrice Berna, France
G. Fond

002 **Schizophrenia pathophysiology: Recent insights from neuroimaging on glutamatergic and neuroinflammatory mechanisms**
Oliver Howes, United Kingdom

003 **The influence of hormones on schizophrenia**
Iris Sommer, The Netherlands

004 **Novel adjunctive therapy approaches for inflammatory disturbances in psychiatric disorders**
Michael Berk, Australia

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-31 **SYMPOSIUM**
08:30–10:00 Congress Hall A 3
Duration of untreated psychosis: From neuroimaging to clinical trials
Chair: *John Kane, USA*
Co-Chair: *Erika Jaaskelainen, Finland*

001 **Is DUP a moderator of effectiveness with comprehensive specialty care in first episode schizophrenia?**
John Kane, USA

002 **The impact of DUP on short and long term outcomes in schizophrenia**
Erika Jaaskelainen, Finland

003 **Is there a relationship between DUP and brain structure?**
Aristotle Voineskos, Canada

004 **MRI resting state functional connectivity and DUP**
Deepak Sarpal, USA

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-32 **SYMPOSIUM**
08:30–10:00 Auditorium 12
New perspectives on transcranial magnetic stimulation in psychiatric disorders
Chair: *Shinsuke Kito, Japan*
Co-Chair: *Motoaki Nakamura, Japan*

001 **Transcranial magnetic stimulation in the treatment of bipolar depression**
Shinsuke Kito, Japan

002 **Clinical application of Quadripulse Stimulation (QPS) to major depression**
Motoaki Nakamura, Japan

003 **Neurophysiological correlates of various transcranial magnetic stimulation paradigms in patients with psychiatric disorders: In search of novel biomarkers**
Yoshihiro Noda, Japan

004 **Combination of computerized cognitive remediation and transcranial magnetic stimulation**
Akihiro Takamiya, Japan

T11: DEPRESSION: BASIC / CLINICAL

S-33 **SYMPOSIUM**
08:30–10:00 Auditorium 10
Epigenetic biomarkers for the diagnosis of mood disorders
Chair: *Tetsuro Ohmori, Japan*
Co-Chair: *Lourdes Fañanás, Spain*

001 **DNA methylation profiles of the Brain-derived Neurotrophic Factor (BDNF) gene as a potent diagnostic biomarker in major depression**
Manabu Fuchikami, Japan

002 **Antenatal prediction of postpartum depression with blood DNA methylation biomarkers**
Zachary Kaminsky, USA

003 **Blood diagnostic biomarkers for major depressive disorder using multiplex DNA methylation profiles**
Shusuke Numata, Japan

004 **Differential methylation and variable methylation in depression: A genome-wide analysis of monozygotic twins**
Aldo Cordova-Palomera, Spain

T40: PSYCHOPATHOLOGY

S-34 **SYMPOSIUM**

08:30–10:00 Auditorium 11

Sex hormones and their wide-ranging effects on psychopathology

Chair: *Andrea Gogos, Australia*
Co-Chair: *Mark Geyer, USA*

001 **Estrogen, raloxifene and schizophrenia**
Cyndi Shannon Weickert, Australia

002 **Cortical gene expression changes underlying estrogen's effect in schizophrenia**
Andrea Gogos, Australia

003 **17b-estradiol effects on psychosis-like attentional abnormalities in rats**
Ina Weiner, Israel

004 **Sex differences in depression: The role of neuro-estrogens**
Christina Dalla, Greece

T27: OBSESSIVE-COMPULSIVE DISORDERS: BASIC / CLINICAL

S-35 **SYMPOSIUM**

08:30–10:00 B3 M3-M4

New insights into the neurobiology and treatment aspects of obsessive compulsive disorder comorbid with schizophrenia and bipolar affective disorder

Chair: *E. Mohandas Warrier, India*
Co-Chair: *Narayan R. Mutalik, India*

001 **Neurobiology of obsessive compulsive disorder comorbid with schizophrenia**
Narayan R. Mutalik, India

002 **Evidence based management of obsessive compulsive disorder comorbid with schizophrenia**
Firoz Kazhungil, India

003 **Neurobiology of obsessive compulsive disorder comorbid with bipolar disorder**
Rajan Nishanth Jayarajan, Australia

004 **Recent updates in the management of obsessive compulsive disorder comorbid with Bipolar Disorder (BP)**
Pawan Sharma, Nepal

T43: SCHIZOPHRENIA: BASIC / CLINICAL

WS-05 **WORKSHOP**

08:30–10:00 B3 M1-M2

Gesture as window to psychosis pathobiology: From aberrant body experience to social interaction

Chair: *Sebastian Walther, Switzerland*
Co-Chair: *Vijay Mittal, USA*

001 **Schizophrenia in the flesh: Empirical studies of anomalous bodily self experiences**
So-Hee Park, USA

002 **Impaired gesture performance in schizophrenia: Neurobiology and clinical consequences**
Sebastian Walther, Switzerland

003 **The neural correlates of natural social-communicative perception processes in patients with schizophrenia: Understanding, recognition and interpretation of verbal and non-verbal information**
Benjamin Straube, Germany

004 **What can gesture-speech mismatch tell us about pathophysiology underlying psychosis-risk syndromes?**
Vijay Mittal, USA

PL-02 **PLENARY SESSION**

10:15–11:00 Auditorium 15

Ketamine: Translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders

Chair: *Gregers Wegener, Denmark*
Speaker: *Carlos Zarate, USA*

D-02 **DEBATE**

11:15–12:45 Auditorium 15

The Research Domain Criteria (RDoC) can create a new kind of taxonomy holding greater promise compared to the traditional Nosological Classification Systems in psychiatry

Chair: *Sabine Herpertz, Germany*
Proponent: *Henrik Walter, Germany*
Opponent: *Henning Saß, Germany*

Scientific Programme / Tuesday, 20 June 2017

T45: SLEEP DISORDERS: BASIC / CLINICAL

TFS-04 WFSBP TASK FORCE SYMPOSIUM
11:15 – 12:45 Congress Hall A 3
Sleep in depression and cognition – from research to clinical practice
Chair: *Edith Holsboer-Trachsler, Switzerland*
Co-Chair: *Birendra N. Mallick, India*

001 **Sleep as biomarker: Predictor of emotional regulation and depression**
Martin Hatzinger, Switzerland

002 **Sleep in dementia: A biomarker of cognition?**
Dimitris Dikeos, Greece

003 **Sleep and synaptic dysfunction in depression**
Anne Eckert, Switzerland

004 **REM sleep and prevention of neurodegeneration: Role of noradrenaline**
Birendra N. Mallick, India

T9: COGNITIVE NEUROSCIENCE

S-36 SYMPOSIUM
11:15 – 12:45 Auditorium 12
The role of the nucleus accumbens in psychiatry
Chair: *Jens Kuhn, Germany*
Co-Chair: *Leonhard Schilbach, Germany*

001 **The anatomy of the nucleus accumbens**
Ioannis Mavridis, Greece

002 **The role of nucleus accumbens in social cognition**
Leonhard Schilbach, Germany

004 **Deep brain stimulation of the nucleus accumbens**
Sina Kohl, Germany

T11: DEPRESSION: BASIC / CLINICAL

S-37 SYMPOSIUM
11:15 – 12:45 Auditorium 10
Neurobiologic imaging studies of mood disorders, neurogenetics and antidepressant action with positron emission tomography
Chair: *J. John Mann, USA*
Co-Chair: *Gitte Moos Knudsen, Denmark*

001 **Familial transmission of 5-HT1A autoreceptor up-regulation: An impaired serotonnergic endophenotype in mood disorders**
J. John Mann, USA

002 **Molecular neuroimaging and genetics**
Gitte Moos Knudsen, Denmark

003 **Predictiveness of clinical and peripheral markers for PET measurement of monoamine oxidase A: Implications for biomarker development in major depressive disorder and prevention of postpartum depression**
Jeffrey Meyer, Canada

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-38 SYMPOSIUM
11:15 – 12:45 Auditorium 11
Treatment resistant schizophrenia: Definitions, psychobiology and clinical treatment
Chair: *John Kane, USA*
Co-Chair: *Ofer Agid, Canada*

001 **Methodological issues in clinical trial designs for TRS**
John Kane, USA

002 **A longitudinal perspective on the evolution of treatment resistance**
Ofer Agid, Canada

003 **The biology of treatment resistance**
Oliver Howes, United Kingdom

004 **Definitions and epidemiology of treatment resistance**
Christoph U. Correll, USA

T49: SUICIDE: BASIC / CLINICAL

WS-06 WORKSHOP
11:15 – 12:45 B3 M1-M2
Neurobiology of suicidal behaviour
Chair: *Leo Sher, USA*
Co-Chair: *Zoltan Rihmer, Hungary*

001 **Testosterone and suicidal behavior in men and women**
Leo Sher, USA

002 **Suicide in men: Clinical and biological correlates**
Zoltan Rihmer, Hungary

003 **Neuroinflammatory biomarkers of suicidal behavior**
Jussi Jokinen, Sweden

004 **Endophenotypes of suicidal behavior for genetic research**
Xénia Gonda, Hungary

T51: MISCELLANEOUS

WS-08 **WORKSHOP**

11:15–12:45 B3 M3-M4

Functional neuroanatomy of hallucinations

Chair: *Rajesh Nagpal, India*

Co-Chair: *Harishchandra Gambheera, Sri Lanka*

001 **Functional neuroanatomy of auditory hallucinations**
E. Mohandas Warrier, India

002 **Neural signature of visual hallucinations**
Venu Gopal Jhanwar, India

003 **Neural mechanisms of somatic, musical and extracampine hallucinations**
Anukant Mital, India

004 **The neural signature overlap between delusions and hallucinations**
Debashis Ray, India

P-06 **POSTER TOUR**

13:00–14:30 Congress Hall A 1

Depression 2

Chair: *Poul Videbech, Denmark*

003 **Early Serum-BDNF-Increase is facilitated by aerobic exercise and associated with lower insomnia severity after 6 weeks of inpatient treatment for depression**
Christian Imboden, Switzerland
J. Beck, M. Gerber, A. Eckert, U. Pühse, E. Holsboer-Trachsler, M. Hatzinger

005 **Effects of the adenosine A(1) receptor neurotransmission on hyper-emotionality of olfactory bulbectomized rat**
Yuma Ogushi, Japan
L. Gotoh, K. Kira, T. Kawaguchi, A. Hatanaka, H. Kawasaki

007 **Risk markers for recurrence in major depression**
Marcus Ising, Germany
P. Belcredi, S. Scheuer, M. Wierzyk, M. Uhr, S. Lucae, F. Holsboer

008 **Attenuation of deficits in behaviour and microglia population in male high anxiety-related behaviour rats by minocycline**
Anna-Kristina Schmidtner, Germany
V. Malik, B. Di Benedetto, D. Slattery, I. Neumann

009 **Hippocampal protein turnover alterations in response to paroxetine treatment**
Michaela Filiou, Germany
C. Webhofer, C. Guillermier, C. Poczatek, A. Chen, C. Turck, C. Lechene

010 **Positron emission tomography assessment of Ketamine binding on the Serotonin transporter in humans**
Marie Spies, Austria
G. James, N. Berroterán Infante, H. Ibeschitz, J. Unterholzner, M. G. Godbersen, J. Jungwirth, M. Mitterhauser, W. Wadsak, S. Kasper, R. Lanzenberger

011 **A pharmacogenetic marker in DISP1 is not associated with antidepressant response in obsessive-compulsive disorder**
Gwyneth Zai, Canada
A. Lisoway, K. Wigg, D. Zhang, N. Freeman, D. Mueller, J. Kennedy, M. Richter

012 **Vortioxetine for the treatment of depression: A systematic review and meta-analysis**
Chi-Un Pae, Republic of Korea

013 **Correlations between middle-term outcome of major depressive disorder and metabolic syndrome**
Tudor Udristoiu, Romania
A. L. Chirita, F. Militaru, I. Udristoiu, S. Ristea

014 **Effects of the proton pump inhibitors omeprazole and pantoprazoleon the cytochrome P450 mediated metabolism of Venlafaxine**
Michael Paulzen, Germany
M. Kuzin, E. Haen, C. Hiemke, G. Gründer, G. Schoretsanitis

015 **Measures of daily mood, stress and reward responses in offspring of depressed parents**
Matthias Guillod, Switzerland
C. Gaillard, R. Recabarren, D. Schoebi, M. Merlo, G. Hasler, C. Martin-Soelch

016 **Does cortisol awakening response indicate the impact of poor sleep on next day's negative affect?: An event sampling study on major depression and controls**
Thorsten Mikoteit, Switzerland
C. Imboden, F. Maier, M. Hatzinger, E. Holsboer-Trachsler, R. Lieb, A. Gloster

017 **Evaluation of affective temperaments, depression and anxiety in different hypertensive conditions**
Xénia Gonda, Hungary
D. Batta, B. Körösi, A. Lászlo, A. Tabák, D. Eörsi, P. Torzsa, O. Cseprekal, A. Tisler, Z. Nemcsik-Bencze, Z. Rihmer, J. Nemcsik

Scientific Programme / Tuesday, 20 June 2017

018 **Exp-ECT: The impact of patients' expectation on effectiveness and tolerability of electroconvulsive therapy**
David Zilles, Germany
M. Belz, M. Besse, L. Krech, I. Methfessel, D. Wedekind

019 **Anxiety attacks with or without life threatening situations, major depressive disorder, and suicide attempt: A nationwide community sample of Korean adults**
Hye-Won Kim, Republic of Korea
K.-W. Kim, K.-W. Choi, H.-J. Jeon

021 **Prevalence and use of mental health services among subjects with comorbid mood and anxiety disorders among Brazilians**
Sergio Blay, Brazil
G. Fillenbaum, M. Mello, M. Quintana, J. Mari, R. Bressan, S. Andreoli

022 **Cholecalciferol treatment reverses depression-like behavior and corticosterone levels in female rats with experimental model of menopause**
Julia Fedotova, Russia
S. Pivina, A. Sushko

P-07 **POSTER TOUR**
13:00–14:30 Congress Hall A 1
Inflammation
Chair: Michael Maes, Thailand

001 **Dyslipidemia in adolescents with early onset psychosis**
Kirsten Wedervang-Resell, Norway
V. Lonning, R. Smelror, K. B. Holven, S. Ulven, I. Agartz, A. M. Myhre

002 **A randomized controlled trial of mindfulness-based cognitive therapy for youth living with Inflammatory Bowel Disease (IBD) and depression**
Tatjana Ewais, Australia
J. Begun

003 **Retinoic acid signaling in anti-inflammatory effects of minocycline**
Vera Clemens, Germany
F. Regen, I. Heuser, J. Hellmann-Regen

004 **Immune system dysregulation in the pathogenesis of first-onset postpartum psychosis: Clues from peripheral markers**
Gopinath Sathyanarayanan, India
H. Thippeswamy, R. Mani, M. M. Venkataswamy, M. Kumar, M. Philip, P. S. Chandra

005 **C-reactive protein and white blood cell levels in schizophrenia, Bipolar Disorders (BP) and depression and associations with mortality and psychiatric outcomes: A Danish population-based study**
Henriette Thisted Horsdal, Denmark
O. Köhler, M. Eriksen Benros, C. Gasse

006 **C-reactive protein levels and associations with treatment resistance in schizophrenia: A Danish population-based study**
Henriette Thisted Horsdal, Denmark
T. Wimberley, M. Eriksen Benros, C. Gasse

007 **A case report of comorbid schizophrenia and psoriasis that illustrates the potential relationship between response to antipsychotics and inmunity**
Guillermo Joaquín Hönig, Argentina
S. Wikinski

008 **Serum inflammatory biomarkers are adjunct diagnostic tools for schizophrenia in clinical practice**
Shohei Nishimon, Japan
T. Ohnuma, Y. Takebayashi, N. Katsuta, M. Takeda, T. Nakamura, T. Sannohe, R. Higashiyama, A. Kimoto, N. Shibata, H. Arai

011 **Serum high-sensitivity C-reactive protein, risk of cardiovascular disease, and disease stages in patients with schizophrenia**
Jeffrey Yao, USA
R. Reddy, J. Gurklis, A. Sonel, E. Sonel, B. Kisslinger, R. Chengappa, M. Keshavan, G. Haas

012 **Peripheral levels of a pro-inflammatory metabolite in the arachidonic acid cascade differentiate pharmacotherapy resistant from pharmacotherapy responding major depressive disorder patients**
Fotini Boufidou, Greece
M. Zoga, P. Oulis, V. G. Masdrakis, P. Pliatsika, S. Foteli, C. Nikolaou

P-08 **POSTER TOUR**
13:00–14:30 Congress Hall A 1
Neuroimaging
Chair: Gitte Moos Knudsen, Denmark

001 **Brain-behavior correlation in a high risk for psychiatric disorders Brazilian cohort: A replication study**
Andrea Jackowski, Brazil
A. Zugman, E. Trejos-Castillo, A. Mastergeorge

002 **Correlation between hypothalamus and third ventricle of patients with affective disorders**
Marie Stroske, Germany
S. Schindler, M. Storch, S. Geyer, P. Schönknecht

003 **Color up your MRI! – Performance of intensity standardisation techniques with 7T high-resolution MRIs**
Stephanie Schindler, Germany
J. Schreiber, P.-L. Bazin, R. Trampel, A. Anwander, S. Geyer, P. Schönknecht

004 **Hypothalamic enlargement in mood disorders – high-resolution in-vivo evidence**
Stephanie Schindler, Germany
L. Schmidt, M. Stroske, M. Storch, A. Michaljov, U. Hegerl, S. Geyer, P. Schönknecht

006 **Higher daily cortisol concentration predicts enhanced functional connectivity between amygdala and hippocampus during emotional processing**
Yuko Hakamata, Japan
S. Komi, Y. Moriguchi, S. Izawa, Y. Motomura, E. Sato, S. Mizukami, Y. Kim, T. Hanakawa, Y. Inoue, H. Tagaya

007 **Amygdala reactivity to fearful faces correlates positively with impulsive aggression**
Sofi Da Cunha-Bang, Denmark
P. Fisher, L. Vadskjaer Hjordt, K. Holst, G. Knudsen

008 **Severity of past aggression coupled to higher baseline oxygenated hemoglobin in right dorsolateral prefrontal cortex in schizophrenia**
Anette Johansson, Sweden
A.-N. Hellsing, L. Harmat, M. Kristiansson, H. Fischer, L. Högman

009 **Increases in dopamine transporter binding potential in amygdala in social anxiety disorder: A case-control study using positron emission tomography**
Olof Hjorth, Sweden
A. Frick, J. Motilla-Hoppe, M. Gingnell, V. Faria, J. Engman, I. Alaie, K. Wahlstedt, M. Jonasson, M. Lubberink, M. Fredrikson, T. Furmark

010 **Mindfulness effects on high and low trait-anxiety: A neuroimaging study**
Guido Bondolfi, Switzerland
Y. Cojan, M. Desseilles, F. Jermann, B. Weber, S. Schwartz, P. Vuilleumier

011 **Interoceptive processing as a white matter correlates of anxiety sensitivity in panic disorder**
Sang-Hyuk Lee, Republic of Korea
M.-K. Kim, B. Kim, T.-K. Choi

012 **Brain volumetric abnormalities in recent first episode manic patients with Bipolar I Disorder (BD)**
Trisha Chakrabarty, Canada
S. S. Arumugham, I. Torres, D. J. Lang, W. Su, W. Honer, R. Lam, L. Yatham

014 **Brain areas processing chronic pain in patients with fibromyalgia: A case-control study using resting state arterial spin labelling**
Monika Mueller, Switzerland
F. Wuethrich, A. Federspiel, R. Wiest, M. Curatolo, S. Walther

015 **Role of neuroimaging in depression with incomplete response and cognitive and social dysfunction**
Tudor Udristoiu, Romania
I. Marinescu, F. Militaru, I. Udristoiu, D. Marinescu

016 **Regulation of neural responses to emotion perception by mobile-based self-help therapy for major depressive disorder**
Bo-Ram Kim, Republic of Korea

017 **Effectiveness verification of CBT program based on mobile application for depression**
Da-Som Park, Republic of Korea

018 **Brain tumor-associated first episode psychosis with severe self-mutilation and extensive religious determination: A case report**
Lars Dutschke, Switzerland
S. Steinau, R. Wiest, S. Walther

019 **Multivariate classification of schizophrenia by local activity features of resting-state fMRI**
Kyoung-Uk Lee, Republic of Korea
C.-H. Park, J.-H. Lee, S. J. Lee, K.-C. Paik

020 **Primary auditory cortex relative surface area alteration and its correlation with hallucination and disease severity in schizophrenia**
Kyoung-Uk Lee, Republic of Korea
J.-H. Oh, K.-C. Paik

021 **Sexual-dimorphism of the planum temporale in schizophrenia: An MRI study**
Alessandro Pigoni, Italy
G. Delvecchio, C. Perlini, M. Barillari, M. Ruggeri, A. C. Altamura, M. Bellani, P. Brambilla

022 **White matter maturation and the association with cognitive domains in children at genetic risk for schizophrenia**
Amanda Lyall, USA
Z. Fitzgerald, O. Pasternak, N. Somes, E. Molokotos, R. Mesholam-Gately, H. Thermenos, S. Whitfield-Gabrieli, J. Gabrieli, M. Keshavan, M. Kubicki, L. Seidman

023 **Connectivity within and between brain areas of the mirror neuron system in schizophrenia**
Yuliya Zaytseva, Czech Republic
M. Bendova, F. Spaniel, J. Horacek

Scientific Programme / Tuesday, 20 June 2017

024 **The normalization of brain F-18-FDG hypometabolism following electroconvulsive therapy in a woman with treatment-resistant depression: Case report**
Se-Hoon Shim, Republic of Korea
J.-S. Kim

025 **Effects of Neurexan® on emotional brain response**
Luisa Fensky, Germany
A. Kühnel, V. Teckentrup, M. Schultz, Y. Fan, M. Walter

026 **Neurexan® influences stress-induced activity of the anterior cingulate cortex and associated brain regions**
Anne Kuehnel, Germany
Y. Fan, L. Fensky, V. Teckentrup, M. Schultz, M. Walter

P-09 **POSTER TOUR**
13:00–14:30 Congress Hall A 1
Bipolar disorder
Chair: Andrew A. Nierenberg, USA

001 **Probable postpartum hypomania and depression in a South African cohort**
Leigh van den Heuvel, South Africa
J. Pingo, B. Vythylingum, S. Seedat

002 **Garcinia mangostana linn (mangosteen) pericarp as an add-on treatment for bipolar depression**
Melanie Ashton, Australia
M. Berk, C. Ng, M. Hopwood, O. Dean

003 **Neurocognitive profile, personality, temperament and creativity in euthymic patients with Bipolar Disorder (BP) and major depressive disorder**
Nam-Woo Kim, Republic of Korea
E.-Y. Kim, S.-H. Kim, H.-J. Lee, Y.-M. Ahn

004 **Obvious impairment of attention and processing speed in patients with schizoaffective disorder**
Chih-Ken Chen, Taiwan
L.-J. Wang

005 **Bipolar Disorder (BP) and pregnancy desire**
Isaac Gonzalez Gonzalez, Spain
A. Hernández Dorta

006 **Eating disorders in Bipolar Disorder I (BP)**
Nuria Corominas, Spain
D. Alberca, S. Alberca

007 **Modeling mitochondrial damage in human neuronal cells by various concentrations of two mitochondrial complex inhibitors**
Nofar Shemesh, Israel
O. Damri, T. Bar-Yosef, G. Las, G. Agam

009 **Cognitive Subgroups in First Episode Bipolar I Disorder: Relation to Clinical and Brain Volumetric Variables**
Trisha Chakrabarty, Canada
I. Torres, L. Yatham

011 **High consumption of caffeine and maniac episode**
Alejandro Hernández Dorta, Spain
I. Gonzalez Gonzalez

012 **Effects of cognitive remediation for bipolar disorders on neurocognition and psychosocial functioning: results of a randomized controlled study**
Clemence Isaac, France
M.-C. Castillo, F. Durand, O. Bolloré, S. Braha-Zeitoun, V. Moulier, D. Januel

013 **The association between school achievement and subsequent development of Bipolar Disorder (BP)**
Steffie Damgaard Pedersen, Denmark
L. Petersen, O. Mors, S. Dinesen Østergaard

014 **International multisite survey of Internet use by patients with Bipolar Disorder (BD): Use of online support groups**
Rita Bauer, Germany
T. Glenn, J. Conell, M. Bauer

015 **Drugs used to treat Bipolar Disorder (BP) act via microRNAs to regulate expression of genes involved in neurogenesis and neurite outgrowth**
Srisaiyini Kidnapillai, Australia
B. Wade, C. Bortolasci, B. Panizzutti, B. Spolding, T. Connor, A. Sanigorski, T. Crowley, S. Jamain, L. Gray, M. Leboyer, M. Berk, K. Walder

016 **Can a gene expression signature be used to identify drugs that may be repurposed for Bipolar Disorder (BP)?**
Chiara Bortolasci, Australia
S. Kidnapillai, B. Panizzutti, B. Spolding, T. Connor, A. Sanigorski, T. Crowley, S. Jamain, L. Gray, M. Leboyer, M. Berk, K. Walder

017 **Volumetric integrity of the pituitary gland in Bipolar Disorder (BP)**
Gian Mario Mandolini, Italy
G. Delvecchio, C. Perlini, M. Barillari, M. Ruggeri, A. C. Altamura, M. Bellani, P. Brambilla

018 **BDNF and COMT polymorphism with lithium response in bipolar disorder: a pharmacogenetic association study**
Pradip Paul, India
R. K. Nadella, S. Sen, V. Kapur, D. S. Vartak, R. Nayak, D. Raveendranathan, N. S. Moily, L. N. Kota, B. Viswanath, M. Purushottam, Y. C. Janardhan Reddy, S. Jain

019 **Structural and functional correlates of serum Soluble IL-6 receptor level in patients with Bipolar Disorder (BP)**
Ya-Mei Bai, Taiwan
P.-C. Tu, C.-T. Li, T.-P. Su

020 **Does N-acetylcysteine decrease oxidative stress biomarkers in urine among patients suffering from Bipolar Disorder (BP)?**
Pernille Kempel Ellegaard, Denmark
R. W. Licht, H. E. Poulsen, C. T. Nielsen

P-10 **POSTER TOUR**
13:00–14:30 Congress Hall A 1
Schizophrenia 1
Chair: Oliver Howes, United Kingdom

001 **Schizotypy in ultra-high risk for psychosis: Its relations with basic symptoms**
Suk-Kyoon An, Republic of Korea
M.-J. Bang

002 **Low level of paraoxonase 1 activity and increased proinflammatory and anti-inflammatory cytokines are associated in drug naïve first episode psychosis**
Chiara Bortolasci, Australia
K. Landucci, F. Brinholi, C. de Farias, L. Higachi, E. Moreira, C. Noto, M. Maes, D. Barbosa

003 **Amisulpride switching in schizophrenic patients who showed suboptimal effect and/or tolerability to current antipsychotics in a naturalistic setting: An explorative study**
Jung-Jin Kim, Republic of Korea
J.-E. Jeong, Y.-M. Kim, S.-M. Wang, K.-P. Kwak, H.-K. Yoon, C.-U. Pae, W.-M. Bahk

004 **Clinical assessment interview for negative symptoms: Validation of the Czech version**
Ladislav Hosák, Czech Republic
K. Hosakova, L. Viktorova, M. Lecbych

005 **Gesture performance as a possible trait marker in schizophrenia: Test-retest reliability of gesture performance in schizophrenia patients, unaffected relatives and healthy controls**
Sarah Eisenhardt, Switzerland
K. Stegmayer, J. Moor, T. Vanbellingen, S. Bohlhalter, S. Walther

006 **Relationship between symptom severity and vitamin D deficiency in first-episode psychosis**
Ricardo Coentre, Portugal
C. Gois, M. L. Figueira, M. Talina

007 **Differences in social functioning among patients with major psychiatric disorders: Interpersonal communication is impaired in patients with schizophrenia and correlates with an increase in schizotypal traits**
Takamitsu Shimada, Japan
K. Ohi, T. Yasuyama, T. Uehara, Y. Kawasaki

008 **First episode of schizophrenia is followed by changes in activity of blood amine oxidases**
Marat Uzbekov, Russia
V. Brilliantova, S. Shikhov, E. Skokina

009 **Validation of the Comprehensive ICF Core Set for schizophrenia from the perspective of psychiatrists**
Laura Nuño Gómez, Spain
M. Barrios, E. Rojo, J. Gómez Benito, G. Guilera

011 **Effect of brexpiprazole on long-term remission in adults with schizophrenia: Results from a randomized, double-blind, placebo-controlled, maintenance study**
Emmanuelle Weiller, Denmark
M. Hobart, S. Pfister, A. Forbes, J. Ouyang, C. Weiss

013 **Clozapine use rate influenced by seasonal birth and onset age: Big data analysis of Korean patients with schizophrenia**
Seung-Hwan Lee, Republic of Korea
J.-S. Kim, S.-W. Hahn, W.-Y. Jung, Y.-M. Jae

014 **Relevant areas of functioning in schizophrenia: From what perspective?**
Oscar Pino López, Spain
M. Barrios, G. Guilera, E. Rojo, J. Gómez

015 **Short-term and long-term efficacy of brexpiprazole in adults with schizophrenia: Effect across Marder factors**
Catherine Weiss, USA
A. Forbes, M. Hobart, S. Pfister, J. Ouyang, E. Weiller

016 **Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: The REAP-AP4 study**
Shih-Ku Lin, Taiwan

017 **Factors affecting quality of life and family burden among the families of patients with schizophrenia**
Chul-Eung Kim, Republic of Korea

019 **Negative symptoms of schizophrenia: there will be a potential role for antidepressants? – a case report**
Raquel Serrano, Portugal
H. Medeiros, J. Ramos, T. Maia

Scientific Programme / Tuesday, 20 June 2017

SA-02 INDUSTRY SPONSORED SATELLITE SYMPOSIUM

13:15–14:45 Auditorium 12

Actelion Satellite Symposium

Please see page 78

ES-02 EDUCATIONAL SESSION

14:00–18:00 B3 M1-M2

Pharmacological treatment and non-invasive brain stimulation

Chair: Florence Thibaut, France
Chair: Frederico Garcia, Brazil

001 **Evidence-based treatment of anxiety disorders**
Borwin Bandelow, Germany

002 **Pharmacological treatment of bipolar disorders**
Andrew A. Nierenberg, USA

003 **Efficacy and safety of antipsychotics in children and adolescents with severe mental disorders**
Christoph U. Correll, USA

004 **TDCS (Transcranial Direct Current Stimulation) and TMS (repetitive Transcranial Magnetic Stimulation)**
Shirley Fecteau, Canada
Jerome Brunelin, France

Start of workshop

T43: SCHIZOPHRENIA: BASIC / CLINICAL

TFS-05 WFSBP TASK FORCE SYMPOSIUM

15:00–16:30 Congress Hall A 3

Biomarkers for schizophrenia: From molecules to brain function. A consensus of the WFSBP Task Force on biological markers

Chair: Andrea Schmitt, Germany
Co-Chair: Daniel Martins de Souza, Brazil

001 **Genetic biomarkers**
Dan Rujescu, Germany

002 **Neuroimaging biomarkers**
Joseph Kambeitz, Germany

003 **Molecular biomarkers**
Daniel Martins de Souza, Brazil

004 **Cognition biomarkers**
Peter Falkai, Germany

T13: EMERGENCY PSYCHIATRY

TFW-02 WFSBP TASK FORCE WORKSHOP

15:00–16:30 Auditorium 12

WFSBP Consensus on the management of agitation in psychiatry

Chair: Siegfried Kasper, Austria
Co-Chair: Eduard Vieta, Spain

001 **Agitation: Causes and differential diagnosis**
Marina Garriga, Spain

002 **Agitation in schizophrenia**
Dieter Naber, Germany

003 **Agitation in Bipolar Disorder (BP)**
Lakshmi Yatham, Canada

004 **WFSBP Consensus on agitation in psychiatry**
Eduard Vieta, Spain

T1: ADDICTIVE DISORDERS

S-39 SYMPOSIUM

15:00–16:30 Auditorium 10

Current research on the use of cannabinoids

Chair: Aviv Weinstein, Israel
Co-Chair: Amine Benyamina, France

001 **Cannabis use disorder and its effects on cognitive function**
Valerie Curran, United Kingdom

002 **The relationship between cannabis and psychosis**
Deepak Cyril D'Souza, USA

003 **The genetics of cannabis use disorder**
Amine Benyamina, France

004 **The effects of chronic use of synthetic cannabinoids on executive brain function**
Aviv Weinstein, Israel

T10: DEMENTIA: BASIC / CLINICAL

S-40 SYMPOSIUM

15:00–16:30 Auditorium 11

Alzheimer's Disease (AD) pathophysiology, prevention and treatment strategies: Where we stand and where we go?

Chair: Jerzy Leszek, Poland
Co-Chair: Ramón Cacabelos, Spain

001 **Pharmacogenetics of cerebrovascular phenotypes of risk in dementia**
Ramón Cacabelos, Spain

002 **Insulin resistance in neurodegeneration: The role of p53 / miRNA / SIRT1 axis**
Kazimierz Gasiorowski, Poland

003 **Alzheimer drug discovery: Targeting synaptic glutamate signaling**
Markku Kurkinen, USA

004 **Nanotechnology for early detection and treatment of Alzheimer's Disease (AD): Where we stand and where we go?**
Jerzy Leszek, Poland

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-41 **SYMPOSIUM**
15:00–16:30 B3 M3-M4
Electroconvulsive therapy for depression – optimising treatment and maintaining recovery
Chair: Declan McLoughlin, Ireland
Co-Chair: Pascal Sienaert, Belgium

001 **The KEEP-WELL Trial: Ketamine for depression relapse prevention following ECT (NCT02414932)**
Declan McLoughlin, Ireland

002 **Immediate and long-term outcomes for Brief-pulse (BP) vs Ultrabrief-pulse (UBP) high-dose unilateral ECT: The ResPECT trials' experience**
Pascal Sienaert, Belgium
H.-P. Spaans, E. Verwijk, F. Bouckaert

003 **Pre- and post-ECT cognitive performance as predictors for outcome and relapse in depression (NTR1304)**
Esmée Verwijk, The Netherlands

004 **The PRIDE Trial – Prolonging remission in depressed elderly (NCT01028508): Results from the randomised phase**
Charles Kellner, USA

T11: DEPRESSION: BASIC / CLINICAL

WS-07 **WORKSHOP**
15:00–16:30 Auditorium 15
Merging evidence and clinical practice in management of depression: The CANMAT experience
Chair: Sidney Kennedy, Canada
Co-Chair: Roumen Milev, Canada

001 **Guidelines for pharmacological management of depression**
Raymond Lam, Canada

002 **Making effective guidelines: Examples of evidence-based dissemination and implementation strategies**
Sagar Parikh, USA

003 **Guidelines for the treatment of depression in specific populations: Making decisions despite gaps in evidence**
Glenda MacQueen, Canada

004 **Guidelines for the use of Complementary and Alternative Medicines (CAM) in major depression**
Arun Ravindran, Canada

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

TFS-06 **WFSBP TASK FORCE SYMPOSIUM**
17:00–18:30 Auditorium 12
Electroconvulsive therapy: Beyond depression
Chair: Georgios Petrides, USA
Co-Chair: William McDonald, USA

001 **ECT for the treatment of catatonia**
Tom Bolwig, Denmark

002 **ECT in autism spectrum disorders: Catatonia and beyond**
Lee Wachtel, USA

003 **ECT for agitation in elderly patients with dementia**
Adriana Hermida, USA

004 **ECT-related mortality rates**
Søren Dinesen Østergaard, Denmark

T22: MOLECULAR NEUROBIOLOGY

S-42 **SYMPOSIUM**
17:00–18:30 Congress Hall A 3
Neuroepigenetic approaches to assess disease risk, mechanism and treatment
Chair: Alfonso Buil, Denmark
Co-Chair: Jonathan Mill, United Kingdom

001 **CACNA1C hypermethylation associated with Bipolar Disorder (BD)**
Anna Starnawska, Denmark
D. Demontis, A. Pen, A. Hedemand, A. L. Nielsen, N. H. Staunstrup, J. Grove, T. D. Als, A. Jarram, N. L. O'Brien, O. Mors, A. McQuillin, A. Børglum

002 **Epigenomic trajectories across human brain development: Relevance for schizophrenia and other neuro-developmental disorders**
Jonathan Mill, United Kingdom

Scientific Programme / Tuesday, 20 June 2017

003 **Neonatal epigenetic profiling in Danish twins discordant for psychiatric disorder**
Shantel Weinsheimer, Denmark
C. Hansen, A. Starnawska, T. Sparsø, W. Mazin, M. Bertalan, J. Grauholm, M. Bækvad-Hansen, A. Buil, D. Hougaard, T. M. Werge

004 **Epigenetics in schizophrenia and association with antipsychotic response to clozapine**
Marta Bosia, Italy

T33: PHARMACOLOGY

S-66 SYMPOSIUM
17:00–18:30 Auditorium 15
NMDA receptor antagonists in psychiatry
Chair: Peter Gass, Germany
Co-Chair: Gerard Sanacora, USA

001 **Glutamatergic mechanisms in schizophrenia: Focus on genetics**
Dan Rujescu, Germany

002 **Insight into Ketamine's effect via cross-species translational neuroimaging**
Oliver Grimm, Germany

003 **Molecular and cellular determinants of the pleiotropic effects of NMDA receptor antagonists**
Dragos Inta, Germany

004 **Antidepressant effects of NMDA receptor targeting drugs**
Gerard Sanacora, USA

FC-06 FREE COMMUNICATION SESSION
17:00–18:30 Auditorium 10
Antipsychotics 1
Chair: Jimmi Nielsen, Denmark
Co-Chair: Hsien-Yuan Lane, Taiwan

001 **Would I take antipsychotics, if I had psychotic symptoms? Examining social determinants of the decision to take antipsychotics**
Fabrice Berna, France
A. S. Göritz, P.-M. Llorca, P. Vidailhet, G. Fond, S. Moritz

002 **Relative NMS risk in older men**
Ronald Gurrera, USA

003 **Sodium benzoate, a D-amino Acid Oxidase Inhibitor, added to Clozapine for the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial**
Hsien-Yuan Lane, Taiwan
C.-H. Lin

004 **Lessons learned from a risperidone therapeutic drug monitoring database**
Georgios Schoretsanitis, Switzerland

005 **Revisiting the Increased prevalence of Clozapine induced cardiotoxicity in Australasia and proposal for a universal monitoring guideline**
Guna Kanniah, New Zealand
S. Kumar

FC-07 FREE COMMUNICATION SESSION
17:00–18:30 Auditorium 11
Anxiety & PTSD
Chair: Jaanus Harro, Estonia
Co-Chair: Ulrike Schmidt, Germany

001 **Inter-hemispheric coordination in posterior sub-network of default mode network: Putative biomarkers for depression and anxiety**
Chien-Han Lai, Taiwan
Y.-T. Wu

002 **Orexin/hypocretin receptor gene (HCRTR1) variation is associated with aggressive behaviour**
Jaanus Harro, Estonia
K. Laas, M. Vaht, J. Parik, J. Mäestu, T. Veidebaum

003 **Epigenetic regulation of stress reactivity in Post Traumatic Stress Disorder (PTSD)**
Ulrike Schmidt, Germany
T. F. Windstetter, M. Schreckenbach, B. Novak

004 **Clinical and biological characterization of HPA-axis reactivity endophenotypes in two independent cohorts of female PTSD patients**
Monika Schreckenbach, Germany
T. Kirmeier, U. Schmidt

005 **Grief shares circuits with pleasantness: Subliminal grief priming activates the orbitofrontal cortex to boost empathic pain**
Takuya Yoshiike, Japan
K. Kuriyama, H. Ikeda, H. Ohmura, M. Honma, Y. Moriguchi, K. Asano, Y. Kim, S. Nakajima

006 **Brain-based treatment selection for social anxiety disorder**
Andreas Frick, Sweden
J. Engman, M. Gingnell, I. Alaie, J. Björkstrand, E.-M. Larsson, K. Wahlstedt, M. Fredrikson, T. Furmark

FC-15 FREE COMMUNICATION SESSION

17:00–18:30 B3 M3-M4

Depression 2

Chair: Flavio Kapczinski, Brazil

Co-Chair: Leo Sher, USA

001 **Therapeutic Drug Monitoring (TDM) in maternal serum, amniotic fluid and umbilical cord blood during pregnancy and delivery**
Michael Paulzen, Germany
S. E. Lammertz, T. Veselinovic, T. W. Goecke, G. Gründer, G. Schoretsanitis

002 **Melatonin and subjective measures of biological rhythms in women at risk for postpartum depression: Preliminary results**
Benicio Frey, Canada
A. Slyepchenko

003 **Depressed multiple suicide attempters: A high risk patient group**
Leo Sher, USA
M. Grunebaum, A. Burke, S. Chaudhury, J. J. Mann, M. Oquendo

004 **Rumination as a mediator between childhood trauma and adulthood depression and anxiety in non-clinical samples**
Seung-Hwan Lee, Republic of Korea
J.-S. Kim, M.-J. Jin, S.-W. Hahn, Y. Jae, Y.-M. Jae

005 **The Wistar Kyoto rat as a preclinical model of depression: Identification of a clinically relevant plasma biomarker**
Jack Prenderville, Ireland
D. O'Driscoll, G. Di Caupa, C. McDonnell, J. Rouine, C. McCreary, J. McKenna, G. Wadsworth, N. Upton, E. Downer, M. Bianchi

ADVERT

WORLD FEDERATION ADHD

7th World Congress on ADHD

From Child to Adult Disorder

25 – 28 April 2019 | Lisbon, Portugal

www.adhd-congress.org

Scientific Programme / Wednesday, 21 June 2017

▶ Wednesday, 21 June 2017

T2: ANTIDEPRESSANTS: BASIC / CLINICAL

S-43 **SYMPOSIUM**

08:30–10:00 Auditorium 15

Novel approaches in mechanisms of action of antidepressant treatment

Chair: *Rainer Rupprecht, Germany*
Co-Chair: *Mark Rasenick, USA*

001 **Signal transduction in membranes as mechanism of action of antidepressants**
Mark Rasenick, USA

002 **Cytoskeleton as target for antidepressants**
Massimiliano Bianchi, Ireland

003 **Biomarkers during antidepressant treatment**
Thomas Baghai, Germany

004 **Antidepressants may affect signaling independently from monoamine reuptake**
Rainer Rupprecht, Germany

T17: GENETICS

S-44 **SYMPOSIUM**

08:30–10:00 Congress Hall A 3

Cannabinoid Receptor (CBR) gene variations in neuropsychiatric disorders

Chair: *Hiroki Ishiguro, Japan*
Co-Chair: *Emmanuel Onaivi, USA*

001 **Environmental stressors induce psychosis based on genetic variation of CB2Rs**
Hiroki Ishiguro, Japan

002 **ECB system alteration in an animal model of autism spectrum disorders**
Eugene Dennis, USA

004 **CBR genetics: From mice to human subjects**
Emmanuel Onaivi, USA

003 **Species differences in CBR genes**
Emmanuel Onaivi, USA

T1: ADDICTIVE DISORDERS

S-45 **SYMPOSIUM**

08:30–10:00 Auditorium 10

Behavioral addictions: Diagnosis, co-morbidity and neurobiology

Chair: *Michel Lejoyeux, France*
Co-Chair: *Aviv Weinstein, Israel*

001 **Internet gaming disorder- addiction, co-morbidity and the brain**
Aviv Weinstein, Israel

002 **Neuroimaging evidence for considering hypersexuality as an addiction**
Florence Thibaut, France

003 **New data on phenomenology and psychiatric comorbidity of compulsive buying**
Michel Lejoyeux, France

004 **The genetic background of gambling behavior**
Csaba Barta, Hungary
Z. Demetrovics, E. Kótyuk, A. Vereczkei, R. Urbán, A. Eisinger, A. Magi, G. Kökönyei, A. Veres-Székely, Á. Gyollai, K. Blum, M. Sasvári-Székely

T50: VIOLENCE: BASIC / CLINICAL

S-46 **SYMPOSIUM**

08:30–10:00 Auditorium 11

Neurobiology and psychopharmacology of aggressive behaviour: Where are we?

Chair: *Stefano Comai, Italy*
Co-Chair: *Gabriella Gobbi, Canada*

001 **Neurobiology and biomarkers of aggression**
Stefano Comai, Italy

002 **Clinical management of aggression in childhood and adolescence**
Pradeep Rao, Australia

003 **Substance use disorders and aggressive behaviour**
Gabriella Gobbi, Canada

004 **Epilepsy, antiepileptic drugs and aggression**
Martin J. Brodie, United Kingdom

T11: DEPRESSION: BASIC / CLINICAL

S-47 **SYMPOSIUM**

08:30–10:00 B3 M1-M2

Catecolamines, anhedonia and depression

Chair: *Jose Luis Ayuso Gutierrez, Spain*

Co-Chair: *Victoria Valdez, Ecuador*

001 **Catecholamines, reward circuits and depression**
Gregor Hasler, Switzerland

002 **Positive affects and depression**
Jorge Tellez-Vargas, Colombia

003 **Anhedonia and suicide behavior**
Maurizio Pompili, Italy

004 **Exploring the role of proinflammatory cytokines in anhedonia**
Ruby Castilla-Puentes, USA

FC-09 **FREE COMMUNICATION SESSION**

08:30–10:00 Auditorium 12

Depression 1

Chair: *Lars Vedel Kessing, Denmark*

Co-Chair: *Vibe G. Frokjaer, Denmark*

001 **Blood biomarkers to predict suicidal behavior**
Bérengère Vire, France
D. Weissmann, N. Salvetat, S. Pointet, Y. Lannay, G. Marcellin, S. van der Laan, F. Molina, P. Courtet, P. A. Saiz

002 **Transcranial direct current stimulation for treatment-resistant depression: An open-label study for 8 weeks**
Galen Hung, Taiwan
M.-S. Li

003 **Season-independent cognitive deficits in seasonal affective disorder and their relation to depressive symptoms**
Liv Vadskjær Hjordt, Denmark
D. S. Stenbæk, B. Ozenne, B. Mc Mahon, I. Hageman, S. G. Hasselbalch, G. M. Knudsen

004 **Functional network-based statistics in depression: theory of mind subnetwork and importance of parietal region**
Chien-Han Lai, Taiwan
Y.-T. Wu

005 **Gene expression profiles within a pharmacologically induced depression model: The role of estrogen in perinatal depression**
Vibe G. Frokjaer, Denmark
D. Mehta, M. Rex-Haffner, A. Pinborg, E. Binder, V. G. Frokjaer

FC-10 **FREE COMMUNICATION SESSION**

08:30–10:00 B3 M3-M4

Antipsychotics 2

Chair: *Kohji Fukunaga, Japan*

002 **Importance of early changes of blood lipid levels to predict long-term dyslipidemia during psychotropic drug treatment**
Aurélie Delacrétaz, Switzerland
F. Vandenberghe, N. Saigi-Morgui, A. Glatard, M. Gholam-Rezaee, A. von Gunten, P. Conus, C. Eap

003 **Association of body mass index with socioeconomic factors in Swiss psychiatric cohorts**
Axel Levier, Switzerland
N. Saigi-Morgui, A. Delacrétaz, F. Vandenberghe, A. Glatard, M. Gholam-Rezaee, R. Panczak, A. von Gunten, P. Conus, C. Eap

004 **Discovery of a novel intracellular dopamine D2 receptor function**
Kohji Fukunaga, Japan
N. Shioda

005 **Altered cerebral concentration of major inhibitory neurotransmitter in the medicated UHR subjects: 1H MRS study**
Petr Menshchikov, Russia
N. Semenova, T. Akhadov

PL-03 **PLENARY SESSION**

10:15–11:00 Auditorium 15

Epigenetic consequences of early adversity: Implications for psychiatric disorders

Chair: *Constantin Soldatos, Greece*

Speaker: *Elisabeth Binder, Germany*

D-03 **DEBATE**

11:15–12:45 Auditorium 15

Deep brain stimulation is a worthwhile treatment method in psychiatry

Chair: *Gregers Wegener, Denmark*

Proponent: *Thomas Schläpfer, Germany*

Opponent: *Marwan Hariz, United Kingdom*

Scientific Programme / Wednesday, 21 June 2017

T20: LIAISON PSYCHIATRY

TFS-07 WFSBP TASK FORCE SYMPOSIUM

11:15–12:45 Congress Hall A 3

Enhancing the role of primary care in looking after people with mental health problems: A new position paper from the Collaborative Care Task Force of the WFSBP

Chair: Nick Kates, Canada

001 **Improving primary mental health care – Definitions, models, principles and challenges**
Nick Kates, Canada

002 **Integrating mental health services within primary care settings**
Henrikje Klasen, The Netherlands

003 **The role of the family physician in delivering mental health care**
Torleif Ruud, Norway

004 **Capacity building, training and adapting the approach for different countries**
Nick Kates, Canada

T32: PHARMACOGENETICS

S-48 SYMPOSIUM

11:15–12:45 Auditorium 12

Pharmacogenetics of drug defense and neuro-protection: From the Neandertal to the modern humans

Chair: Julia Stingl, Germany
Co-Chair: Magnus Ingelman-Sundberg, Sweden

001 **The evolutionary aspect of trait biomarkers in drug metabolism and neuroprotection**
Magnus Ingelman-Sundberg, Sweden

002 **Pharmacogenetic polymorphisms on behavioral and structural brain phenotypes uncovered by neuro-imaging data**
Roberto Viviani, Germany

003 **Prevention of drug toxicity to the brain: The vulnerable brain and ADRs of nervous system disorders**
Julia Stingl, Germany

004 **Serotonin Transporter Expression Variability: Role in Neurogenesis and Pharmacological Modulation**
Abdul-Karim Barakat, Germany

T11: DEPRESSION: BASIC / CLINICAL

S-49 SYMPOSIUM

11:15–12:45 Auditorium 10

Evidence-based guidelines for treatment of major depressive disorder: Contrasting views across the world

Chair: Roumen Milev, Canada
Co-Chair: Allan Young, United Kingdom

001 **Evolution of WFSBP depression guidelines**
Michael Bauer, Germany

002 **The evolution of the CANMAT guidelines**
Raymond Lam, Canada

003 **The view from the UK: BAP guidelines for Mood Disorders (MD)**
Allan Young, United Kingdom

004 **Even the best guidelines don't work unless they are implemented**
Sagar Parikh, USA

T6: BIPOLAR DISORDERS: BASIC / CLINICAL

S-50 SYMPOSIUM

11:15–12:45 Auditorium 11

Real time assessment of psychopathology and behavior in Bipolar Disorder (BP) using e-mental health technologies

Chair: Lars Kessing, Denmark
Co-Chair: Michael Bauer, Germany

001 **Mood instability and Bipolar Disorder (BD): Deriving useful biosignatures from multidimensional, time stamped, streamed data**
John Geddes, United Kingdom

002 **Smartphones as objective electronic behavioral biomarkers of illness activity in Bipolar Disorder (BP)**
Lars Kessing, Denmark

003 **Voice recognition as objective electronic behavior-al biomarkers of illness activity in Bipolar Disorder (BP)**
Maria Fauerholt-Jepsen, Denmark

004 **Smartphone based ambulatory assessment of early warning signs in Bipolar Disorder (BP)**
Michael Bauer, Germany

T43: SCHIZOPHRENIA: BASIC / CLINICAL

WS-09 **WORKSHOP**

11:15–12:45 B3 M1-M2

Schizophrenia research in Chile

Chair: *Hernan Silva, Chile*

Co-Chair: *Veronica Larach, Chile*

001 **BDNF as a biomarker of cognitive function in schizophrenia: A study in Chilean population**
Hernan Silva, Chile

002 **Pragmatic and linguistic disorders in schizophrenia since the first episode**
Eduardo Duran, Chile

003 **Atypical antipsychotics and psychosis spectrum: Chilean experience**
Eugenio Olea, Chile

004 **Universal coverage for schizophrenia: The GES program in Chile**
Veronica Larach, Chile

GENERAL ASSEMBLY

13:00–15:00 Auditorium 11

WFSBP General Assembly



ADVERT

ESAS
European Scientific Association on Schizophrenia and other Psychoses

6th European Conference on Schizophrenia Research (ECSR)

Advancing Research – Promoting Recovery

organized by the European Scientific Association on Schizophrenia and other Psychoses (ESAS)

14 – 16 September 2017
Berlin, Germany

in cooperation with
EPA
DGPPN
ACSR
Competence Network Schizophrenia

www.schizophrenianet.eu

Scientific Programme / Wednesday, 21 June 2017

P-11 **POSTER TOUR**

13:00–14:30 Congress Hall A 1

Schizophrenia 2

Chair: NN

002 **A meta-analysis of lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis**
Blazej Misiak, Poland
B. Stanczykiewicz, Ł. Łaczmanski, D. Frydecka

003 **Elevated levels of Asymmetric Dimethylarginine (ADMA) in first-episode schizophrenia patients: A cross-sectional study with meta-analysis**
Blazej Misiak, Poland
M. Fleszar, J. Wisniewski, D. Frydecka

004 **Impact of val-allele of Catechol-O-Methyl transferase on frontal executive functions in schizophrenia using novel MBIAL computerised battery: A case-control study**
Narayan R. Mutalik, India
J. P. John, H. HN, S. Jain

005 **Altered age-related subcortical trajectories in familial high-risk of schizophrenia with transition to psychosis**
Synthia Guimond, USA
S. Sarvode, C. Makowski, M. Chakravarty, M. Keshavan

006 **Collapsin-response mediator Protein-5 gene RS13017554 polymorphism and schizophrenia**
Sofi Atshemyan, Armenia
R. Zakharyan, A. Arakelyan

007 **The role of complexin family single nucleotide polymorphisms in schizophrenia**
Sofi Atshemyan, Armenia
R. Zakharyan, A. Arakelyan

009 **Symptomatic differences between remitted schizophrenia and non-remitted schizophrenia**
Yeon-Ho Joo, Republic of Korea
S.-Y. Park, J.-S. Lee

011 **Medication adherence in schizophrenia: The role of insight, therapeutic alliance and perceived trauma**
David Misdrahi, France
A. Tessier, L. Boyer, F. Baylé, M. Husky, P.-M. Llorca

012 **Exploring adherence profile to antipsychotics in patients with schizophrenia in a 6 month MEMS device follow-up post discharged study**
David Misdrahi, France
A. Tessier, M. Husky, A. C. Lange, B. Vrijens, P.-M. Llorca, F. Baylé

014 **Hallucinations and delusions differ in response to antipsychotic medication**
Jill Bjarke, Norway
I. Sinkeviciute, R. Gjestad, R. A. Kroken, E.-M. Løberg, H. A. Jørgensen, E. Johnsen

015 **Cannabidiol attenuates the behavioral changes induced by repeated administration of a NMDA receptor antagonist through a 5HT1A receptor-dependent mechanism**
Francisco Guimaraes, Brazil
N. Rodrigues, N. R. Silva, F. V. Gomes

016 **Factors predicting personal and social performance in schizophrenia patients**
Seung-Hyun Kim, Republic of Korea

017 **Evidence on the use of antipsychotics for people at ultra-high risk of psychosis**
Adriana Carapucinha, Portugal
R. Trindade, R. Catarino

018 **Neurocognition and social cognition in parents with schizophrenia or Bipolar Disorder**
Aja Neergaard Greve, Denmark
J. R. Moellegaard Jepsen, E. L. Rasmussen, D. L. Gantriis, D. Ellersgaard, C. J. Christiani, K. S. Spang, N. Hemager, A. Thorup, M. Nordentoft, K. Plessen, O. Mors, V. Bliksted

019 **Neurocognitive deficits in patients with early-onset schizophrenia, and their nonpsychotic siblings**
Nora S. Vyas, United Kingdom
L. Burke, M. Sirota, S. Netherwood, P. Caviston, M. Simic, K. J. Aitchison

020 **"No gain, more pain": Impact of reward on pain threshold and tolerance to experimental pain (Cold pressor task) in healthy subjects and patients with schizophrenia**
Noomane Bouaziz, France
V. Moulier, S. Regat, D. Januel, R. Benadhira

021 **Niacin response abnormality in patients with first-episode psychosis: A potential schizophrenia endophenotype**
Fotini Boufidou, Greece
M. Zoga, P. Oulis, V. G. Masdrakis, P. Pliatsika, S. Foteli, C. Nikolaou

P-12 **POSTER TOUR**

13:00–14:30 Congress Hall A 1

Cognitive neuroscience

Chair: NN

003 **Spatial attention modulates conscious somatosensory perception**
Deniz Doruk Camsari, USA
L. Chanes, A. Malavera, L. Merabet, A. Valero-Cabre, F. Fregni

006 **Mental fatigue effects cognitive functioning after acute cardiac events**
Julius Burkauskas, Lithuania
A. Bunevicius, J. Brozaitiene, N. A. Fineberg, D. Wellsted, N. Mickuviene, R. Bunevicius

008 **Computer-assisted cognitive remediation in schizophrenia and Bipolar Disorder BP): A prospective, randomized, double-blind, sham-controlled study**
Chih-Ming Cheng, Taiwan
M.-H. Chen, T.-P. Su, C.-T. Li

009 **The effects of varenicline in a ketamine-based rat model of cognitive dysfunction**
Agnieszka Nikiforuk, Poland
A. Potasiewicz, P. Popik

P-13 **POSTER TOUR**

13:00–14:30 Congress Hall A 1

Sleep & eating disorders

Chair: Elisabeth Binder, Germany

001 **Saccadic control in anorexia nervosa: Implications for the potential neurobiological underpinnings of anorexia nervosa**
David Castle, Australia
A. Phillipou, S. Rossell, C. Gurvich, L. Abel

002 **Eating disorders and psychiatric comorbidity in ambulatory care: A case series**
Maria Marta Jalon Urbina, Spain
A. González Fernández, L. Gómez de Segura Iriarte, P. González García

004 **Physical activity in depressed and non-depressed patients with obesity**
Hubertus Himmerich, United Kingdom
P. Ueck, R. Mergl, G. Gordon, U. Hegerl, C. Sander

005 **Kynurenine-pathway and microbial diversity in anorexia nervosa: Relationship or independency? Preliminary data**
Sabrina Mörkl, Austria
A. Meinitzer, S. Lackner, C. Blesl, A. Painold, G. Gorkiewicz, K. Kashofer, S. Holasek

006 **Subjective sleepiness and objectively measured EEG-based wakefulness in obese patients and healthy controls**
Hubertus Himmerich, United Kingdom
F. M. Schmidt, M. Murray, N. Albayrak, B. Dalton, I. C. Campbell, U. Hegerl, C. Sander

009 **The role for insomnia and somatic anxiety in the symptomatology and pharmacotherapy in remitted depression**
Takuya Yoshiike, Japan
Y. Nakasato, K. Kuriyama, M. Nakamura

011 **Heart rate variability measures during sleep distinguish between insomnia and restoring sleep**
Thorsten Mikoteit, Switzerland
M. Pawlowski, N. Seiffert, E. Seelig, S. Bilz, M. Hatzinger, E. Holsboer-Trachsler

012 **Sleep loss is associated with medial prefrontal cortex activity during an emotional distracter task**
Annika Dimitrov, Germany
M. Adli, J. Schaake, A. Ligdorf, N. Oei, H. Walter, I. Veer

013 **Cerebral metabotropic glutamate receptors of subtype 5 (mGluR5) are part of the molecular network regulating sleep need in humans and mice**
Sebastian Holst, Denmark
A. Sousek, K. Stingelin, S. S. Moghadam, A. Buck, S. M. Ametamey, M. Scheidegger, P. Franken, A. Henning, E. Seifritz, M. Tafti, H.-P. Landolt

P-14 **POSTER TOUR**

13:00–14:30 Congress Hall A 1

Neurostimulation

Chair: NN

001 **Psychiatric deep brain stimulation: Recurrent and neglected ethical issues**
Laura Cabrera, USA
R. McKenzie, R. Bluhm

002 **Invasiveness of deep brain stimulation for obsessive-compulsive disorder: patient perspective**
Simon Raymaekers, Belgium
K. Demyttenaere, L. Luyten, B. Nuttin, L. Gabriels, C. Bervoets

003 **ECT-related anxiety: What have we (not) learned?**
Jasmien Obbels, Belgium
E. Verwijk, F. Bouckaert, P. Sienaert

004 **Attitudes towards ECT: A survey of Polish mental health professionals**
Anna Antosik-Wójciñska, Poland
G. Gazdag, L. Swiecicki, J. Rybakowski, B. Majtczak, A. Wichniak

Scientific Programme / Wednesday, 21 June 2017

005 **Electroconvulsive therapy for treatment of parkinsonism with on-off phenomenon with dementia: a case series**
Tak Youn, Republic of Korea
I.-W. Chung, Y.-S. Kim

006 **Electroconvulsive stimulation transiently enhances the permeability of the rat blood-brain barrier and induces astrocytic changes**
Masanobu Ito, Japan
T. Kinjo, A. Furuta, D. McLoughlin, T. Suzuki, H. Arai

007 **Transcranial magnetic stimulation for the treatment of major depression during pregnancy: Efficacy and safety of a novel therapeutical strategy**
Ygor Ferrão, Brazil
R. Felipe, R. Lieberknecht

009 **Electroconvulsive therapy for treatment resistant psychosis**
Tak Youn, Republic of Korea
I.-W. Chung, Y.-S. Kim, Y.-W. Jeong

010 **Impact of Theta Burst Transcranial Stimulation (TBS) on auditory hallucinations in schizophrenia**
Noomane Bouaziz, France
V. Moulier, S. Braha, F. Thomas, R. Benadhira, D. Januel

P-15 **POSTER TOUR**
13:00–14:30 Congress Hall A 1
Miscellaneous
Chair: Eduard Vieta, Spain

001 **Protocol for the management of psychiatric patients with psychomotor agitation**
Eduard Vieta, Spain
M. Garriga, L. Cardete, M. Bernardo, M. Lombraña, J. Blanch, R. Catalán, M. Vázquez, V. Soler, N. Ortuño, A. Martínez Arán

002 **The relationship between depression, anxiety, somatization, personality and symptoms of lower urinary tract symptoms suggestive of benign prostatic hyperplasia**
Chi-Un Pae, Republic of Korea

003 **Gender differences in psychological vulnerability in donors and recipients for kidney transplantation**
Young-Myo Jae, Republic of Korea

004 **Psychotic-like experiences in individuals with rheumatic disease: Preliminary results**
Juan L. Prados, Spain
A. Escudero, R. Luque, J. A. Alcalá, E. Collantes

007 **Huntington's disease with psychiatric presentation – a case report**
Raquel Serrano, Portugal
H. Medeiros, M. Nascimento, T. Maia

008 **DESATA study: An 8-year retrospective analysis of mechanical restraint application in an acute mental health unit, clinical and organizational factors**
Jose Maria Villagran Moreno, Spain
R. Guerrero Vida, J. I. Pérez Revuelta, F. González Sáiz

009 **Psycopathy and twins**
Alejandro Hernández Dorta, Spain
I. Gonzalez Gonzalez

010 **The Chemo brain: Severe cognitive decline following chemotherapy of breast cancer**
Wolfgang Kaschka, Germany
J. Steyer, M. Jandl, I. Kaschka, S. Hodgkinson

011 **Delirious Mania**
Isaac Gonzalez Gonzalez, Spain
A. Hernández Dorta

012 **Gender differences of occupational stress associated with suicide ideation among South Korean employees**
Sun-Young Kim, Republic of Korea
D.-E. Lee, S.-W. Lim, D.-W. Shin, Y.-C. Shin, K.-S. Oh

013 **Overlapping effect of the components of occupational stress associated with depressive symptoms and suicidal idea among Korean employees**
Sun-Young Kim, Republic of Korea
D.-E. Lee, S.-W. Lim, D.-W. Shin, Y.-C. Shin, K.-S. Oh, C.-H. Jung

014 **What kind of stress associated with depression, anxiety and suicidal ideation in Korean employees?**
Da-Eun Lee, Republic of Korea
S.-Y. Kim, S.-W. Lim, D.-W. Shin, Y.-C. Shin, K.-S. Oh

015 **The brain-heart connection in TakoTsubo cardiomyopathy: A case report**
João Fonseca, Portugal
R. Rodrigues

016 **Effects of a prevention program on perceived stress and cortisol level using an ambulatory assessment approach among university students in Switzerland**
Romina Recabarren, Switzerland
C. Gaillard, M. Guillod, C. Martin-Sölch

P-16 **POSTER TOUR**

13:00–14:30 Congress Hall A 1

Suicide

Chair: Lars Vedel Kessing, Denmark

001 **The identification of two subgroups in Korean suicide attempters using cluster analysis**
Hye-Young Kim, Republic of Korea
B. Kim, K. Ha, J.-W. Lee, Y.-M. Ahn

002 **Comparison of suicidal behavior between a hospital-based cohort and a community-based cohort: Korean cohort for the model prediciting a suicide and suicidal behavior (K-COMPASS)**
Christopher Hyung Keun Park, Republic of Korea
J.-W. Lee, H.-Y. Kim, Y.-M. Ahn

003 **Serum lipids as state and trait marker of aggression in recent suicide attempters**
Marie Asp, Sweden
Å. Westrin, L. Träskman Bendz, L. Ambrus

004 **Measuring quality of life through the Seville Questionnaire in patients with suicidal attempts at a psychiatry emergency hospital**
Eduardo Rubio, Argentina
B. López

005 **Is parity a protective factor against suicide attempts in women who have suffered sexual violence?**
Victoria Valdez, Ecuador
P. Dueñas, J. Jimenez

006 **Association between altered lipid profile and suicide attempt among Tunisian patients with schizophrenia**
Ahmed Mhalla, Tunisia
R. Mensi, A. Messaoud, B. Amamou, A. Mrad, W. Douki, L. Gaha

007 **Alcohol-induced disinhibition is associated with impulsivity, depression, and suicide attempt: A nationwide community sample of Korean adults**
Kwan-Woo Choi, Republic of Korea
K.-W. Kim, E.-J. Na, H.-J. Jeon

008 **Tryptophan metabolism via Serotonin and Kynurenine biomarkers in major depression patients with suicide attempts**
Stefano Comai, Italy
A. Messaoud, M. Rym, D. Wahiba, L. Gaha, G. Gobbi, F. Valtorta

009 **Clinical factors of the index suicide attempt predicting later death by suicide**
Kyoung-Uk Lee, Republic of Korea
M.-S. Kim, K.-C. Paik

010 **Factors affecting suicide method lethality among suicide attempters in the Korea National Suicide Survey**
Tae-Sung Yeum, Republic of Korea
B. Kim, E.-Y. Kim, S.-H. Kim, K. Ha, Y.-M. Ahn

011 **Risk factors in demographic variables to depressive symptoms and suicidality of elderly who live alone in South Korea**
Kyu-Young Lee, Germany
H.-S. Park

012 **Suicidal behavior in monozygotic twins, Lima, Peru**
Freddy Vasquez, Peru
Y. Nicolas, S. Falconi

013 **Similarities between platelet proteome and cerebrospinal fluid proteome: In search of potential biomarker candidates for suicide with proteomics (Preliminary results)**
Erika Semancikova, Slovakia
S. Tkacikova, J. Simonova, I. Talian, M. Benckova, J. Firment, E. Palova, J. Sabo

015 **Suicide attempt and completed suicide by jumping in patients with electroencephalographic (EEG) abnormalities**
Freddy Vasquez, Peru
Y. Nicolas, S. Falconi

P-17 **POSTER TOUR**

13:00–14:30 Congress Hall A 1

Anxiety, OCD & PTSD

Chair: Ulrike Schmidt, Germany

001 **Clinical utility of heart rate variability during head-up tilt test in subjects with chronic Post-traumatic Stress Disorder (PTSD)**
Moon-Yong Chung, Republic of Korea
S.-H. Kang, K.-C. Paik, J.-E. Park

002 **Heart rate variability of chronic Post-traumatic Stress Disorder (PTSD) in the Korean veterans**
Joo-Eon Park, Republic of Korea
S.-H. Kang, K.-C. Paik, M.-Y. Chung, T.-Y. Kim, H.-K. Chung, J.-H. Choi, H.-S. So

004 **7.8 earthquake in Ecuador: Comparing Post Traumatic Stress Disorder between urban and rural premedical students**
Victoria Valdez, Ecuador
J. Jimenez, P. Dueñas

005 **Combination of an epigenetic modulator and a regulator of a differentially methylated pathway reverses PTSD in a Rat model: A novel approach to PTSD treatment**
Gal Warhaftig, Israel
N. Zifman, C.-M. Sokolig, R. Massart, O. Gabay, V. Farida, M. Szyf, G. Yadid

Scientific Programme / Wednesday, 21 June 2017

007 **Investigating differential expression in PTSD patients versus controls: An RNA-Seq study**
Sian Hemmings, South Africa
L. Dicks, M. Jalali, J. Gamielddien, S. Seedat, L. van den Heuvel

008 **Cho / Cr ratios in Anterior Cingulate Gyrus in a prospective study in pediatric sample exposed to multiple types of violence**
Andrea Parolin Jackowski, Brazil
A. C. Milani, B. Foester, M. Feijó de Mello

010 **Tumor necrosis factor-alpha and Post-Traumatic Stress Disorder (PTSD)**
Serkan Hussein, United Kingdom
H. Himmerich, B. Dalton

011 **Inflammatory markers in adult women with Post-traumatic Stress Disorder (PTSD)**
Hiroaki Hori, Japan
M. Itoh, M. Lin, M. Niwa, K. Ino, R. Imai, S. Ogawa, A. Sekiguchi, H. Kunugi, T. Kamo, Y. Kim

012 **Fornix integrity associated with early trauma in panic disorder**
Sang-Hyuk Lee, Republic of Korea
S.-T. Yu

013 **Reduced cortical thickness in paralimbic regions and inferior frontal gyrus of patients with panic disorder**
Sang-Hyuk Lee, Republic of Korea

014 **Relationship between monoaminergic and hormonal systems and endogenous intoxication in anxious depression**
Marat Uzbekov, Russia
N. Maximova

017 **Application of mobile app and paper survey of PTSD checklist in the elderly Korean veterans of the Vietnam war**
Tae-Yong Kim, Republic of Korea
H.-G. Chung, J.-H. Choi, H.-S. Soh, S.-H. Kang

018 **Characterization of a rare Slitrk1 frame-shift mutation in mice**
Dorothy Grice, USA
Y. Kajiwara, J. D. Buxbaum

019 **Cerebral activation associated with the influences of symptom provocation during memory retrieval in patients with obsessive-compulsive disorder**
Jong-Chul Yang, Republic of Korea
K.-C. Paik

020 **Descriptive phenomenology of depressive and anxious symptoms in patients with obsessive-compulsive disorder**
Ygor Ferrão, Brazil
M. Damion, N. Morais, M. A. de Mathis

021 **A pilot study of novel bilateral thermal capsulotomy with focused ultrasound for treatment-refractory obsessive-compulsive disorder: 2-Year follow-up**
Chan-Hyung Kim, Republic of Korea
S.-J. Kim, H.-H. Jung, J.-W. Chang

024 **Direct exposure to oxytocin results in increased social behavior and mobility performances in a zebrafish animal model**
Ioana-Miruna Balmus, Romania
S.-A. Strungaru, G. Plavan, M. Nicoara, A. Ciobica

T51: MISCELLANEOUS

TFS-08 WFSBP TASK FORCE SYMPOSIUM
15:00–16:30 Congress Hall A 3
Men's mental health: Contemporary aspects
Chair: Leo Sher, USA
Co-Chair: Timothy Rice, USA

001 **Future research and clinical directions in the field of men's mental health**
Leo Sher, USA

002 **Towards a neuropsychiatric model of disruptive behavior disorders in boys and young men: Developmental deficits in the emotion regulation system, their origin, and their therapeutic address**
Timothy Rice, USA

003 **Sex differences in addictive disorder and its clinical connotation**
Shih-Ku Lin, Taiwan

004 **Sex differences in early predictors of adult personality and intelligence**
Trine Flensborg-Madsen, Denmark

T6: BIPOLAR DISORDERS: BASIC / CLINICAL

TFW-03 WFSBP TASK FORCE WORKSHOP
15:00–16:30 Auditorium 12
WFSBP Treatment Guideline Session: Do bipolar mixed states merit a treatment guideline on its own?
Chair: Siegfried Kasper, Austria
Co-Chair: Heinz Grunze, United Kingdom

001 **Clinical manifestations of bipolar mixed states-epidemiological and clinical research**
Jean-Michel Azorin, France

002 **The changing concept of mixed states over time: DSM5 broadening and downgrading at the same time**
Eduard Vieta, Spain

003 **The WFSBP Treatment guideline for mixed states-evidence and recommendations**
Heinz Grunze, United Kingdom

004 **What the CINP guideline recommends in mixed states**
Konstantinos Fountoulakis, Greece

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-51	SYMPOSIUM
15:00–16:30	Auditorium 15
Advances in biomarker development for neuro-stimulation	
Chair:	*Paul Croarkin, USA*
Co-Chair:	*Motoaki Nakamura, Japan*

001 **Stimulation-induced neuroplasticity of prefrontal cortex in adult autism spectrum disorder**
Motoaki Nakamura, Japan

002 **Glutamatergic biomarker development for repetitive transcranial magnetic stimulation**
Paul Croarkin, USA

003 **Neurocognitive effects of major depressive disorder and neurostimulation therapies**
Shawn McClintock, USA

004 **Predicting remission of suicidal ideation following Magnetic Seizure Therapy (MST) in patients with treatment-resistant depression**
Zafiris J. Daskalakis, Canada

T3: ANTIPSYCHOTICS: BASIC / CLINICAL

S-52	SYMPOSIUM
15:00–16:30	Auditorium 10
The G protein coupled receptors as a target for psychotropic drugs	
Chair:	*Andrzej Pilc, Poland*
Co-Chair:	*Jeffrey P. Conn, USA*

001 **Positive allosteric modulators of GPCRs as a novel treatment for schizophrenia**
Jeffrey P. Conn, USA

002 **The mGlu5 receptor imaging in schizophrenia and depression**
Gregor Hasler, Switzerland

003 **The mGlu2 / 3 receptor as a novel therapeutic target for treatment-resistant depression**
Shigeyuki Chaki, Japan

004 **The allosteric modulation of group III mGlu receptors as target for antipsychotic or antidepressant drugs**
Andrzej Pilc, Poland

T49: SUICIDE: BASIC / CLINICAL

S-53	SYMPOSIUM
15:00–16:30	B3 M3-M4
Suicidal behavior: Neurobiological and genetic determinants	
Chair:	*Yogesh Dwivedi, USA*

001 **Epigenetic modifications in brain of suicide individuals: Focus on global and site-specific changes in 5-hydroxymethylcytosine**
Gustavo Turecki, Canada

002 **Genetics of intermediate phenotypes for suicidal behavior: Focus on impulsivity and aggression**
Dan Rujescu, Germany

003 **Toxoplasmagondii seropositivity and suicidal behavior**
Teodor Postalache, USA

004 **Non-coding RNAs: Novel epigenetic regulators in suicidal behavior**
Yogesh Dwivedi, USA

T23: MOOD STABILISERS: BASIC / CLINICAL

S-55	SYMPOSIUM
15:00–16:30	Auditorium 11
Rediscovering Lithium	
Chair:	*David Taylor, United Kingdom*
Co-Chair:	*Jonathan Meyer, USA*

001 **The evidence for Lithium's antisuicide properties and impact on mortality**
Jimmi Nielsen, Denmark

002 **The evidence for Lithium's neuroprotective properties**
Barrat Luft, United Kingdom

003 **What is the risk for end stage renal disease with Lithium: A sophisticated review**
Ursula Werneke, Sweden
M. Ott, E. Salander Renberg, B. Stegmayr

004 **An update on assessing and managing Lithium's renal effects**
Jonathan Meyer, USA

Scientific Programme / Wednesday, 21 June 2017

T43: SCHIZOPHRENIA: BASIC / CLINICAL

WS-10 WORKSHOP

15:00–16:30 B3 M1-M2

Evidence for brain stimulation methods in schizophrenia

Chair: *Joachim Cordes, Germany*
Co-Chair: *Christian Plewnia, Germany*

001 **Effects of transcranial direct current stimulation (tDCS) on executive functions**
Christian Plewnia, Germany

002 **rTMS for the treatment of negative symptoms in residual schizophrenia**
Joachim Cordes, Germany

003 **The treatment of hallucinations in schizophrenia spectrum disorders**
Iris Sommer, The Netherlands

004 **Predictors of response to ECT in treatment-resistant schizophrenia**
Tomasz Pawelczyk, Poland

T50: VIOLENCE: BASIC / CLINICAL

TFS-09 WFSBP TASK FORCE SYMPOSIUM

17:00–18:30 Congress Hall A 3

Providing acute inpatient care for children, adolescents and young adults from a men's mental health perspective: Focus on violence reduction

Chair: *M. Pilar Trelles, USA*
Co-Chair: *Lesha Shah, USA*

001 **Brain development: A focus on normal male development and psychopathology**
M. Pilar Trelles, USA

002 **Asking for the IM: What to do when the disruptive male child appears to seek punishment**
Timothy Rice, USA

003 **Agression in adolescence**
Lesha Shah, USA

004 **Violent and suicidal behavior among young male veterans on an inpatient psychiatric unit**
Leo Sher, USA

T51: MISCELLANEOUS

S-54 SYMPOSIUM

17:00–18:30 Auditorium 12

Lithium as a neuroprotective agent: When and how?

Chair: *Galila Agam, Israel*
Co-Chair: *Changlian Zhu, People's Republic of China*

001 **In vivo lithium-induced augments mitochondrial function, reduced neuroinflammation and increased autophagy**
Galila Agam, Israel

002 **Lithium as a novel approach to treat developing brain injury**
Changlian Zhu, People's Republic of China

003 **GSK3beta inhibition-independent lithium-induced neuroprotection in stroke: The involvement of increased miR-124 expression, reduced RE1-silencing transcription factor abundance and decreased protein deubiquitination**
Thorsten Doeppner, Germany

004 **A fully integrated new model for lithium's mode of action: Lithium utilizes hidden cellular fail-safe-mechanisms**
Ernie van Woerkom, United Kingdom

FC-08 FREE COMMUNICATION SESSION

17:00–18:30 B3 M3-M4

Addictive disorders

Chair: *Fabricio Moreira, Brazil*
Co-Chair: *Philippe Jaury, France*

001 **New UK Government recommended guidelines on the "safe limits" of alcohol for adult males and its impact upon everyday prospective memory function**
Thomas Heffernan, United Kingdom
A.-M. Marshall

002 **Bacloville: A clinical efficacy study of high dose baclofen in reducing alcohol consumption in high risk drinkers**
Philippe Jaury, France

003 **Is there a role for cannabidiol in psychiatry?**
Frederico Garcia, Brazil
J. Khoury, M. Neves, M. Roque, D. Queiroz, A. Freitas, Â. de Fátima, F. Moreira

004 **The electronic cigarette: A tool of withdrawal or a new addiction?**
Samia Ben Saadi, Tunisia
O. Moula, O. Zerria, R. Triki, R. Ghachem

005 **Clock genes SNP array identifies a key role of the PER1 / HES7 gene in the risk of cannabis addiction and psychiatric comorbidities**
Geneviève Lafaye, France
A. Benyamina

006 **Evidence for a role of A2A-D2 heteroreceptor complexes in cocaine addiction**
Malgorzata Filip, Poland
K. Wydra, A. Suder, E. Przegalinski, K. Fuxe

007 **Predictors of online-gambling in a population of English students**
Tuba Mazhari, United Kingdom
G. Ofori-Attah, N. Knights, A. Lineham

FC-11 FREE COMMUNICATION SESSION
17:00–18:30 Auditorium 11
Inflammation
Chair: Michael Maes, Thailand
Co-Chair: Jose Maria Pelayo Teran, Spain

002 **A review article: An overview of the role of celecoxib in treatment of psychiatric disorders**
Mohammadreza Shalbafan, Iran
S. Donboli, F. Malekpour, E. Shirazi

003 **Differential cytokine levels between early withdrawal and remission states in patients with alcohol dependence**
San-Yuan Huang, Taiwan
M.-C. Shih

004 **Parental infections during pregnancy as risk factors for mental disorders in childhood and adolescence: A nationwide Danish study**
Cecilie Lydholm, Denmark
O. Köhler-Forsberg, M. Nordentoft, R. Yolken, L. Petersen, M. E. Benrós

005 **Vitamin D deficit in patients with schizophrenia or depression**
Jose Maria Pelayo Teran, Spain
Y. Zapico Merayo, N. Martin Navarro, M. A. Reguero Palacio, M. M. Martinez Perez, L. Garcia Menendez, A. Diez Hernandez

FC-12 FREE COMMUNICATION SESSION
17:00–18:30 Auditorium 15
Schizophrenia
Chair: Oliver Howes, United Kingdom
Co-Chair: Rakesh Karmacharya, USA

001 **Motion analysis in schizophrenia: Impaired gestures are linked to increased movement and prolonged motor planning and execution**
Lars Dutschke, Switzerland
K. Stegmayer, F. Ramseyer, S. Bohlhalter, T. Vanbellingen, W. K. Strik, S. Walther

002 **A typology of homeless persons with mental health issues: Effects of mental and physical illness on rehabilitation**
Jean-Pierre Bonin, Canada
C. Larue, J.-F. Pelletier, H. Racine

003 **Patient-derived stem cells to study the neurobiology of schizophrenia**
Rakesh Karmacharya, USA
B. Watmuff, B. Liu

004 **Environment and vulnerability to schizophrenia: A case-control study of warly parental loss in schizophrenia**
Ofer Agid, Canada
C. Siu, G. Fervaha, H. Shireen, H. Takeuchi, R. Zipursky, G. Foussias, G. Remington

005 **Levels of glutamate and GABA are associated with cognitive deficits in antipsychotic-naïve patients with schizophrenia**
Kirsten Borup Bojesen, Denmark
B. Fagerlund, M. Jensen, K. Jessen, A. Sigvard, G. Saltoft Andersen, E. Rostrup, B. V. Broberg, B. Glenthøj

FC-13 FREE COMMUNICATION SESSION
17:00–18:30 Auditorium 10
Genetics
Chair: Thomas Werge, Denmark
Co-Chair: Hannelore Ehrenreich, Germany

001 **Risk of psychiatric disorders among individuals with the 22q11.2 deletion or duplication: A Danish nation-wide register based study**
Louise Hoeffding, Denmark
B. B. Trabjerg, L. Olsen, W. Mazin, T. Sparsø, A. Vangkilde, P. B. Mortensen, C. B. Pedersen, T. Werge

002 **Identification of differentially methylated loci associated with late-life depression**
Ruby Tsang, Australia
S. Reppermund, N. Armstrong, A. Thalamuthu, D. Ames, M. Wright, P. Sachdev, K. Mather

Scientific Programme / Wednesday, 21 June 2017

003 **Polygenic risk score analysis of suicidal behaviour severity in Bipolar Disorder (BP)**
Clement Zai, Canada
A. Tiwari, V. de Luca, J. Kennedy

005 **OTTO: A new strategy to extract mental disease-relevant combinations of GWAS hits from individuals**
Hannelore Ehrenreich, Germany
M. Mitjans, B. Oliveira, S. van der Auwera, T. P. Centeno, M. Begemann, H. J. Grabe, S. Bonn, K.-A. Nave

FC-14 FREE COMMUNICATION SESSION
17:00–18:30 B3 M1-M2
Neuroimaging 2
Chair: Bjørn H. Ebdrup, Denmark
Co-Chair: Yuan-Hwa Chou, Taiwan

001 **Behavioral, neurotransmitter and metabolic changes following selective activation of the nigrostriatal dopaminergic pathway**
Mikael Palner, Denmark
A. Casado-Sainz, S. Baerentzen, E. N. L'Estrade, F. G. Edgar, C. Kjaerby, H. Lee, H. Benveniste, M. Herth

002 **18F-Fallypride binding potential correlates differently with executive function in medication-naïve schizophrenia patients and healthy volunteers**
Nora S. Vyas, United Kingdom
D. S. Lehrer, B. Merrill, A. DeCastro, N. A. Doninger, B. T. Christian, I. Mukherjee, M. S. Buchsbaum

003 **Dopamine transporter and hippocampal volume in schizophrenia**
Yuan-Hwa Chou, Taiwan

004 **Improving prognostic accuracy in subjects at clinical high risk for psychosis: Systematic review of predictive models and meta-analytical sequential testing simulation**
André Schmidt, Switzerland
M. Cappucciati, J. Radua, G. Rutigliano, M. Rocchetti, L. Dell'Osso, P. Politi, S. Borgwardt, T. Reilly, L. Valmaggia, P. McGuire, P. Fusar-Poli

005 **Neural correlates of childhood trauma with cognitive impairment in young healthy adults: A resting-state fMRI study**
Shaojia Lu, People's Republic of China
F. Pan, W. Gao, M. Huang, S. Hu, Y. Xu, L. Li

ADVERT

WASAD
International Congress of the World Association for Stress Related and Anxiety Disorders
in conjunction with the
Collaborative Research Centers SFB-TRR 58, Fear, Anxiety, Anxiety Disorders
14 – 17 September 2017 | Würzburg, Germany

www.wasad-congress.org

▶ Thursday, 22 June 2017

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-56 **SYMPOSIUM**

08:30–10:00 Auditorium 15

Clinical effects and neural mechanisms of electroconvulsive therapy in major depression and schizophrenia

Chair: *Robert Christian Wolf, Germany*
Co-Chair: *Philipp Thomann, Germany*

001 **ECT in major depression and schizophrenia: Indications and clinical effects**
Dusan Hirjak, Germany

002 **Effects of ECT on brain structure and function: Lessons from major depressive disorder**
Robert Christian Wolf, Germany

003 **ECT-related effects on regional brain volume and structural networks in patients with schizophrenia and major depressive disorder**
Philipp Thomann, Germany

004 **Modulation of intrinsic network connectivity by ECT in patients with schizophrenia and major depressive disorder**
Fabio Sambataro, Italy

T6: BIPOLAR DISORDERS: BASIC / CLINICAL

S-57 **SYMPOSIUM**

08:30–10:00 Congress Hall A 3

Causes and consequences of inflammation in Bipolar Disorder (BP)

Chair: *Lars Kessing, Denmark*
Co-Chair: *Flavio Kapczinski, Brazil*

001 **Peripheral inflammation in Bipolar Disorder (BP): Trait and state related alterations**
Klaus Munkholm, Denmark

002 **Targeting mitochondrial inflammation in Bipolar Disorder (BP)**
Ana Andreazza, Canada

003 **Relationships between inflammation, elevated body mass index, and depressive relapse in Bipolar Disorder (BP)**
David Bond, USA

004 **Genetic and central nervous system aspects of immune dysregulation in Bipolar Disorder (BP)**
Bartholomeus Haarman, The Netherlands

T51: MISCELLANEOUS

S-58 **SYMPOSIUM**

08:30–10:00 Auditorium 12

Novel therapeutics for neurodegenerative disorders

Chair: *Ramón Cacabelos, Spain*

001 **ASS234, as a new multi-target directed propargylamine for Alzheimer's Disease (AD) therapy**
José Marco-Contelles, Spain

002 **EB101 immunotherapy against amyloid: A promising strategy for treating Alzheimer's Disease (AD)**
Iván Carrera, Spain

003 **The Intelligent Pharmacogenetic Card (PGx-iCard) for neuropsychiatric disorders**
Juan C. Carril, Spain

004 **Neuroprotective effects of Atremorine in Cerebral Ischemia and Parkinson disease-related models**
Javier Egea, Spain

005 **Basic and clinical studies with E-PodoFavalin-15999 (Atremorine®) in Parkinson's Disease: Selective dopaminergic neuroprotection and pharmacogenetics**
Ramón Cacabelos, Spain

T22: MOLECULAR NEUROBIOLOGY

S-59 **SYMPOSIUM**

08:30–10:00 Auditorium 10

The relevance of Neuregulin1-ErbB4 signaling for neuropsychiatric pathomechanisms: Converging insights from mouse genetics, physiology, and human studies

Chair: *Peter Falkai, Germany*
Co-Chair: *Moritz Rossner, Germany*

001 **The relevance of Neuregulin1-ErbB4 signaling for neuropsychiatric pathomechanisms: Insights from human studies**
Cyndi Shannon Weickert, Australia

002 **Neuregulin1-ErbB4 signaling: Integration at the network level**
Beatriz Rico, United Kingdom

003 **The relevance of Neuregulin1-ErbB4: Insights from mouse physiological analyses**
Andrés Buonanno, USA

004 **Neuregulin1-ErbB4 signaling: Insights from mouse genetics**
Markus Schwab, Germany

Scientific Programme / Thursday, 22 June 2017

T22: MOLECULAR NEUROBIOLOGY

S-60 **SYMPOSIUM**
08:30–10:00 Auditorium 11
Multi-omics and psychiatry: The missing molecular link
Chair: *Michaela Filiou, Germany*
Co-Chair: *Anthony Zannas, Germany*

001 **Stress-related phenotypes and epigenetic aging**
Anthony Zannas, Germany

002 **From proteomics to biological mechanisms involved in schizophrenia**
Daniel Martins de Souza, Brazil

003 **Multi-omics driven discovery of pharmacological targets for stress-related disorders**
Michaela Filiou, Germany

004 **Role of CYP2C19 in major depressive disorder? Translational study**
Marin Jukic, Sweden

T49: SUICIDE: BASIC / CLINICAL

S-61 **SYMPOSIUM**
08:30–10:00 B3 M1-M2
Suicide: Aspects that burn
Chair: *Konstantinos Fountoulakis, Greece*
Co-Chair: *Dina Popovic, Israel*

001 **Genetic basis of suicidal behaviour**
Alessandro Serretti, Italy

002 **Mixed features and suicidality: Is DSM 5 wrong?**
Dina Popovic, Israel

003 **How does clinical prediction of suicidality affect our daily clinical practice?**
Mark Weiser, Israel
M. Davidson

004 **Suicidality and overlaping geographical maps: Spurious correlations or cues for an underlying biological substrate?**
Konstantinos Fountoulakis, Greece

ES-03 **EDUCATIONAL SESSION**
09:00–13:00 B3 M3-M4
Update on research
Chairs: *Sabine Herpertz, Germany*
Ladislav Hosák, Czech Republic

001 **What do we learn from genetics**
Dan Rujescu, Germany

002 **Biomarkers in psychiatry**
Peter Riederer, Germany

003 **What do we learn from meta-analysis?**
Alessandro Serretti, Italy

004 **Highlights in structural and functional imaging in the schizophrenia spectrum**
Iris Sommer, The Netherlands

PL-04 **PLENARY SESSION**
10:15–11:00 Auditorium 15
Lithium in mood disorders including a homage to Danish contribution
Chair: *Tudor Udristoiu, Romania*
Speaker: *Janusz Rybakowski, Poland*

T49: SUICIDE: BASIC / CLINICAL

S-62 **SYMPOSIUM**
11:00–12:30 Auditorium 15
Innovative approaches in suicide research
Chair: *Philippe Courtet, France*
Co-Chair: *Sidney Kennedy, Canada*

001 **Initiative for research network**
Sidney Kennedy, Canada

002 **Neurosciences based phenomenology of suicidal behaviour**
Philippe Courtet, France

003 **MeMind project: Ambulatory assessment in suicide behaviour. Do different things to expect different results?**
Enrique Baca Garcia, Spain

004 **The use of machine learning and big data to predict suicide**
Michael Berk, Australia

T33: PHARMACOLOGY

S-63 **SYMPOSIUM**
11:00–12:30 Congress Hall A 3
Atypical neurotransmitters in psychiatry: Relevance for future therapeutics
Chair: *Gregers Wegener, Denmark*
Co-Chair: *Sâmia Joca, Brazil*

001 **Nitric oxide signalling in psychiatric disorders: Evidence from Gene x Environment x Development (GxExD) studies**
Gregers Wegener, Denmark

002 **ATP and NO interaction in stress models of depression**
Sâmia Joca, Brazil

003 **The endocannabinoid and endovanilloid system in stress-coping responses**
Fabricio Moreira, Brazil

004 **Neurotrophins and psychiatric disorders**
Eero Castrén, Finland

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-64 **SYMPOSIUM**
11:00–12:30 Auditorium 12
Operationalizing the dysconnection syndrome: Translational approaches reveal brain network dysfunction in schizophrenia
Chair: Bernat Kocsis, USA
Co-Chair: Vaibhav Diwadkar, USA

001 **Dysconnection in rodent models of schizophrenia: Directed connectivity analyses of frequency-tagged oscillatory coupling of frontal-hippocampal signals**
Bernat Kocsis, USA

002 **Ketamine disrupts the functional state of corticothalamic systems: A mechanistic model for prodromal schizophrenia**
Didier Pinault, France

003 **Structural and functional brain dysconnectivity predating the onset of psychosis**
Stefan Borgwardt, Switzerland

004 **The dynamics of the functional "dysconnectome" in schizophrenia: Network modeling of in vivo fMRI signals**
Vaibhav Diwadkar, USA

T24: NEUROPATHOLOGY

S-65 **SYMPOSIUM**
11:00–12:30 Auditorium 10
Cell-type specific epigenetic, proteomic and gene expression signatures in schizophrenia: New findings from post-mortem investigations
Chair: Peter Falkai, Germany
Co-Chair: Andrea Schmitt, Germany

001 **Alteration of genome-wide gene expression in hippocampal CA4 pyramidal neurons in schizophrenia**
Andrea Schmitt, Germany

002 **Is the energy dysfunction observed in schizophrenia brains being originated in oligodendrocytes?**
Daniel Martins de Souza, Brazil

003 **Integrated analysis of cell-type specific epigenome-wide methylation changes in schizophrenia brains**
Theo Kraus, Germany
A. Schmitt, J. Spanner, P. Falkai, A. Giese

004 **Epigenetic signatures in the brain of schizophrenia patients**
Andre Fischer, Germany

T11: DEPRESSION: BASIC / CLINICAL

S-67 **SYMPOSIUM**
11:00–12:30 B3 M1-M2
Spectrum of Mood Disorders (MD): Where is the place for mixed states?
Chair: Trisha Suppes, USA

002 **Bipolar mixed states: Review of clinical presentation, treatment and outcomes**
Mark Frye, USA

003 **Major depressive disorder with mixed features: Epidemiology, clinical characteristics and prognosis**
Allan Young, United Kingdom

004 **Major depressive disorder with mixed features: Review of current treatment options**
Trisha Suppes, USA

P-18 **POSTER TOUR**
13:00–14:30 Congress Hall A 1
Pharmacology & pharmacogenetics
Chair: Dan Rujescu, Germany

001 **In vitro inhibition of human cytochrome P450 isoenzymes by the novel atypical atipsychotic drug iloperidone**
Jacek Wójcikowski, Poland
P. Danek, W. A. Daniel

002 **The stimulating effect of 5-HT2 receptor activation in the hypothalamic arcuate nuclei (ARC) on cytochrome P450 activity in rat liver**
Marta Rysz, Poland
E. Bromek, A. Haduch, W. A. Daniel

003 **Activation of 5-HT1A receptors in the hypothalamic Paraventricular Nuclei (PVN) negatively regulates cytochrome P450 expression in rat liver**
Anna Haduch, Poland
E. Bromek, M. Rysz, J. Wójcikowski, W. A. Daniel

Scientific Programme / Thursday, 22 June 2017

004 **Gender related differences in reporting side-effects in Glasgow Antipsychotic Side-effects Scale for Clozapine (GASS-C scale)**
Dragana Ignjatovic Ristic, Serbia and Montenegro
J. Jovic, D. Cohen

005 **Pharmacological characterization of receptor-mediated Gi/o activation in postmortem human prefrontal cortical membranes**
Yuji Odagaki, Japan
M. Kinoshita, T. Ota, J. J. Meana, L. F. Callado, J. A. Garcia Sevilla

006 **Mania induced by levetiracetam treatment: A case report**
João Fonseca, Portugal
D. Vilaverde, P. Morgado

007 **Improvement of social interaction and cognition by oxytocin for autism-like behaviors in valproic acid-exposed rats**
Kohji Fukunaga, Japan
K. Matsuo, Y. Yabuki

008 **Melatonin improved PTSD-like behaviors observed in FABP3 null mice**
Kohji Fukunaga, Japan
Y. Yabuki, Y. Shinoda

009 **Memantine activates CaMKII and improves cognition via KATP channels**
Kohji Fukunaga, Japan
S. Moriguchi

010 **Modafinil for the treatment of Attention Deficit Hyperactivity Disorder (ADHD): A meta-analysis**
Sheng-Min Wang, Republic of Korea
C.-U. Pae

012 **The use of statins for the treatment of depression in patients with acute coronary syndrome**
Sung-Wan Kim, Republic of Korea
J.-M. Kim, I.-S. Shin, H. Kim, Y.-H. Lee, J.-W. Kim, M. Berk, J.-S. Yoon

013 **No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia**
Bjørn Ebdrup, Denmark
P. Ishøy, B. Fagerlund, B. Broberg, N. Bak, F. Knop, B. Glenthøj

014 **Neuro-PGx Card: A new approach to the personalized treatment of CNS disorders**
Juan C. Carril, Spain
R. Cacabelos

015 **The associations between polymorphisms HTR2A and development of antipsychotic-induced metabolic disturbances: Preliminary results of prospective study in Russian patients**
Regina Nasyrova, Russia
S. Dmiriy, T. Vera, I. Dmitriy, S. Kristina, E. Evgeniy, N. Nicolay

016 **Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patience with alcohol use disorder**
Mikhail Zastrozhin, Russia

017 **The impact of a single nucleotide polymorphism in SIGMAR1 on depressive symptoms in major depressive disorder and Bipolar Disorder (BP)**
Laura Mandelli, Italy
C.-U. Pae, A. Serretti

018 **Association of the Leptin Receptor gene (LEPR) polymorphism with blood pressure in patients with schizophrenia who are taking clozapine**
Shi-Hyun Kang, Republic of Korea
J.-I. Lee

020 **Establishment of evidence-based CYP2C19 genotype-guided escitalopram dosing recommendations – a naturalistic study based on 2,088 patients**
Marin Jukic, Sweden
E. Molden, M. Ingelman-Sundberg

P-19 **POSTER TOUR**
13:00–14:30 Congress Hall A 1
Neuropathology & neurophysiology
Chair: Gregers Wegener, Denmark

001 **The effects of intestinal endotoxemia on APP, PS1 and BACE expression in Alzheimer's Disease**
Bai Han, People's Republic of China
F. Wu, C. Li, X. Shan, Q. Sun, K. Liu

002 **A novel Alzheimer's Disease vaccine: A promising dual effect for preventing and treating neuropathological hallmarks**
Iván Carrera, Spain
L. Fernandez Novoa, C. Vigo, R. Cacabelos

004 **A case of psychiatric presentation of anti NMDA receptor encephalitis**
Jose Ildefonso Pérez Revuelta, Spain
J. Pascual Juliá, J. M. Pascual Paño, C. Rodríguez Gómez, J. M. Villagran Moreno

005 **Effects of intestinal endotoxemia on learning memory ability and brain levels of Aβ; Tau protein in rats with Alzheimer's Disease (AD)**
Bai Han, People's Republic of China
F. Wu, C. Li, X. Shan, Q. Sun, K. Liu

007 **Characteristics of oxygenated hemoglobin concentration changes in patients with major depressive disorder measured by multi-channel NIRS during pleasant and unpleasant image recall tasks**
Akihiko Kondou, Japan
K. Morita, Y. Shoji, Y. Ishii, S. Nakano, Y. Kato, Y. Yamashita, M. Inoue, H. Yanagimoto, N. Uchimura

008 **Single-event-related changes in Oxy-Hb during verbal discrimination tasks in patients with schizophrenia spectrum disorders**
Youhei Ishii, Japan
K. Morita, Y. Shoji, Y. Yamashita, J. Okawa, Y. Kato, A. Kondou, S. Nakano, M. Sato, H. Yanagimoto, N. Uchimura

010 **Comparison of changes in the oxygenated hemoglobin level during Baum task pairing between healthy subjects and patients with schizophrenia**
Yoshihisa Shoji, Japan
K. Morita, H. Igimi, Y. Ishii, Y. Kato, Y. Yamashita, A. Kondou, S. Nakano, M. Inoue, H. Yanagimoto, N. Uchimura

011 **Modulation of the Serotonin system in an animal model of psilocin-induced psychosis: Time-course of quantitative EEG changes**
Filip Tyls, Czech Republic
C. Vejmola, L. Kaderabek, V. Piorecka, V. Koudelka, T. Novak, T. Palenicek

012 **Bright light enhances precocious expression of motor skill consolidation while optimizing speed-accuracy trade-off in humans**
Takuya Yoshiike, Japan
M. Honma, K. Kuriyama

P-20 **POSTER TOUR**
13:00–14:30 Congress Hall A 1
Genetics
Chair: Thomas Werge, Denmark

001 **Relevance of vascular risk polymorphisms in cognitive deterioration**
Juan C. Carril, Spain
R. Cacabelos

002 **Risk polymorphisms associated with dementia in the Spanish population**
Juan C. Carril, Spain
O. Teijido, R. Cacabelos

003 **Association between ULK2 gene polymorphisms and the risk of schizophrenia in Korean population**
Jong-Woo Kim, Republic of Korea
W.-S. Kang, J.-W. Paik, J.-Y. Song

004 **Association of MYCBP2 gene polymorphisms to schizophrenia susceptibility in Korean population**
Won-Sub Kang, Republic of Korea
J.-Y. Song, J.-W. Paik, J.-W. Kim

005 **Association between cytokine gene polymorphisms with panic disorder**
Yong-Ku Kim, Republic of Korea
H.-J. Kim

006 **Genetic role of 5-HTTLPR on psychological resilencelience of the patients with Mood Disorder (MD)**
Eun-Jeong Joo, Republic of Korea
K.-Y. Lee, J.-K. Lee, K.-S. Choi

007 **Importance of polygenic risk scores to predict lipid levels and dyslipidemia development in a psychiatric population receiving dyslipidemia-inducing psychotropic drugs**
Aurélie Delacrétaz, Switzerland
P. Santos Lagares, N. Saigi-Morgui, F. Vandenberghe, A. Glatard, M. Gholam-Rezaee, F. Gamma, A. von Gunten, P. Conus, C. Eap

008 **Epigenomic profile in dementia-related disorders**
Oscar Teijido, Spain
I. Carrera, J. C. Carril, R. Cacabelos

009 **Epigenomics for advanced understanding of psychiatric diseases**
Oscar Teijido, Spain
I. Carrera, J. C. Carril, R. Cacabelos

010 **Influence of the APOE4 allele on brain networks in healthy elderly subjects**
Ivan Tellado, Spain
J. C. Carril, C. Fraile, R. Cacabelos

011 **Associations between disease trajectory and genomics in schizophrenia**
Morten Dybdahl Krebs, Denmark

013 **Money breaks the rhythm in your head: CLOCK gene polymorphisms interact with financial status to affect migraine**
Xénia Gonda, Hungary
D. Baksa, G. Juhasz

016 **Statistical epistasis between COMT, PRODH and ZDHHC8 on chromosome 22q11 for schizophrenia in Koreans**
Yu-Sang Lee, Republic of Korea
K. S. Hong, S. Y. Lee, E.-Y. Cho

Scientific Programme / Thursday, 22 June 2017

P-21 **POSTER TOUR**

13:00–14:30 Congress Hall A 1

Schizophrenia 3

Chair: Janusz Rybakowski, Poland

001 **Variability of 128 schizophrenia-associated gene variants across distinct ethnic populations**
Kazutaka Ohi, Japan
T. Shimada, T. Yasuyama, T. Uehara, Y. Kawasaki

002 **Association study between Dysbindin gene and schizophrenia in a Korean population**
Kyu-Young Lee, Germany
E.-J. Joo

003 **Low methylation rates of dopamine receptor D2 gene promoter sites in Japanese schizophrenia subjects**
Yuta Yoshino, Japan
K. Kawabe, Y. Mori, K. Yamazaki, J.-I. Iga, S.-I. Ueno

005 **Gender-specific associations of the brain-derived neurotrophic factor Val66Met polymorphism with neurocognitive and clinical features in schizophrenia**
Sung-Wan Kim, Republic of Korea
Y.-H. Lee, T.-Y. Yoo, J.-Y. Lee, J.-M. Kim, I.-S. Shin, J.-S. Yoon

006 **Sequencing of neurotrophic tyrosine receptor kinase 1 gene region in Armenian schizophrenia patients**
Roksana Zakharyan, Armenia
A. Arakelyan

007 **Clinical characteristics of formal thought disorder in schizophrenia**
Ho-Seon Lee, Republic of Korea
S.-C. Park

009 **SorCS1 regulates inhibitory networks and gamma-oscillations – a link to schizophrenia?**
Peter Lund Ovesen, Denmark
U. Bølcho, K. M. Pedersen, S. Mølgaard Jensen, S. Glerup, M. M. Holm, A. Nykjær

010 **Impact of familial loading on prefrontal activation in major psychiatric disorders: A Near-Infrared Spectroscopy (NIRS) study**
Kazutaka Ohi, Japan
T. Shimada, H. Kihara, T. Yasuyama, K. Sawai, K. Oshima, H. Okubo, Y. Nitta, T. Uehara, Y. Kawasaki

011 **Total and high-affinity-state dopamine D2 receptors in the striatum of antipsychotic-free patients with schizophrenia: A PET study with [11C] raclopride and [11C] MNPA**
Manabu Kubota, Japan
T. Nagashima, H. Takano, F. Kodaka, H. Fujiwara, K. Takahata, S. Moriguchi, Y. Kimura, M. Higuchi, Y. Okubo, H. Takahashi, T. Suhara

013 **Brain anatomy of symptom stratification in schizophrenia: A voxel based morphometry study**
Giuseppe Delvecchio, Italy
A. Lorandi, C. Perlini, M. Barillari, M. Ruggeri, A. C. Altamura, M. Bellani, P. Brambilla

014 **White matter correlates of impaired gesture performance and recognition in schizophrenia**
Petra Viher, Switzerland
P. Savadjiev, K. Stegmayer, N. Makris, S. Karmacharya, A. Federspiel, S. Bohlhalter, T. Vanbellingen, R. Wiest, M. E. Shenton, W. K. Strik, M. Kubicki, S. Walther

015 **Is the perception of language cues different in schizophrenia?: A pilot study**
Marie Bendova, Czech Republic
Y. Zaytseva, M. Kolarova, M. Mojzisek, J. Rydlo, R. Gaspar, F. Spaniel

016 **Amelioration of abnormal beliefs in subjects at ultra high-risk for psychosis linked to longitudinal increase in ventral striatal function during salience processing**
André Schmidt, Switzerland
M. Antoniades, P. Allen, A. Egerton, C. Chaddock, S. Borgwardt, P. Fusar-Poli, J. Roiser, O. Howes, P. McGuire

017 **The N-Methyl D-Aspartate glutamate receptor antagonist ketamine disrupts the functional state of the corticothalamic pathway**
Paul Anderson, The Netherlands
N. Jones, T. O'Brien, D. Pinault

018 **Impact of trauma on negative symptoms of schizophrenia**
Ombline Bolloré, France
D. Fouques, C. Isaac, D. Januel

020 **Formal thought disorder in schizophrenia patients: Gender differences**
Joon-Ho Choi, Republic of Korea
J.-E. Park, S.-C. Park

021 **The validity and sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study**
Søren Dinesen Østergaard, Denmark
L. Foldager, O. Mors, P. Bech, C. U. Correll

022 **Novel strategies of treatment of mental disorders based on D-cell hypothesis**
Keiko Ikemoto, Japan

P-22 **POSTER TOUR**

13:00–14:30 Congress Hall A 1

Dementia

Chair: Alessandro Seretti, Italy

002 **Functional connectivity pattern between the fornix and other brain regions in mild cognitive impairment: A resting-state functional magnetic resonance imaging study**
Dong-Woo Kang, Republic of Korea
I.-H. Paik

005 **Morphological and functional connectivity change of basal ganglia in amnestic mild cognitive impairment**
Dong-Woo Kang, Republic of Korea
I.-H. Paik

006 **The effects of tanshinone II A on a rat model of Alzheimer's Disease (AD) with Intestinal Endotoxemia (IETM)**
Bai Han, People's Republic of China
F. Wu, C. Li, X. Shan, Q. Sun, K. Liu

007 **The mixture of rhubarb and salvia miltiorrhiza, Tanshinone II A on the prevention and treatment of Alzheimer's Disease (AD**
Bai Han, People's Republic of China
F. Wu, C. Li, X. Shan, Q. Sun, K. Liu

008 **25-Hydroxyvitamin D levels in dementia and psychiatric disorders**
Ivan Tellado, Spain
L. Corzo, S. Rodriguez, R. Cacabelos

009 **Comorbidity of psychiatric disorders and the characteristics of the therapy of the hospitalized patients**
Balázs Móra, Hungary
L. Péter

010 **DNA methylation changes at TREM2 intron 1 and TREM2 mRNA expression in patients with Alzheimer's Disease**
Yuki Ozaki, Japan

011 **Blood and CSF markers of inflammation related to anxiety and depression in older adults with and without cognitive impairment**
Julius Popp, Switzerland

012 **Disruptions on cortical networks associated with vascular dementia**
Ivan Tellado, Spain
C. Fraile, R. Cacabelos

013 **Polypharmacy, drug compliance and cognitive decline in elderly population: A nationwide population-based survey**
Chih-Ming Cheng, Taiwan
W.-H. Chang, C.-H. Yang, C.-F. Tsai

014 **Relationship between delusion of theft and cognitive functions in patients with mild Alzheimer's disease**
Hae Ran Na, Republic of Korea

T25: NEUROIMAGING: GENETIC, FUNCTIONAL, STRUCTURAL

S-68 **SYMPOSIUM**

15:00–16:30 Auditorium 15

Dynamical brain: How brain complexity changes with aging and mental illness?

Chair: Chih-Chieh Yang, USA
Co-Chair: Tetsuya Takahashi, Japan

001 **Dynamical analysis of brain activity: A new research dimension**
Chih-Chieh Yang, USA

002 **Assessment of neurophysiological changes with electroconvulsive therapy in mental disorders using nonlinear approach**
Ryoko Okazaki, Japan

003 **Increasing signal variability during development and its relevance to autism spectrum disorders**
Tetsuya Takahashi, Japan

004 **Neurophysiological basis of creativity in healthy elderly people using nonlinear approach**
Kanji Ueno, Japan

T19: INFLAMMATION PSYCHIATRY

S-69 **SYMPOSIUM**

15:00–16:30 Congress Hall A 3

Increased intestinal permeability and bacterial translocation in neuro-psychiatric disorders

Chair: Michael Maes, Thailand
Co-Chair: Yolanda Sanz, Spain

001 **Increased intestinal permeability and bacterial translocation in depression and chronic fatigue syndrome**
Michael Maes, Thailand

002 **Increased intestinal permeability and bacterial translocation in chronic stress animal models**
Javier Caso, Spain

003 **Increased intestinal permeability and bacterial translocation in neurodevelopmental disorders**
Yolanda Sanz, Spain

004 **Increased intestinal permeability and bacterial translocation in schizophrenia**
Emily Severance, USA

Scientific Programme / Thursday, 22 June 2017

T26: NEUROPHYSIOLOGY

S-70 **SYMPOSIUM**

15:00–16:30 Auditorium 12

Current use of EEG-based techniques in psychiatry

Chair: *Martijn Arns, The Netherlands*
Co-Chair: *Adam Wichniak, Poland*

001 **Epilepsy spectrum disorders and episodic psychiatric symptoms**
Nash Boutros, USA

002 **Results of the international multi-center iSPOT-A study in ADHD: EEG predictors of treatment outcome to methylphenidate**
Martijn Arns, The Netherlands

003 **Did the No-Go P300 component help to predict relapse in recently detoxified alcoholic patients?**
Salvatore Campanella, Belgium

004 **Polysomnographic measures of sleep in psychiatry: Implications for diagnosis and treatment**
Adam Wichniak, Poland

T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC / CLINICAL

S-71 **SYMPOSIUM**

15:00–16:30 Auditorium 10

Sex-specific neuroendocrinological findings in conduct disorder

Chair: *Sabine Herpertz, Germany*
Co-Chair: *Christine Freitag, Germany*

001 **The brain oxytocin system in intermale and female aggression in rodents**
Trynke De Jong, Germany
I. Neumann

002 **Sex-specific differences in oxytocin effects on the brain's salience circuit**
Haang Jeung, Germany

003 **Sex-specific differences and the effects of puberty on emotional processing in adolescents with and without conduct disorder**
Kerstin Konrad, Germany

004 **The role of basal and reactive steroid hormones and neuropeptides in female conduct disorder**
Christine Freitag, Germany
A. Martinelli, K. Ackermann, A. Bernhard, FemNAT-CD study team

T6: BIPOLAR DISORDERS: BASIC / CLINICAL

S-72 **SYMPOSIUM**

15:00–16:30 Auditorium 11

Socio-demographic and clinical differences between Bipolar I and II Disorder (BP) and implications for treatment

Chair: *Terence Ketter, USA*
Co-Chair: *Bernardo Dell'Osso, Italy*

001 **Bipolar I vs II Disorder (BP): Characterization of socio-demographic and clinical variables in Italian and American samples**
Bernardo Dell'Osso, Italy

002 **Clinical implications of predominant polarity and polarity index in Bipolar Disorders (BP)**
Eduard Vieta, Spain

003 **Epidemiology and clinical correlates of suicide and suicide attempts in Bipolar Disorders (BP)**
Maurizio Pompili, Italy

004 **Do we have evidence for differentiating pharmacological treatment of Bipolar I from Bipolar II Disorder (BP)?**
Terence Ketter, USA

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-73 **SYMPOSIUM**

15:00–16:30 B3 M1-M2

Neuropathologic implication of abnormal cortico-basal ganglia connectivity in schizophrenia hallucination and its models

Chair: *Hiroyuki Nawa, Japan*

001 **Neuropathologic implication of pallidal hyperactivity in the auditory abnormality of schizophrenia animal models**
Hiroyuki Nawa, Japan

002 **The rat ketamine model of schizophrenia shows aberrant oscillatory activity in the cortico-basal ganglia circuit**
Miguel Valencia, Spain

003 **Prefrontal – Basal ganglia circuit dysfunction associated with psychosis in schizophrenia**
Jong Yoon, USA

004 **Subcortical modulation in auditory processing and auditory hallucinations**
Toshikazu Ikuta, USA

FC-16 **FREE COMMUNICATION SESSION**

15:00–16:30 B3 M3-M4

Childhood & adolescent disorders

Chair: *Ryo Kimura, Japan*

Co-Chair: *Marina Mitjans, Germany*

002 **Management of impulsivity in adult ADHD comorbid groups: A factor analysis**
Srinivas Kandrakonda, India
S. K. Jaiswal, P. Sravana Sandhya, J. Shyam Kumar

003 **Multiple environmental hits before adulthood predict violent aggression**
Marina Mitjans, Germany
J. Seidel, B. Oliveira, M. Begemann, F. Bockhop, V. Bansal, J. Wesolowski, F. Kovacevic, L. Fañanás, H. Wolf, J. Müller, B. Arias, H. Ehrenreich

004 **Aberrant expression of microRNAs as specific blood-based biomarkers for autism spectrum disorder**
Ryo Kimura, Japan
M. Nakata, T. Awaya, T. Kato, Y. Funabiki, T. Murai, T. Heike, M. Hagiwara

005 **Randomised controlled trial of prolonged exposure therapy and supportive counselling for adolescent posttraumatic stress disorder: Task-shifting to nurses in a low resource setting**
Jaco Rossouw, South Africa
E. Yadin, D. Alexander, S. Seedat

CC-01 **CLOSING CEREMONY**

16:30–17:30 Auditorium 15

Closing Ceremony

ADVERT

Current Psychopharmacology



Editor-in-Chief:
Silvio Bellino
University of Turin
Italy

ISSN (Print) : 2211-5560
ISSN (Online) : 2211-5579

Aims & Scope

Current Psychopharmacology publishes peer-reviewed expert reviews, original research articles and single topic guest edited issues on all aspects of pre-clinical and clinical research in psychopharmacology. The journal aims to be the leading forum for expert review articles in the field. The journal also accepts high-level original research articles on outstanding topics of preclinical and clinical psychopharmacology. Data must be published for the first time in Current Psychopharmacology.

www.benthamscience.com

BENTHAM SCIENCE

20% Subscription Discount

To Attendees of "13th World Congress of Biological Psychiatry"
To apply, refer discount code "BSPPRTCO16"
and email at: marketing@benthamscience.org

Publishers of Quality Research

For Subscriptions
Contact: subscriptions@benthamscience.org

For Advertising & Online Trials
Contact: marketing@benthamscience.org

Congress Information

CONGRESS VENUE

Bella Center Copenhagen
Conference Entrance
Center Boulevard 5
2300 Copenhagen S, Denmark

CONGRESS REGISTRATION COUNTER

The congress counter will be located in the Congress Foyer.

Opening hours	
Saturday, 17 June 2017	16:00–19:00
Sunday, 18 June 2017	07:30–19:00
Monday, 19 June 2017	08:00–18:30
Tuesday, 20 June 2017	08:00–18:30
Wednesday, 21 June 2017	08:00–18:30
Thursday, 22 June 2017	08:00–17:30

During these hours the congress registration counter can be reached at: +45–3247 2952

CONGRESS AND EXHIBITION OFFICE

CPO HANSER® SERVICE

Phone: +49–30–300 669-0
Email: wfsbp2017@cpo-hanser.de

NAME BADGES

All participants are kindly requested to wear their name badge at all times during the congress including the Opening Ceremony and Welcome Reception.

The colours of the name badges have the following significance:

Congress delegate: ▸ orange
Exhibitor: ▸ purple
Staff: ▸ grey

CONGRESS LANGUAGE

The official language of the WFSBP Congress 2017 is English.

CERTIFICATE OF ATTENDANCE / CME CERTIFICATES

For certificates of attendance and CME certificates, please contact the staff at the registration counter.
From 27 June 2017 on, you can also print your CME certificate online at **www.wfsbp-congress.org** by logging in with your participant number or with your congress login credentials.

CONGRESS INFORMATION SYSTEM

The web based Congress Information System CO CONGRESS ONLINE® has been installed at **www.wfsbp-congress.org**

CO CONGRESS ONLINE® will provide information on:

- Updated scientific programme
- Programme by day
- Programme by format with accepted abstracts
- Programme search
- List of exhibitors and sponsors
- General congress information
- City of Copenhagen
- Travel information
- Private mailbox

TECHNICAL EXHIBITION

The WFSBP Congress 2017 will be accompanied by a technical exhibition taking place in Congress Hall A1 of the Bella Center.

Exhibition hours	
Monday, 19 June 2017	09:00–17:00
Tuesday, 20 June 2017	09:00–17:00
Wednesday, 21 June 2017	09:00–17:00

WFSBP 2017 CONGRESS APP

The WFSBP 2017 Congress App is free for congress participants and provides iPhone/iPad and android smartphone users at WFSBP 2017 in Copenhagen with on-the-go access to the congress. The most up-to-date congress schedule is available at your fingertips during the congress.

- Mark your favorite sessions and personalise your experience.
- Quickly find your way through the most up-to-date congress schedule.
- Access vital information around the congress.
- Receive push notifications regarding important sessions
- Network with other WFSBP participants

Download on the App Store | GET IT ON Google Play

The WFSBP 2017 App is powered by GLOBIT GmbH in cooperation with esanum GmbH.

Further information is given at www.wfsbp-congress/app.

Congress Information

WIFI

Please select the WiFi network **BC Guest**, no password is required.

SPEAKERS' CENTRE

The Speakers' Centre is located in Meeting Room 6. Speakers are asked to hand in their CD-ROM or USB stick containing the PowerPoint presentation (IBM format or compatible, no multisession) preferably one day before their presentation, but at the latest three hours prior to the presentation. On-site technical staff will offer support.

Due to time and technical reasons we kindly ask the speakers not to use their own notebook. In the Speakers' Centre there are several PC working stations, where speakers can also work on their presentation charts in a quiet area. Technical staff will be happy to assist.

Operated by ESTENSIS The Conference Company.

Opening hours	
Saturday, 17 June 2017	16:00–19:00
Sunday, 18 June 2017	07:30–18:30
Monday, 19 June 2017	08:00–18:00
Tuesday, 20 June 2017	08:00–18:00
Wednesday, 21 June 2017	08:00–18:00
Thursday, 22 June 2017	08:00–15:30

POSTER EXHIBITION

The poster exhibition is located in Congress Hall A1. Posters will be changed daily and are on display for the entire day of the respective poster tour. They will be sorted by topics and will be numbered within those topics. The poster exhibition is open to all registered delegates:

Poster exhibition times for P-01 to P-05

Monday, 19 June 2017	09:00–17:00
Guided Poster Tours	13:00–14:30

Poster exhibition times for P-06 to P-10

Tuesday, 20 June 2017	09:00–17:00
Guided Poster Tours	13:00–14:30

Poster exhibition times for P-11 to P-17

Wednesday, 21 June 2017	09:00–17:00
Guided Poster Tours	13:00–14:30

Poster exhibition times for P-18 to P-22

Thursday, 22 June 2017	09:00–17:00
Guided Poster Tours	13:00–14:30

Interested participants can meet the authors for discussions of their poster presentation during the time of the poster tour.

Set-up and dismantling times for posters

Posters need to be put up and dismantled on the day of the respective poster tour within the following times:

Set-up:	08:00 – 09:00
Dismantling:	17:00 – 18:00

Posters which have not been removed will be disposed of. Poster material to put up the poster is available at the poster service desk.

BEST POSTER AWARDS

All posters will be evaluated on site by the WFSBP Prize Committee. The WFSBP Prize Committee will shortlist 5 posters per day that will be exhibited at a Best Poster area in Congress Hall A1 in the afternoon. Two of these will win a Best Poster Award which will be announced on the day of the session. A total of 8 Best Poster Awards for young investigators under 40 years will be presented. All Best Poster Award winners will also be mentioned during the Closing Ceremony on Thursday, 22 June 2017.

PROGRAMME CHANGES

The organisers cannot assume liability for any changes in the congress programme due to external or unforeseen circumstances.

SNACK BARS

The congress provides snack bars in the exhibition area in Congress Hall A1 and in the Auditorium Foyer close to the Registration Counter. Beverages and snacks can be purchased there.

CASH MACHINE

An ATM/cash machine is located in the Bella Sky Hotel, adjacent to Bella Center, next to the front desk.

Congress Information

FIRST AID
In case of emergency, please contact the registration counter.

CURRENCY
The Danish currency is the Danish Krone (DKK). The Danish Krone is pegged to the Euro and convertible on world currency markets. The exchange rate fluctuates daily depending on the money market.
www.oanda.com

VISA
The entry formalities for Denmark vary according to the country of origin. The Ministry of Foreign Affairs of Denmark provides a list of countries that require a visa to enter the country. Please visit the website **http://um.dk/en.**

INSURANCE
Please note that the congress fee does not include insurance. All participants should arrange for their own insurance. Health and accident insurance is strongly recommended and will need to be purchased in the country of origin.

FORCE MAJEURE
For reasons beyond its control (such as war, strikes, lockouts, riots or any such civil disturbances, any natural disaster, including but not limited to earthquakes, floods, droughts and typhoons and any other cause of circumstance of whatsoever nature beyond control) that have an impact on the arrangements, timetables or planning of the 13th World Congress of Biological Psychiatry (WFSBP 2017) and its corresponding activities in Copenhagen, WFSBP has the right to immediately alter or cancel the activities or events or any of the arrangements, timetables, plans or other items relating directly or indirectly thereto. No party involved shall be entitled to any compensation for damages that result from such alteration or cancellation.

GENERAL CONDITIONS
The conditions published in the web will apply.
www.wfsbp-congress.org

CLIMATE
Copenhagen is in the oceanic climate zone. Summer months are moderately warm and quite pleasant. June is the sunniest month of the year with an average of about eight hours of sunshine a day and the temperature varies between 11°c (52 °F) and 19°c (66°F).

COPENHAGEN INFORMATION COUNTER
A Copenhagen Information Counter is located in the registration area and open during the congress. Please contact the staff for city information on Copenhagen or reservations.

HOW TO GET TO THE BELLA CENTRE
Public transportation in Copenhagen is reliable, punctual, and it goes everywhere in the city. In Copenhagen the trains, metro and busses (including waterbuses) can be accessed with the same ticket. All you need to know is how many zones you will pass on your journey.

HOW TO GET FROM COPENHAGEN CITY CENTRE TO THE BELLA CENTER
By Metro It only takes a few minutes to get from the centre of Copenhagen (metro stops Nørreport and Kongens Nytorv) to Bella Center. Take Metro line M1, direction Vestamager and get off at "Bella Center" – the stop is located by Bella Center's east entrance.
By Train Take an S-train (any line) to Nørreport and connect to Metro line M1, direction Vestamager. Get off at "Bella Center".
By Bus Take bus line 30 from Copenhagen Central Station – travel time is approx. 20-25 minutes.
By Taxi Bella Center is just a 10 – 15 minute taxi drive from Copenhagen Central Station and not more than 10 minutes from Copenhagen Airport. A taxi from Bella Center to the city centre costs about DKK 200-250. A taxi from Bella Center to Copenhagen Airport costs about DKK 150-200.
Shuttle Bus from / to Airport Bella Center offers a complimentary shuttle bus connecting Copenhagen Airport with Crowne Plaza Copenhagen Towers and AC Hotel Bella Sky Copenhagen.
It runs twice an hour and is offered on a first come first served basis for hotel and conference guests.

Congress Information

CITY OF COPENHAGEN

Copenhagen is not only the capital of Denmark. It is a cultural and economic center of Northern Europe. More than 1,2 million citizens live in the greater Copenhagen region.

The city is located on the Danish Island „Saeland" (Danish: Sjælland) and next to the „Øresund" – a Baltic sea seagate and natural borderline to Sweden. Due to this geographic location, Copenhagen – together with the Swedish city Malmö – represents the binational „Øresund Region". It is a unique metropolis area, where two countries and cities are connected via the 8 km „Øresund Bridge".

The Copenhagen Palaces Christiansborg and Amalienborg are the seat of the Danish Parliament and the residence of the Danish Queen Margrethe II. Architecture, design and music make Copenhagen an outstanding cultural hotspot in Northern Europe. It is famous for its innovative improvements which can be seen and experienced throughout the city.

Also, Copenhagen has great museums to offer, for example Louisiana and The National Gallery of Denmark. The Royal Danish Opera, located directly at the habor front, is combining modern Danish architecture with international performances. The main sightseeing spots and touristic attractions are the Tivoli Gardens, Christiansborg, and of course the „Little Mermaid" – the famos sculpture of Edvard Eriksen at the waterside.

The University of Copenhagen offers a wide range of academic disciplines. With over 40,000 students and more than 9,000 employees, the University of Copenhagen is one of the largest institutions of research and education in the Nordic countries.

Due to short distances within the city of Copenhagen, its good public transportation system, and especially the well developed cycle paths, Copenhagen is a convenient place for meetings.

ADVERT

Our passion ignites progress

At Eisai, *human health care* is our goal. We give our first thoughts to patients and their families as well as helping to increase the benefits health care provides. Our therapies are designed to make a difference and have an impact on patients' lives. We are Eisai, where medicine is more than just our business — it's our passion.

Eisai

hhc human health care

CORP-US0024 ©2016 Eisai Inc. All rights reserved. Oct 2016 www.eisai.com

List of Exhibitors / Exhibition Floor Plan

LIST OF EXHIBITORS

Company	Booth No
Actelion Pharmaceuticals Ltd	5
Attention Deficit Hyperactivity Disorder – ADHD Congress 2019, Lisbon	
European College of Neuropsychopharmacology – ECNP 2017	16
European Conference on Schizophrenia Research – ECSR Congress 2017	15
INPDA	11
International Society for the Study of Personality Disorders – ISSPD 2017 Heidelberg	
John Wiley & Sons Ltd.	3
MagVenture A/S	6
Neuroelectrics	13
REMED Co., Ltd.	9

Company	Booth No
Sunovion	4
Taylor & Francis Group	14
The International College of Neuropsychopharmacology – CINP 2017 Prague/ CINP 2018	18
The World Journal of Biological Psychiatry	10
World Association for Stress-related and Anxiety Disorders – WASAD 2017, Würzburg, Germany	12
Wisepress Ltd	17
WFSBP	2
WPA XVII WORLD CONGRESS OF PSYCHIATRY BERLIN 2017	1
ybrain Inc.	8



Acknowledgements

The organisers of the 13th World Congress of Biological Psychiatry gratefully acknowledge the support of the following companies (as per May 2017)

MAJOR SPONSOR

- Sunovion Pharmaceuticals
- Sumitomo Dainippon Pharma

SPONSORS

- Actelion
- Eisai Japan
- John Wiley



70% off for new subscribers!

Indexed in: Current Contents (LS), Science Citation Index, MEDLINE, EMBASE and SCOPUS

Pharmacopsychiatry

Editor-in-Chief: M. Bauer

2017/Volume 50/6 issues p.a./ISSN 0176-3679

Americas
Individuals: starting at $297 (contact customerservice@thieme.com)
Institutions: starting at $1,298 (contact esales@thieme.com)

Europe, Africa, Asia, Australia, New Zealand
Individuals: starting at €208 (contact customerservice@thieme.de)
Institutions: starting at €848 (contact eproducts@thieme.de)

(Please add shipping charges:
Germany €39.40, Europe €43.90, Africa, Asia, Australia, New Zealand €49.90)

Bangladesh, Bhutan, India, Nepal, Pakistan, and Sri Lanka
For subscription rates in INR, please contact customerservice@thieme.in

Subscribe at www.thieme.com/pharma

Special introductory rates are only valid for new subscribers and are limited to the first year of subscription. Only qualified professionals and students are eligible for individual subscriptions. Orders from individuals must include the recipient's name and private address, and be paid by private funds.

Thieme

ORDER TODAY http://www.thieme.com

Industry Sessions

▶ Monday, 19 June 2017

SA-01 INDUSTRY SPONSORED SATELLITE SYMPOSIUM

13:15 – 14:45 Auditorium 12

Psychopharmacology in management of schizophrenia: Recent advances and challenges

(Sunovion)

Chair: John Kane, USA

001 **Findings from scientific trials and clinical reality: How much progress did we make?**
John Kane, USA

002 **Managing metabolic outcomes of antipsychotic treatment: A balancing act with individualised approach**
David Taylor, United Kingdom

003 **Cognitive and functional outcomes in treatment of schizophrenia: Current options and future hope**
Stein Opjordsmoen, Norway

▶ Tuesday, 20 June 2017

SA-02 INDUSTRY SPONSORED SATELLITE SYMPOSIUM

13:15 – 14:45 Auditorium 12

Orchestrating the differential diagnosis of organic psychosis: Shining a spotlight on NP-C

(Actelion)

Chair: Hans-Hermann Klünemann, Germany

001 **Think NP-C: An insidious yet treatable psychiatric disease**
Hans-Hermann Klünemann, Germany

002 **Spotting the signs: When does psychosis point to NP-C?**
Oliver Bonnot, France

003 **Diagnostic challenges in NP-C: Using the right tools to make the diagnosis**
Christian Hendriksz, United Kingdom

004 **Challenging differential diagnoses: Recognising NP-C in frontotemporal dementia**
Alessandro Padovani, Italy

Q & A

Summary and close
Hans-Hermann Klünemann, Germany

List of Chairpersons, Authors and Co-Authors

A

Abdel-Hamid, M. ... 33
Abel, K. ... 33
Abel, L. ... 55
Abroms, M. ... 32
Ackermann, K. ... 70
Adli, M. ... 55
Agam, G. ... 44, 60
Agartz, I. ... 42
Agerbo, E. ... 34
Agid, O. ... 31, 40, 61
Ahn, Y.-M. ... 44, 57
Aitchison, K. J. ... 54
Akhadov, T. ... 51
Alaie, I. ... 43, 48
Albayrak, N. ... 55
Alberca, D. ... 44
Alberca, S. ... 44
Alcalá, J. A. ... 56
Alcalá Partera, J. ... 31
Aleksic, B. ... 29
Alexander, D. ... 71
Ali, A. ... 33
Allen, P. ... 68
Als, T. D. ... 47
Altamura, C. ... 26, 43, 44, 68
Alvarez Pedrero, A. ... 31
Amamou, B. ... 57
Ambrus, L. ... 57
Ames, D. ... 61
Ametamey, S. M. ... 55
Amir, N. ... 34
An, S.-K. ... 45
Anagboso, U. ... 32
Andersen, K. K. ... 34
Andersen, S. ... 32
Anderson, P. ... 68
Andreazza, A. ... 63
Andreoli, S. ... 42
Anmella, G. ... 30
Antoniades, M. ... 68
Antosik-Wójcińska, A. ... 55
Anwander, A. ... 43
Aouizerate, B. ... 23
Arai, H. ... 32, 42, 56
Arakelyan, A. ... 54, 68
Arango, V. ... 28
Arias, B. ... 71
Armstrong, N. ... 61
Arns, M. ... 70
Arumugham, S. S. ... 43
Asano, K. ... 48
Asara, J. ... 32
Ashton, M. ... 23, 44
Asp, M. ... 57
Atshemyan, S. ... 54
Atti, A. R. ... 31
Auer, B. ... 37
Augusto, P. ... 30
Awaya, T. ... 33, 71
Ayuso Gutierrez, J. L. ... 51
Azorin, J.-M. ... 58

B

Baaré, W. ... 32
Baca Garcia, E. ... 64
Bækvad-Hansen, M. ... 48
Baerentzen, S. ... 62
Baghai, T. ... 50
Bahk, W.-M. ... 45
Bai, Y.-M. ... 45
Bak, N. ... 66
Baksa, D. ... 67
Balcells, M. ... 30
Balmus, I.-M. ... 58
Bandelow, B. ... 36, 46
Bang, M.-J. ... 45
Bansal, V. ... 71
Barakat, A.-K. ... 23, 52
Barbosa, D. ... 45
Barillari, M. ... 43, 44, 68
Baroni, S. ... 24, 32
Barrio, P. ... 30
Barrios, M. ... 45
Barry, B. ... 32
Barta, C. ... 50
Barth, B. ... 36
Bartova, L. ... 34
Bar-Yosef, T. ... 44
Batra, A. ... 30
Batta, D. ... 41
Bauer, M. ... 44, 52
Bauer, R. ... 44
Baylé, F. ... 54
Bazin, P.-L. ... 43
Beato, L. ... 33
Bech, P. ... 34, 68
Beck, J. ... 34, 41
Begemann, M. ... 62, 71
Begun, J. ... 42
Belcredi, P. ... 41
Bellani, M. ... 43, 44, 68
Belz, M. ... 42
Belzung, C. ... 35
Benadhira, R. ... 54, 56
Benckova, M. ... 57
Bendova, M. ... 43, 68
Benegal, V. ... 30
Benros, M. ... 34, 61
Ben Saadi, S. ... 60
Benson, S. ... 37
Benveniste, H. ... 62
Benyamina, A. ... 46, 61
Berger, M. ... 33
Berk, L. ... 23
Berk, M. ... 23, 24, 25, 38, ... 44, 64, 66
Berkson, S. ... 32
Berna, F. ... 38, 48
Bernardo, M. ... 22, 31, 56
Bernhard, A. ... 70
Berretta, S. ... 27
Berroterán Infante, N. ... 41
Bertalan, M. ... 48
Bertolino, A. ... 24
Bertrand, D. ... 37
Bertrand, S. ... 37
Bervoets, C. ... 55
Besse, M. ... 42
Bhide, P. ... 24
Bianchi, M. ... 49, 50
Biederman, J. ... 24
Bilz, S. ... 55
Binder, E. ... 51, 55
Birkenhäger, T. K. ... 23
Bjarke, J. ... 54
Björkstrand, J. ... 48
Blanch, J. ... 56
Blay, S. ... 42
Blennow, K. ... 24, 26
Blesl, C. ... 55
Bliksted, V. ... 54
Bluhm, R. ... 55
Blum, K. ... 50
Bockhop, F. ... 71
Boggild, S. ... 33
Bohlhalter, S. ... 45, 61, 68
Bolati, K. ... 32
Bølcho, U. ... 33, 68
Bolloré, O. ... 44, 68
Bolwig, T. ... 22, 47
Bond, D. ... 63
Bondolfi, G. ... 43
Bonin, J.-P. ... 61
Bonn, S. ... 62
Bonnot, O. ... 78
Børglum, A. ... 47
Borgwardt, S. ... 62, 65, 68
Borroto-Escuela, D. ... 23
Bortolasci, C. ... 23, 24, 44, 45
Borup Bojesen, K. ... 61
Bosch, O. G. ... 35
Bosia, M. ... 48
Bote, B. ... 31
Bouaziz, N. ... 54, 56
Bouckaert, F. ... 47, 55
Boufidou, F. ... 42, 54
Boumba, V. ... 37
Bouna-Pyrrou, P. ... 32
Boutros, N. ... 70
Bowie, C. ... 29
Boyer, L. ... 54
Braha, S. ... 56
Braha-Zeitoun, S. ... 44
Brambilla, P. ... 26, 28, 33, ... 43, 44, 68
Brancaglion, M. ... 37
Braun, B. ... 32
Brennand, K. ... 26, 35
Bressan, R. ... 42
Briciet Lauritsen, M. ... 36
Brilliantova, V. ... 45
Brinholi, F. ... 45
Broberg, B. ... 61, 66
Brodie, M. J. ... 50
Bromek, E. ... 65
Brozaitiene, J. ... 55
Brückmann, C. ... 30
Bruguera, P. ... 30
Brunelin, J. ... 35, 46
Brunovsky, M. ... 35
Buchsbaum, M. S. ... 62
Buck, A. ... 55
Buil, A. ... 47, 48
Buitelaar, J. ... 32
Bunevicius, A. ... 55
Bunevicius, R. ... 55
Buoli, M. ... 26
Buonanno, A. ... 63
Burkauskas, J. ... 55
Burke, A. ... 49
Burke, L. ... 54
Buttenschøn, H. ... 24
Buxbaum, J. D. ... 58

C

Cabrera, L. ... 55
Cacabelos, R. ... 32, 46, 63, ... 66, 67, 69
Caligiorne, S. ... 37
Callado, L. F. ... 66
Callaly, E. ... 24
Campanella, S. ... 70
Campbell, I. C. ... 55
Cappucciati, M. ... 62
Carapucinha, A. ... 54
Cardete, L. ... 56
Carhart-Harris, R. ... 28
Caroff, S. ... 31
Carrera, I. ... 32, 63, 66, 67
Carril, J. C. ... 63, 66, 67
Casado-Sainz, A. ... 62
Caso, J. ... 69
Castilla-Puentes, R. ... 22, 51
Castillo-Gómez, E. ... 37
Castillo, M.-C. ... 44
Castle, D. ... 55
Castrén, E. ... 65
Castro e Couto, T. ... 37
Catalán, R. ... 56
Catarino, R. ... 54
Caviston, P. ... 54
Centeno, T. P. ... 62
Cerrato, F. ... 31
Ceskova, E. ... 22
Chaddock, C. ... 68
Chaki, S. ... 59
Chakrabarty, T. ... 43, 44
Chakravarty, M. ... 54
Chan, H.-N. ... 34
Chand, P. ... 30
Chandra, P. S. ... 42
Chanes, L. ... 55
Chang, J.-W. ... 58
Chang, W.-H. ... 69
Chang, Y.-J. ... 33
Charpeaud, T. ... 23
Chaudhury, S. ... 49
Chen, A. ... 32, 41
Chen, C.-K. ... 44
Chen, M.-H. ... 55
Chengappa, R. ... 42
Cheng, C.-M. ... 55, 69
Chi, H.-U. ... 33
Chirita, A. L. ... 41
Cho, E.-Y. ... 67
Cho, H. ... 30
Choi, J.-H. ... 57, 58, 68
Choi, K.-S. ... 67
Choi, K.-W. ... 42, 57
Choi, T.-K. ... 43
Chou, Y.-H. ... 62
Christian, B. T. ... 62
Christiani, C. J. ... 54
Chun, J.-W. ... 30
Chung, H.-G. ... 58
Chung, H.-K. ... 57
Chung, I.-W. ... 30, 56
Chung, M.-Y. ... 57
Ciobica, A. ... 58
Clemens, V. ... 32, 42
Coentre, R. ... 45
Cohen, A. ... 32
Cohen, D. ... 66
Cojan, Y. ... 43
Collantes, E. ... 56
Comai, S. ... 50, 57
Conell, J. ... 44
Conn, J. P. ... 59
Connor, T. ... 24, 44
Conus, P. ... 51, 67
Cordes, J. ... 60
Cordova-Palomera, A. ... 38
Corominas, N. ... 44
Corrales, A. ... 36
Corrêa, H. ... 37
Correll, C. U. ... 29, 40, 46, 68
Corzo, L. ... 69
Costantini, M. ... 37
Courtet, P. ... 23, 51, 64
Crippa, A. ... 33
Croarkin, P. ... 59
Crowley, T. ... 44
Cryan, J. F. ... 15, 26

List of Chairpersons, Authors and Co-Authors

Csepreka, O. 41
Cui, X. 33
Curatolo, M. 43
Curran, V. 46

D

Da Cunha-Bang, S. 43
Dahale, A. 30
Dalla, C. 39
Dalton, B. 55, 58
Dam, V. H. 32
Damion, M. 58
Damri, O. 44
Danek, P. 65
Daniel, W. A. 65
Daskalakis, Z. J. 59
Davidson, M. 64
De Alarcón, R. 31
Dean, O. 23, 44
DeCastro, A. 62
de Farias, C. 45
de Fátima, Â. 30, 60
De Jong, T. 70
Delacrétaz, A. 51, 67
Delgado, E. 31
Della, C. D.,.34
Dell'Osso, B. 70
Dell'Osso, L. 62
de Luca, V. 62
Delvecchio, G. 43, 44, 68
de Mathis, M. A. 58
Demetrovics, Z. 50
Demontis, D. 24, 47
Demyttenaere, K. 55
Dennis, E. 50
De Ronchi, D. 31
Desseilles, M. 43
Devasenapathy, S. 30
Devine, M. 27
Di Benedetto, B. 41
Di Caupa, G. 49
Dicks, L. 58
Dietrich, A. 32
Diez Hernandez, A. 61
Dikeos, D. 40
Dimitrov, A. 55
Dinesen Østergaard, S. ..... 25, 29, ... 34, 44, 47, 68
Diwadkar, V. 65
Dmiriy, S. 66
Dmitriy, I. 66
Dodd, S. 24
Doeppner, T. 60
Dold, M. 34
Donboli, S. 61
Doninger, N. A. 62
Donohoe, G. 29
Doruk Camsari, D. 55
Douki, W. 57
Downer, E. 49
D'Souza, D. C. 46
Dueñas, P. 57
Duffy, A. 23
Durand, F. 44
Duran, E. 53
Dutschke, L. 43, 61
Dwivedi, Y. 59

E

Eap, C. B. 29, 51, 67
Ebdrup, B. 62, 66
Eckert, A. 40, 41
Edgar, F. G. 62
Egea, J. 63
Egerton, A. 68
Ehlis, A.-C. 36
Ehrenreich, H. ..... 36, 37, 61, ... 62, 71
Eisenhardt, S. 45
Eisinger, A. 50
Ellegaard, P. K. 45
Ellersgaard, D. 54
Elliott, R. 33
Elsenbruch, S. 37
Engler, H. 37
Engman, J. 43, 48
Eörsi, D. 41
Erez, G. 27
Erfurth, A. 25
Eriksen Benros, M. 42
Erritzoe, D. 25
Escobar, F. 22
Escudero, A. 56
Eurviriyanukul, K. 34
Evgeniy, E. 66
Ewais, T. 42
Eyles, D. 33

F

Fabrazzo, M. 31
Fagerlund, B. 61, 66
Falaschi, V. 32
Falcone, T. 22
Falconi, S. 57
Falkai, P. 34, 36, 46, 63, 65
Fallgatter, A. J. 36
Fan, Y. 44
Fañanás, L. 38, 71
Faria, V. 43
Farida, V. 57
Fauerholt-Jepsen, M. 34, 52
Fecteau, S. 35, 46
Federspiel, A. 43, 68
Fedotova, J. 42
Feijó de Mello, M. 36, 58
Feldman, E. 32
Felipe, R. 56
Fensky, L. 44
Fernandez Novoa, L. 32, 66
Ferrão, Y. 56, 58
Ferri, F. 37
Fervaha, G. 61
Figueira, M. L. 45
Filiou, M. 32, 41, 64
Filip, M. 23, 61
Fillenbaum, G. 42
Fineberg, N. A. 55
Firment, J. 57
Fischer, A. 65
Fischer, H. 43
Fisher, P. 32, 43
Fitzgerald, Z. 43
Flensborg-Madsen, T. 58
Fleszar, M. 54
Foester, B. 36, 58
Foldager, L. 68
Fond, G. 38, 48
Fonseca, J. 56, 66
Forbes, A. 45
Foster, J. 34
Foteli, S. 42, 54
Fountoulakis, K. 59, 64
Fouques, D. 68
Foussias, G. 61
Fraile, C. 67, 69
Frangou, S. 36
Franken, P. 55
Fredrikson, M. 43, 48
Freeman, N. 41
Fregni, F. 55
Freitag, C. 70
Freitas, A. 30, 60
Frey, B. 23, 49
Frick, A. 30, 43, 48
Fried, R. 24
Frieling, H. 25
Frokjaer, V. G. 32, 33, 51
Frydecka, D. 54
Frye, M. 65
Fuchikami, M. 38
Fujiwara, H. 68
Fukunaga, K. 51, 66
Fumagalli, F. 22
Funabiki, Y. 71
Furmark, T. 30, 43, 48
Furuta, A. 56
Fusar-Poli, P. 62, 68
Fuxe, K. 23, 61

G

Gabay, O. 57
Gabrieli, J. 43
Gabriels, L. 55
Gaha, L. 57
Gaillard, C. 41, 56
Galderisi, S. 24
Galea, L. A. M. 33
Galecki, P. 24
Galletly, C. 37
Gambheera, H. 41
Gamielddien, J. 58
Gamma, F. 67
Gantriis, D. L. 54
Gao, W. 62
Garcia, F. 30, 37, 46, 60
Garcia Gonzalez, L. 31
Garcia Menendez, L. 61
García Rizo, C. 31
Garcia Sevilla, J. A. 66
Garriga, M. 31, 46, 56
Gasiorowski, K. 47
Gaspar, R. 68
Gass, P. 48
Gasse, C. 42
Gatti, E. 33
Gazdag, G. 55
Geddes, J. 52
Gegenhuber, J. 32
Geissberger, N. 37
Gerber, M. 34, 41
Geyer, M. 39
Geyer, S. 42, 43
Ghachem, R. 60
Gholam-Rezaee, M. 51, 67
Gibbons, A. 34
Giese, A. 65
Giménez, A. 30
Gingnell, M. 43, 48
Gjestad, R. 54
Glatard, A. 51, 67
Glenn, T. 44
Glennon, J. 32
Glenthøj, B. 61, 66
Glerup, S. 24, 32, 33, 68
Gloster, A. 41
Gobbi, G. 50, 57
Gobom, J. 24
Godbersen, M. G. 41
Godin, A. 30
Goecke, T. W. 49
Gogos, A. 39
Gois, C. 45
Goltz, J. 32
Gomes da Costa, S. P. 30
Gomes, F. V. 54
Gómez Benito, J. 45
Gómez de Segura Iriarte, L. 31, 55
Gómez, J. 45
Gonda, X. 40, 41, 67
González Fernández, A. 31, 55
González García, P. 55
Gonzalez Gonzalez, I. 44, 56
Gonzalez Pinto, A. 22, 25
González Sáiz, F. 31, 56
Gordon, G. 55
Göritz, A. S. 48
Gorkiewicz, G. 55
Gotoh, L. 41
Gourley, S. 22
Grabe, H. J. 36, 62
Graf, E. 33
Grau, A. 22
Grauholm, J. 48
Gray, L. 24, 44
Greisen Søndergaard, M. 34
Greve, A. N. 54
Grice, D. 58
Grimm, O. 48
Groppa, S. 36
Grove, J. 29, 47
Grözinger, M. 25
Grünblatt, E. 36
Gründer, G. 29, 31, 41, 49
Grunebaum, M. 49
Grunze, H. 58, 59
Guerrero Vida, R. 56
Guilera, G. 45
Guillermier, C. 41
Guillod, M. 41, 56
Guimaraes, F. 54
Guimond, S. 54
Guizzaro, L. 31
Gurklis, J. 42
Gurrera, R. 31, 48
Gurvich, C. 55
Gustafsen, C. 24
Gutiérrez Santaló, C. 31
Gyollai, Á. 50

H

Ha, K. 57
Haarman, B. 63
Haas, G. 42
Haduch, A. 65
Haen, E. 31, 41
Hageman, I. 51
Hageman Pedersen, I. 25
Hagi, K. 31
Hagiwara, M. 33, 71
Hahn, S.-W. 32, 45, 49
Hakamata, Y. 43
Halaris, A. 24, 25
Han, B. 25, 66, 67, 69
Hanakawa, T. 43
Hansen, C. 48
Hansen, N. 32
Hansson, A. 23
Hariz, M. 51
Harmat, L. 43
Harro, J. 48
Hasebe, K. 23, 24

List of Chairpersons, Authors and Co-Authors

Hasler, G. 41, 51, 59
Hasselbalch, S. G. 51
Hatanaka, A. 41
Hatzinger, M. 34, 40, 41, 55
Hedemand, A. 47
Heffernan, T. 30, 60
Hegerl, U. 43, 55
Heike, T. 33, 71
Hellmann-Regen, J. 32, 42
Hellsing, A.-N. 43
Hemager, N. 54
Hemmings, S. 58
Hemze, R. 28
Hendriksz, C. 78
Henning, A. 55
Henriksen, B. 33
Hermann, S. 27
Hermida, A. 47
Hernández Dorta, A. 44, 56
Herpertz, S. 39, 64, 70
Herth, M. 62
Heuser, I. 32, 42
Hiemke, C. 29, 31, 41
Higachi, L. 45
Higashiyama, R. 42
Higuchi, M. 68
Hill, A. 23
Himmerich, H. 55, 58
Hirjak, D. 63
Hjordt, L. V. 32, 51
Hjorth, O. 43
HN, H. 54
Hobart, M. 45
Hodgkinson, S. 56
Hoeffding, L. 61
Hoekstra, P. 32
Hofer, A. 24
Högman, L. 43
Holasek, S. 55
Hollmann, M. 37
Holmén Larsson, J. 24
Holm, M. M. 68
Holsboer, F. 35, 41
Holsboer-Trachsler, E. 34, 40,
..... 41, 55
Holst, K. 43
Holst, S. 55
Hölttä, M. 24
Holven, K. B. 42
Honer, W. 34, 43
Hong, K. S. 67
Hönig, G. J. 42
Honma, M. 48, 67
Hopwood, M. 44
Horacek, J. 43
Hori, H. 58
Horstmann, J.-P. 36
Hosák, L. 34, 45, 64
Hosakova, K. 45
Hougaard, D. 48
Howes, O. 26, 38, 40,
..... 45, 61, 68
Hu, S. 62
Huang, M. 62
Huang, S.-Y. 61
Hubert, M. 32
Hudak, J. 36
Hung, G. 51
Husky, M. 54
Hussein, S. 58
Husted Andersen, J. 34
Hýža, M. 34

I

Ibeschitz, H. 41
Iga, J.-I. 68
Igimi, H. 67
Ignjatovic Ristic, D. 66
Ikeda, H. 48
Ikemoto, K. 68
Ikuta, T. 70
Imai, R. 58
Imboden, C. 34, 41
Ingelman-Sundberg, M. 52, 66
Ino, K. 58
Inoue, M. 67
Inoue, Y. 43
Inta, D. 26, 48
Isaac, C. 44, 68
Ishiguro, H. 50
Ishii, Y. 67
Ishøy, P. 66
Ising, M. 23, 41
Islam, S. 30
Itoh, M. 58
Ito, M. 32, 56
Iwanami, A. 25
Izawa, S. 43

J

Jaaskelainen, E. 38
Jackowski, A. 42
Jacomb, I. 37
Jae, Y.-M. 45, 49, 56
Jaehde, U. 23
Jagannathan, N. 24
Jain, S. 30, 44, 54
Jaiswal, S. K. 32, 71
Jalali, M. 58
Jalon Urbina, M. M. 31, 55
Jamain, S. 44
Jambunathan, S. 34
James, G. 41
Jandl, M. 56
Januel, D. 44, 54, 56, 68
Jarram, A. 47
Jaury, P. 60
Jayarajan, R. N. 39
Jelínková, M. 34
Jensen, H. M. 30
Jensen, M. 61
Jeon, H.-J. 30, 33, 42, 57
Jeong, J.-E. 30, 45
Jeong, Y.-W. 56
Jermann, F. 43
Jessen, K. 61
Jeung, H. 70
Jhanwar, V. G. 41
Jimenez, J. 57
Jin, M.-J. 49
Joca, S. 22, 64, 65
Johansson, A. 43
John, J. P. 54
Johnsen, E. 54
Jokinen, J. 28, 40
Jonasson, M. 43
Jones, N. 68
Joo, E.-J. 67, 68
Joo, Y.-H. 54
Jørgensen, A. 34
Jørgensen, H. A. 54
Jovic, J. 66
Joyce, E. 27
Juhasz, G. 67
Jukic, M. 64, 66
Jung, C.-H. 56
Jung, H.-H. 58
Jung, W.-Y. 45
Jungwirth, J. 41

K

Kaas, M. 24
Kaderabek, L. 67
Kaess, M. 28
Kajiwara, Y. 58
Kalayda, A. 23
Kalita, P. 34
Kambeitz, J. 46
Kaminsky, Z. 38
Kamo, T. 58
Kamperman, A. M. 23
Kampman, O. 31
Kanchanatawan, B. 23
Kandrakonda, S. 32, 71
Kane, J. 31, 38, 40, 78
Kaneko, Y. 31
Kang, D.-W. 69
Kang, S.-H. 57, 58, 66
Kang, U.-G. 30
Kang, W.-S. 67
Kanniah, G. 48
Kapczinski, F. 23, 49, 63
Kapogiannis, D. 23
Kapur, V. 44
Karmacharya, R. 61
Karmacharya, S. 68
Kaschka, I. 56
Kaschka, W. 56
Kashofer, K. 55
Kasper, S. 34, 35, 37, 41, 46, 58
Kates, N. 52
Kato, T. 33, 71
Kato, Y. 67
Katsuta, N. 42
Kautzky, A. 34
Kawabe, K. 68
Kawada, R. 30
Kawaguchi, T. 41
Kawasaki, H. 41
Kawasaki, Y. 45, 68
Kazhungil, F. 39
Kellner, C. 47
Kennedy, J. 35, 41, 62
Kennedy, S. 27, 34, 47, 64
Keshavan, M. 29, 42, 43, 54
Kessing, L. V. 34, 51, 52, 57, 63
Ketter, T. 70
Khan, A. H. 24
Khandelwal, S. 24
Khoury, J. 60
Kidnapillai, S. 24, 44
Kihara, H. 68
Kim, B. 43, 57
Kim, B.-R. 33, 43
Kim, C.-E. 45
Kim, C.-H. 58
Kim, D.-H. 25
Kim, D. J. 30
Kim, E.-Y. 44, 57
Kim, H. 66
Kim, H.-J. 67
Kim, H.-W. 33, 42
Kim, H.-Y. 57
Kim, J.-J. 45
Kim, J.-M. 66, 68
Kim, J.-S. 44, 45, 49
Kim, J.-W. 66, 67
Kim, K. 30
Kim, K.-W. 42, 57
Kim, M.-K. 43
Kim, M.-S. 57
Kim, N.-W. 44
Kim, S.-H. 44, 54, 57
Kim, S.-J. 58
Kim, S.-K. 33
Kim, S.-W. 66, 68
Kim, S.-Y. 56
Kim, T.-Y. 57, 58
Kim, Y. 43, 48, 58
Kim, Y.-K. 67
Kim, Y.-M. 45
Kim, Y.-S. 30, 56
Kimoto, A. 42
Kimura, R. 33, 71
Kimura, Y. 68
Kinjo, T. 32, 56
Kinoshita, M. 66
Kira, K. 41
Kirmeier, T. 48
Kis, B. 33
Kishore, B. 30
Kisslinger, B. 42
Kito, S. 38
Kjaerby, C. 62
Klasen, H. 52
Klöbl, M. 37
Klünemann, H.-H. 78
Knights, N. 61
Knop, F. 66
Knorr, U. 34
Knudsen, G. M. 32, 40, 42,
..... 43, 51
Kobor, M. 30
Kocsis, B. 65
Kodaka, F. 68
Kodani, Y. 31
Koefoed, P. 34
Köhler-Forsberg, O. 61
Köhler, O. 42
Kohl, S. 40
Kökönyei, G. 50
Kolarova, M. 68
Kolevzon, A. 32
Komi, S. 43
Kondou, A. 67
Konrad, K. 70
Kornhuber, J. 32
Körösi, B. 41
Kota, L. N. 44
Kótyuk, E. 50
Koudelka, V. 67
Kovacevic, F. 71
Kraus, C. 37
Kraus, S. 27
Kraus, T. 65
Krebs, M. D. 67
Krech, L. 42
Kristiansson, M. 43
Kristina, S. 66
Kroken, R. A. 54
Kubicki, M. 43, 68
Kubota, M. 68
Kudo, T. 23
Kuehnel, A. 44
Kufert, Y. 32
Kühnel, A. 44
Kuhn, J. 40
Kulkarni, K. 30
Kumar, M. 42
Kumar, S. 48
Kunugi, H. 58
Kuriyama, K. 48, 55, 67
Kurkinen, M. 47

List of Chairpersons, Authors and Co-Authors

Kuzin, M. ... 41
Kwak, K.-P. ... 45
Kwon, M.-S. ... 33

L

Laas, K. ... 48
Labrenz, F. ... 37
Lackner, S. ... 55
Lackshmana, M. ... 32
Łaczmanski, Ł. ... 54
Lafaye, G. ... 61
Lai, C.-H. ... 48, 51
Lakshmi Valaparla, V. ... 24
Lam, R. ... 43, 47, 52
Lamm, C. ... 37
Lammertz, S. E. ... 49
Landén, M. ... 24
Landolt, H.-P. ... 55
Landucci, K. ... 45
Lane, H.-Y. ... 25, 48
Lang, D. J. ... 43
Lange, A. C. ... 54
Lannay, Y. ... 51
Lanzenberger, R. ... 37, 41
Larach, V. ... 53
Larsson, E.-M. ... 48
Larue, C. ... 61
Las, G. ... 44
Lászlo, A. ... 41
Lavania, S. ... 24
Leboyer, M. ... 44
Lecbych, M. ... 45
Lechene, C. ... 41
Lee, B.-Y. ... 33
Lee, C. H. ... 25
Lee, D.-E. ... 56
Lee, H. ... 30, 62
Lee, H.-J. ... 44
Lee, H.-K. ... 33
Lee, H.-S. ... 68
Lee, J.-H. ... 33, 43
Lee, J.-I. ... 66
Lee, J.-K. ... 67
Lee, J.-S. ... 54
Lee, J.-W. ... 57
Lee, J.-Y. ... 68
Lee, K.-U. ... 43, 57
Lee, K.-Y. ... 57, 67, 68
Lee, S.-B. ... 33
Lee, S.-H. ... 33, 43, 45, 49, 58
Lee, S. J. ... 43
Lee, S. Y. ... 67
Lee, Y.-H. ... 66, 68
Lee, Y.-S. ... 67
Lehrer, D. S. ... 62
Lehtimäki, T. ... 31
Leinonen, E. ... 31
Lejoyeux, M. ... 50
Lenroot, R. ... 37
Lenz, B. ... 32
Leonard, B. ... 25, 37
Lepage, M. ... 29
L'Estrade, E. N. ... 62
Leszek, J. ... 46, 47
Levier, A. ... 51
Lewczuk, P. ... 26
Li, C. ... 25, 66, 67, 69
Li, C.-T. ... 45, 55
Li, L. ... 62
Li, M.-S. ... 51
Licht, R. W. ... 45
Lieberknecht, R. ... 56
Lieb, K. ... 36
Lieblich, S. E. ... 33
Lieb, R. ... 41
Ligdorf, A. ... 55
Lim, S.-W. ... 56
Lin, C.-H. ... 25, 48
Lin, M. ... 58
Lin, S.-K. ... 45, 58
Lineham, A. ... 61
Lisoway, A. ... 41
Liu, B. ... 61
Liu, D. ... 37
Liu, K. ... 25, 66, 67, 69
Lligoña, A. ... 30
Llorca, P.-M. ... 23, 38, 48, 54
Løberg, E.-M. ... 54
Loebel, A. ... 31
Lombraña, M. ... 56
Lonning, V. ... 42
López, A. ... 30
López, B. ... 57
Lorandi, A. ... 68
Lorenzo, C. ... 31
Lotze, M. ... 36
Lu, S. ... 62
Lubberink, M. ... 43
Lucae, S. ... 23, 41
Luft, B. ... 59
Lundhede, J. ... 24
Lund Ovesen, P. ... 68
Luque, R. ... 56
Luyten, L. ... 55
Lyall, A. ... 43
Lydholm, C. ... 61
Lyytikäinen, L.-P. ... 31

M

MacQueen, G. ... 28, 36, 47
Madsen, J. ... 32
Madsen, M. ... 32
Madsen, P. ... 33
Maes, M. ... 23, 24, 42, 45, 61, 69
Mäestu, J. ... 48
Maggioni, E. ... 33
Magi, A. ... 50
Maia, T. ... 45, 56
Maier, F. ... 41
Maihofer, E. ... 25
Maj, M. ... 24
Majtczak, B. ... 55
Makinodan, M. ... 29
Makowski, C. ... 54
Makris, N. ... 68
Malavera, A. ... 55
Malekpour, F. ... 61
Malhotra, P. ... 27
Malik, V. ... 41
Mallick, B. N. ... 40
Mallorqui, A. ... 31
Mandelli, L. ... 66
Mandolini, G. M. ... 44
Mani, R. ... 42
Manikandan, V. ... 34
Manji, H. ... 28
Mann, J. J. ... 40, 49
Marazziti, D. ... 24, 32
Marcellin, G. ... 51
Marco-Contelles, J. ... 63
Mari, J. ... 42
Marin, C. ... 31
Marinescu, D. ... 43
Marinescu, I. ... 43
Maron, E. ... 30
Marshall, A.-M. ... 60
Martinelli, A. ... 70
Martínez Arán, A. ... 56
Martínez-Cengotitabengoa, M. ... 25
Martinez Perez, M. M. ... 61
Martin Navarro, N. ... 61
Martin, S. ... 24
Martins de Souza, D. ... 46, 64, 65
Martin-Sölch, C. ... 41, 56
Masdrakis, V. G. ... 42, 54
Massart, R. ... 57
Mastergeorge, A. ... 42
Mather, K. ... 61
Matías, J. ... 31
Matsubara, T. ... 33
Matsuo, K. ... 66
Matsushima, K. ... 33
Matsuzaki, S. ... 25
Mauri, M. ... 33
Mavreas, V. ... 37
Mavridis, I. ... 40
Maximova, N. ... 58
Mazhari, T. ... 61
Mazin, W. ... 48, 61
McClintock, S. ... 59
McCreary, C. ... 49
McCullumsmith, R. ... 27
McDonald, W. ... 47
McDonnell, C. ... 49
McGee, S. ... 24
McGuire, P. ... 62, 68
McKenna, J. ... 49
McKenzie, R. ... 55
McLoughlin, D. ... 25, 47, 56
McMahon, B. E. M. ... 32, 51
McQuillin, A. ... 47
Meana, J. J. ... 66
Medeiros, H. ... 45, 56
Mehta, D. ... 51
Meinitzer, A. ... 55
Mello, M. ... 42
Mendlewicz, J. ... 34
Menshchikov, P. ... 51
Mensi, R. ... 57
Merabet, L. ... 55
Mergl, R. ... 55
Merlo, M. ... 41
Merrill, B. ... 62
Mesa, S. ... 25
Mesholam-Gately, R. ... 43
Messaoud, A. ... 57
Mestre Morales, J. ... 31
Methfessel, I. ... 42
Meyer, J. ... 25, 40, 59
Mhalla, A. ... 57
Michaljov, A. ... 43
Michel, T. ... 36
Mickuviene, N. ... 55
Mikoteit, T. ... 35, 41, 55
Milani, A. C. ... 36, 58
Milev, R. ... 34, 47, 52
Militaru, F. ... 41, 43
Mill, J. ... 47
Ming, G.-L. ... 26
Misdrahi, D. ... 54
Misiak, B. ... 54
Miskowiak, K. ... 29
Mital, A. ... 41
Mitjans, M. ... 37, 62, 71
Mittal, V. ... 39
Mitterhauser, M. ... 41
Miyata, J. ... 30
Mizukami, S. ... 43
Moellegaard Jepsen, J. R. ... 54
Moghadam, S. S. ... 55
Moily, N. S. ... 44
Mojzisek, M. ... 68
Mok, Y. M. ... 34
Molden, E. ... 66
Mølgaard Jensen, S. ... 68
Mølgaard, S. ... 24, 33
Molina, F. ... 51
Möller, H.-J. ... 27
Molokotos, E. ... 43
Molteni, M. ... 33
Mondon, S. ... 30
Mongil San Juan, J. M. ... 31
Mononen, N. ... 31
Montgomery, S. ... 34
Moon, Y.-S. ... 25
Moor, J. ... 45
Móra, B. ... 69
Morais, N. ... 58
Moreira, E. ... 45
Moreira, F. ... 30, 60, 65
Moreno Sánchez, M. L. ... 31
Morgado, P. ... 66
Mori, K. ... 31
Mori, Y. ... 68
Moriguchi, S. ... 66, 68
Moriguchi, Y. ... 43, 48
Morita, K. ... 67
Moritz, S. ... 48
Mörkl, S. ... 55
Moroni, I. ... 32
Mors, O. ... 44, 47, 54, 68
Mortensen, P. B. ... 34, 61
Mortillaro, G. ... 31
Mössner, R. ... 35
Motilla-Hoppe, J. ... 43
Motomura, Y. ... 43
Moula, O. ... 60
Moulier, V. ... 44, 54, 56
Mrad, A. ... 57
Mucci, A. ... 24
Mucci, F. ... 24, 32
Muehlhan, M. ... 30
Mueller, D. ... 41
Mueller, M. ... 43
Mühle, C. ... 32
Mukherjee, I. ... 33, 62
Müller, D. ... 29
Müller, H. ... 33
Müller, J. ... 71
Munkholm, K. ... 25, 63
Munk-Olsen, T. ... 34
Murai, T. ... 30, 71
Murphy, M. ... 32
Murray, M. ... 55
Murthy, P. ... 30
Musliner, K. L. ... 34
Mutalik, N. R. ... 39, 54
Muthuraman, M. ... 36
Myhre, A. M. ... 42

N

Na, E.-J. ... 30, 57
Na, H. R. ... 69
Naber, D. ... 46
Nadella, R. K. ... 44
Naderi-Heiden, A. ... 34
Nagasaki, H. ... 31
Nagashima, T. ... 68
Nagpal, R. ... 41
Nakajima, S. ... 48
Nakamura, M. ... 38, 55, 59
Nakamura, T. ... 42
Nakano, S. ... 67

List of Chairpersons, Authors and Co-Authors

Nakasato, Y. 55
Nakashima, A. 31
Nakata, M. 33, 71
Nascimento, M. 56
Nasyrova, R. 66
Nave, K.-A. 62
Nawa, H. 70
Nayak, R. 44
Nemcsik-Bencze, Z. 41
Nemcsik, J. 41
Netherwood, S. 54
Neumann, I. 41, 70
Neuwirth, M. 25
Neves, M. 37, 60
Newcorn, J. 24
Ng, B. 22
Ng, C. 23, 44
Nicoara, M. 58
Nicolas, Y. 57
Nicolay, N. 66
Nielsen, A. L. 47
Nielsen, C. T. 45
Nielsen, J. 48, 59
Nieratschker, V. 30
Nierenberg, A. A. 29, 44, 46
Nikiforuk, A. 55
Nikolaou, C. 42, 54
Nishimon, S. 42
Nitsch, R. 36
Nitta, Y. 68
Niwa, M. 58
Nobile, M. 28, 33
Noda, Y. 38
Nordentoft, M. 34, 54, 61
Nørgaard, M. 32
Nosaka, T. 31
Nosarti, C. 28
Noto, C. 45
Novak, B. 48
Novak, T. 67
Numata, S. 38
Nuño Gómez, L. 45
Nussbaumer, M. 32
Nuttin, B. 55
Nyengaard, J. 33
Nykjær, A. 24, 33, 68

O

Obbels, J. 55
O'Brien, N. L. 47
O'Brien, T. 68
Odagaki, Y. 66
O'Donnell, M. 37
O'Driscoll, D. 49
Oei, N. 55
Ofori-Attah, G. 61
Ogawa, S. 58
Ogushi, Y. 41
Oguz Karamustafa, K. 27
Oh, J.-H. 43
Oh, K.-S. 56
Ohi, K. 45, 68
Ohmori, T. 38
Ohmura, H. 48
Ohnuma, T. 42
Okawa, J. 67
Okazaki, R. 69
Okubo, H. 68
Okubo, Y. 68
Olbrich, S. 35
Olea, E. 53
Oliveira, B. 37, 62, 71
Oliveira, C. 31
Oliveras, C. 30
Olsen, L. 61
Onaivi, E. 50
Opjordsmoen, S. 78
Oquendo, M. 49
Ortuño, N. 56
Oshima, K. 68
Ota, A. 31
Ota, M. 31
Ota, T. 66
Ott, M. 59
Otto, M. 26
Oulis, P. 42, 54
Ouyang, J. 45
Overgaard, A. 33
Ozaki, Y. 69
Ozenne, B. 51

P

Padberg, F. 35
Padovani, A. 78
Pae, C.-U. 41, 45, 56, 66
Paik, I.-H. 69
Paik, J.-W. 67
Paik, K.-C. 43, 57, 58
Painold, A. 55
Palenicek, T. 28, 67
Palm Suppli, N. 34
Palner, M. 62
Palova, E. 57
Pan, F. 62
Pan, H. 37
Panczak, R. 51
Pandey, G. 25, 28
Panizzutti, B. 24, 44
Parik, J. 48
Parikh, S. 33, 47, 52
Park, C.-H. 43
Park, C. H. K. 57
Park, D.-S. 43
Park, H.-S. 57
Park, J.-E. 57, 68
Park, S.-C. 68
Park, S.-H. 39
Park, S.-Y. 54
Park, Y.-S. 33
Parmar, A. 24
Parolin Jackowski, A. 36, 58
Pascual Juliá, J. 66
Pascual Paño, J. M. 31, 66
Pasternak, O. 43
Pattojoshi, A. 24
Paul, P. 44
Paulzen, M. 31, 41, 49
Pawelczyk, T. 60
Pawlowski, M. 36, 55
Pedersen, C. B. 61
Pedersen, K. M. 68
Pedersen, S. D. 44
Pelayo Teran, J. M. 61
Pelletier, J.-F. 61
Pen, A. 47
Pereira, R. 37
Perez Gomez, L. 31
Pérez Revuelta, J. I. 31, 56, 66
Perlini, C. 43, 44, 68
Pernicková, D. 34
Péter, L. 69
Petersen, C. M. 24
Petersen, L. 44, 61
Petrides, G. 47
Petrikis, P. 37
Pfabigan, D. 37
Pfister, S. 45
Philip, M. 42
Philipsen, A. 33
Phillipou, A. 55
Piccinni, A. 24, 32
Pigoni, A. 43
Pikalov, A. 31
Pilc, A. 59
Pinault, D. 65, 68
Pinborg, A. 51
Pingo, J. 44
Pino López, O. 45
Pinzón, J. E. 30
Piorecka, V. 67
Pivina, S. 42
Plavan, G. 58
Plessen, K. 54
Pletnikov, M. 27, 35
Plewnia, C. 35, 60
Pliatsika, P. 42, 54
Poczatek, C. 41
Pogarell, O. 30
Pointet, S. 51
Politi, P. 62
Pompili, M. 51, 70
Popik, P. 55
Popovic, D. 64
Popp, J. 69
Porcelli, S. 34
Post, R. 28
Postalache, T. 59
Potasiewicz, A. 55
Potenza, M. 27
Poulsen, H. E. 45
Powell, H. 37
Prados, J. L. 56
Prados Ojeda, J. L. 31
Praschak-Rieder, N. 34
Preller, K. 28, 35
Prenderville, J. 49
Prüss, H. 37
Przegalinski, E. 61
Puerto Garrido, F. J. 31
Pühse, U. 34, 41
Purushottam, M. 30, 44

Q

Queiroz, D. 60
Quintana, M. 42

R

Rabl, U. 34
Racine, H. 61
Radua, J. 62
Ramachandran, M. 33
Ramos, J. 45
Ramseyer, F. 61
Rantamäki, T. 22
Rao, P. 32, 50
Rasenick, M. 50
Rasmussen, E. L. 54
Raveendranathan, D. 44
Ravindran, A. 47
Ray, D. 41
Raymaekers, S. 55
Recabarren, R. 41, 56
Reddy, R. 42
Reddy, Y. C. J. 44
Regat, S. 54
Regen, F. 32, 42
Reguero Palacio, M. A. 61
Reilly, T. 62
Remington, G. 61
Reppermund, S. 61
Rex-Haffner, M. 51
Riba, J. 28
Rice, T. 32, 58, 60
Richter, M. 41
Rico, B. 63
Rico del Viejo, A. B. 31
Riederer, P. 36, 64
Rihmer, Z. 40, 41
Ristea, S. 41
Rivera, A. 23
Rivetti, A. 36
Rocca, P. 24
Rocchetti, M. 62
Rodrigues, N. 54
Rodrigues, R. 56
Rodríguez Gómez, C. 31, 66
Rodriguez Gomez-Carreño, C. ... 33
Rodriguez Mercado, C. M. 31
Rodriguez, S. 69
Roh, S.-C. 33
Roiser, J. 68
Rojo, E. 45
Roque, M. 60
Rosenfield, P. 32
Rossell, S. 55
Rossi, A. 24
Rossner, M. 63
Rossouw, J. 71
Rostrup, E. 61
Rouine, J. 49
Rubio, E. 57
Ruggeri, M. 43, 44, 68
Ruisch, H. 32
Ruiz de Azúa, S. 25
Rujescu, D. 35, 46, 48,
..... 59, 64, 65
Rupprecht, R. 50
Rutigliano, G. 62
Ruud, T. 52
Rybakowski, J. 55, 64, 68
Rydlo, J. 68
Rym, M. 57
Rysz, M. 65

S

Sabbe, B. C. G. 23
Sabo, J. 57
Sacchi, C. 33
Sachdev, P. 61
Sachs, G. 24, 25
Safyer, G. 32
Saigi-Morgui, N. 51, 67
Saito, K. 25
Saito, T. 30, 36
Saiz, P. A. 51
Salamero, M. 31
Salander Renberg, E. 59
Salazar, L. 33
Salazar, S. 33
Saltoft Andersen, G. 61
Salvetat, N. 51
Sambataro, F. 63
Sampedro, C. 32
San, L. 22
Sanacora, G. 48
Sanada, K. 25
Sander, C. 55
Sanigorski, A. 44
Sannohe, T. 42
Santos Lagares, P. 67
Sanz, Y. 69

List of Chairpersons, Authors and Co-Authors

Sarpal, D. 38
Sartorius, A. 25
Sarvode, S. 54
Saß, H. 39
Sasvári-Székely, M. 50
Sathyanarayanan, G. 42
Sato, E. 43
Sato, M. 67
Savadjiev, P. 68
Sawai, K. 68
Schaake, J. 55
Schedlowski, M. 37
Scheidegger, M. 55
Scheuer, S. 41
Schilbach, L. 40
Schindler, S. 42, 43
Schläpfer, T. 51
Schmidt, A. 62, 68
Schmidt, F. M. 55
Schmidt, L. 43
Schmidtner, A.-K. 41
Schmidt, U. 48, 57
Schmitt, A. 34, 46, 65
Schoebi, D. 41
Scholl, C. 23
Schönknecht, P. 42, 43
Schoretsanitis, G. 31, 41, 48, 49
Schreckenbach, M. 48
Schreiber, J. 43
Schrijvers, D. 23
Schultz, M. 44
Schwab, M. 63
Schwartz, S. 43
Scudellari, P. 31
Secin, R. 22
Seedat, S. 27, 44, 58, 71
Seelig, E. 55
Segura, E. 33
Seidel, J. 71
Seidman, L. 43
Seiffert, N. 55
Seifritz, E. 35, 55
Sekiguchi, A. 58
Sellgren, C. 24
Semancikova, E. 57
Semenova, N. 51
Sen, S. 44
Seoane, S. 32
Seppälä, N. 31
Seretti, A. 69
Serrano, L. 31
Serrano, R. 45, 56
Serretti, A. 25, 34, 35, 64, 66
Severance, E. 69
Shah, L. 60
Shalbafan, M. 61
Shan, X. 25, 66, 67, 69
Shankarappa, B. 30
Shannon Weickert, C. 27, 39
Sharan, P. 24
Sharma, P. 30, 39
Sharma, U. 24
Shemesh, N. 44
Shenton, M. E. 68
Sher, L. 40, 49, 58, 60
Shibata, N. 42
Shih, M.-C. 61
Shikhov, S. 45
Shimada, T. 45, 68
Shim, S.-H. 32, 44
Shin, D.-W. 56
Shin, I.-S. 66, 68
Shin, Y.-C. 56
Shinoda, Y. 66
Shioda, N. 51
Shirazi, E. 61
Shireen, H. 61
Shoji, Y. 67
Shyam Kumar, J. 71
Sidharthan, M. 33
Sienaert, P. 30, 47, 55
Sigvard, A. 61
Silhán, P. 22, 34
Silva, H. 53
Silva Neto, L. 30
Silva, N. R. 54
Simic, M. 54
Simonova, J. 57
Sinkeviciute, I. 54
Sirota, M. 54
Siu, C. 61
Skapinakis, P. 37
Skeldahl, S. 33
Skokina, E. 45
Skoloudík, D. 34
Slattery, D. 41
Slyepchenko, A. 49
Smelror, R. 42
So, H.-S. 57
Soh, H.-S. 58
Sohn, H.-Y. 33
Sokolig, C.-M. 57
Soldatos, C. 51
Soler, V. 56
Solismaa, A. 31
Somes, N. 43
Sommer, I. 38, 60, 64
Søndergaard, S. 34
Sonel, A. 42
Sonel, E. 42
Song, D.-H. 33
Song, J.-Y. 67
Soriano, E. 26
Souery, D. 34
Sousek, A. 55
Spaans, H.-P. 47
Spang, K. S. 54
Spaniel, F. 43, 68
Spanner, J. 65
Sparsø, T. 48, 61
Spies, M. 41
Spolding, B. 24, 44
Sravana Sandhya, P. 71
Srisurapanont, M. 34
Stanczykiewicz, B. 54
Stanton, C. 37
Starnawska, A. 47, 48
Staunstrup, N. H. 47
Stegmann, B. 31
Stegmayer, K. 45, 61, 68
Stegmayr, B. 59
Steiger, A. 35
Steinau, S. 43
Steiner, J. 34, 37
Stenbæk, D. S. 32, 51
Sterchele, A. 32
Steudte-Schmiedgen, S. 30
Steyer, J. 56
Stingelin, K. 55
Stingl, J. 23, 52
Storch, M. 42, 43
Straube, B. 39
Strik, W. K. 61, 68
Stroh, A. 36
Stroske, M. 42, 43
Strungaru, S.-A. 58
Stürkat, I.-L. 37
Su, K.-P. 25
Su, T.-P. 45, 55
Su, W. 43
Suder, A. 61
Sughondhabirom, A. 23
Suhara, T. 68
Sun, Q. 25, 66, 67, 69
Suppes, T. 65
Sushko, A. 42
Suttajit, S. 34
Suzuki, T. 32, 56
Svarer, C. 32
Swiecicki, L. 55
Swoboda, H. 25
Szyf, M. 57

T

Tabák, A. 41
Tafti, M. 55
Tagaya, H. 43
Takahashi, A. 25
Takahashi, H. 30, 68
Takahashi, T. 69
Takahata, K. 68
Takami, G. 31
Takamiya, A. 38
Takano, H. 68
Takebayashi, Y. 42
Takeda, M. 26, 42
Takeuchi, H. 61
Talian, I. 57
Talina, M. 45
Tan, Q.-R. 23
Tandon, R. 27
Tangwongchai, S. 23
Tapken, D. 37
Taubman, D. 33
Tayama, M. 30
Taylor, D. 59, 78
Tebartz van Elst, L. 33
Teckentrup, V. 44
Teijido, O. 67
Tellado, I. 67, 69
Tellez-Vargas, J. 51
Teplytska, L. 32
Tessier, A. 54
Thalamuthu, A. 61
Tharayil, H. M. 33
Thennarasu, K. 30
Thermenos, H. 43
Thibaut, F. 27, 36, 46, 50
Thippeswamy, H. 42
Thisted Horsdal, H. 42
Thomann, P. 63
Thomas, F. 56
Thompson, W. 34
Thorup, A. 54
Tik, M. 37
Timmerby, N. 34
Tisler, A. 41
Tiwari, A. 62
Tkacikova, S. 57
Tom, V. 23
Tomiwa, K. 33
Torres, I. 43, 44
Torzsa, P. 41
Trabjerg, B. B. 61
Trampel, R. 43
Träskman Bendz, L. 57
Trautmann, S. 30
Trejos-Castillo, E. 42
Trelles, M. P. 32, 60
Tremey, A. 23
Triki, R. 60
Trindade, R. 54
Trippe, R. 37
Tsai, C.-F. 69
Tsang, R. 61
Tsuchiya, K. 29
Tsurumi, K. 30
Tu, P.-C. 45
Tuescher, O. 36
Turck, C. 32, 41
Turecki, G. 28, 59
Tyls, F. 67
Tzallas, A. 37

U

Uchimura, N. 67
Udristoiu, I. 41, 43
Udristoiu, T. 41, 43, 64
Ueck, P. 55
Uehara, T. 45, 68
Ueno, K. 69
Ueno, S.-I. 68
Uhr, M. 41
Ulrichsen, M. 33
Ulven, S. 42
Unterholzner, J. 41
Upton, N. 49
Urbán, R. 50
Urretavizcaya, M. 22
Uzbekov, M. 45, 58

V

Vadskjaer Hjordt, L. 43
Vaht, M. 48
Valdez, V. 27, 36, 51, 57
Valencia, M. 70
Valero-Cabre, A. 55
Valmaggia, L. 62
Valtorta, F. 57
Vanbellingen, T. 45, 61, 68
Van Den Ameele, S. 23
Vandenberghe, F. 51, 67
van den Heuvel, L. 44, 58
van der Auwera, S. 62
van der Laan, S. 51
van Diermen, L. 23
Vangkilde, A. 61
Vantuch, J. 34
van Woerkom, E. 60
Varnado, P. 34
Vartak, D. S. 44
Vasquez, F. 57
Vasudevan, R. 37
Vaz Domínguez, G. 31
Vázquez, M. 56
Veer, I. 55
Veidebaum, T. 48
Vejmola, C. 67
Velamoor, V. 31
Venkataswamy, M. M. 42
Vera, T. 66
Vereczkei, A. 50
Veres-Székely, A. 50
Verheij, M. 22
Verwijk, E. 47, 55
Veselinovic, T. 49
Vidailhet, P. 48
Videbech, P. 41
Vieta, E. ..... 22, 29, 31, 46, ... 56, 58, 70
Vigo, C. 66
Viher, P. 68
Viikki, M. 31

List of Chairpersons, Authors and Co-Authors

Viktorova, L. 45
Vilaverde, D. 66
Villagran Moreno, J. M. ..... 31, 56, ... 66
Vinberg, M. 34
Vire, B. 51
Viswanath, B. 30, 44
Viviani, R. 52
Vogt, J. 36
Voineskos, A. 38
von Diemen, L. 22
von Gunten, A. 51, 67
Voon, V. 27
Voulgari, P. 37
Vrijens, B. 54
Vuilleumier, P. 43
Vyas, N. S. 54, 62
Vythylingum, B. 44

W

Wachtel, L. 47
Waddington, J. 27, 35
Wade, B. 44
Wadsak, W. 41
Wadsworth, G. 49
Wahiba, D. 57
Wahlstedt, K. 43, 48
Walder, K. 23, 24, 44
Wallace, C. 34
Walsh, D. 23
Walter, H. 55
Walter, M. 44
Walther, A. 32
Walther, S. 39, 43, 45, 61, 68
Wang, H.-N. 23
Wang, L.-J. 44
Wang, S.-M. 45, 66
Wang, X.-X. 23
Warhaftig, G. 57
Warrier, E. M. 39, 41
Watmuff, B. 61
Weber, B. 43
Webhofer, C. 41
Wedekind, D. 42
Wedervang-Resell, K. 42
Wegener, G. ..... 22, 25, 39, ... 51, 64, 66
Weickert, C. S. 37, 63
Weickert, T. 37
Weidenauer, A. 34
Weiller, E. 45
Weiner, I. 39
Weinland, C. 32
Weinsheimer, S. 48
Weinstein, A. 46, 50
Weiser, M. 64
Weiss, C. 45
Weissmann, D. 51
Wellsted, D. 55
Werge, T. 48, 61, 67
Werneke, U. 59
Wesolowski, J. 71
Westrin, Å. 57
Whitfield-Gabrieli, S. 43
Wichniak, A. 55, 70
Wierzyk, M. 41
Wiest, R. 43, 68
Wigg, K. 41
Wikinski, S. 42
Willeit, M. 34
Wimberley, T. 42
Windischberger, C. 37
Windstetter, T. F. 48
Wisniewski, J. 54
Wójcikowski, J. 65
Woletz, M. 37
Wolf, H. 71
Wolf, R. C. 63
Wong, S. 33
Wright, M. 61
Wu, F. 25, 66, 67, 69
Wu, Y.-T. 48, 51
Wuethrich, F. 43
Wydra, K. 61

X

Xu, Y. 62

Y

Yabuki, Y. 66
Yadid, G. 57
Yadin, E. 71
Yalcin, I. 22
Yamashita, Y. 67
Yamazaki, K. 68
Yanagimoto, H. 67
Yang, C.-C. 69
Yang, C.-H. 69
Yang, J.-C. 58
Yang, Y. K. 34
Yao, J. 42
Yasuyama, T. 45, 68
Yatham, L. 28, 43, 44, 46
Yeum, T.-S. 57
Yolken, R. 61
Yoon, H.-K. 45
Yoon, J. 70
Yoon, J.-S. 66, 68
Yoo, T.-Y. 68
Yoshiike, T. 48, 55, 67
Yoshino, Y. 68
Young, A. 26, 52, 65
Youn, T. 56
Yu, S.-T. 58

Z

Zai, C. 62
Zai, G. 41
Zainal, N. Z. 34
Zakharyan, R. 54, 68
Zannas, A. 64
Zapico Merayo, Y. 61
Zarate, C. 39
Zastrozhin, M. 66
Zaytseva, Y. 43, 68
Zerria, O. 60
Zetterberg, H. 24, 26
Zhang, D. 41
Zhang, Z.-J. 23
Zhu, C. 60
Zifman, N. 57
Zilles, D. 42
Zimmermann, W.-H. 37
Zipursky, R. 61
Zoga, M. 42, 54
Zohar, J. 34
Zugman, A. 42

ADVERT

ISSPD XV

International Society for the Study of Personality Disorders

XV. ISSPD Congress

Personality disorder, functioning and health

September 25 – 28, 2017 | Heidelberg, Germany

SAVE THE DATE

WELCOME TO VANCOUVER

WFSBP Congress 2019

14th World Congress of Biological Psychiatry

2 – 6 June 2019 | Vancouver, Canada

Vancouver Convention Centre East

www.wfsbp-congress.org

Hosted by the Canadian Network for Mood and Anxiety Treatments (CANMAT)

Latuda® ▼ (lurasidone)
PRESCRIBING INFORMATION-SCHIZOPHRENIA FILM-COATED TABLETS
Please refer to the full Summary of Product Characteristics (SPC) before prescribing, particularly in relation to adverse reactions, precautions and contraindications. **Presentations:** Latuda film-coated tablets, containing lurasidone hydrochloride equivalent to 18.6mg, 37.2mg and 74.5mg lurasidone. **Indication:** Latuda is indicated for the treatment of schizophrenia in adults (≥18 years). **Dosage and Administration:** For oral administration. Adults: Recommended starting dose: 37mg once daily with a meal. No initial dose titration is required. Effective dose range: 37 to 148mg once daily. Dose increase should be based on physician judgement and observed clinical response. Maximum dose: 148mg per day. Elderly (≥65 years): Caution when treating with higher doses. Children and adolescents (<18 years): Not recommended, safety and efficacy not established. Dose adjustments are required in moderate and severe hepatic and renal impairment, see SPC for further details. **Contraindications:** Hypersensitivity to the active substance or any excipients. Concomitant administration of strong CYP3A4 inhibitors and inducers. **Warnings and Precautions:** Clinical improvement may take a few days to some weeks; closely monitor patient during this period. Use with caution in elderly patients with dementia who have risk factors for stroke. Not studied in elderly patients with dementia. Discontinue if patient develops signs or symptoms of neuroleptic malignant syndrome. Consider discontinuation if signs of tardive dyskinesia appear. May exacerbate underlying parkinsonism symptoms. Risk of extrapyramidal symptoms. Caution and clinical monitoring is recommended in patients with a history of seizures or conditions which potentially reduce seizure threshold, cardiovascular disorders, orthostatic hypotension, diabetes or risk factors for diabetes and weight gain. May elevate prolactin levels. All risk factors for venous thromboembolism (VTE) should be identified before and during treatment and preventative measures taken. Caution in patients with a family history of QT prolongation, hypokalaemia and concomitant medication known to prolong the QT interval. Closely supervise high risk patients for risk of suicide. Avoid grapefruit juice. **Pregnancy and lactation:** Do not use during pregnancy unless potential benefit clearly outweighs potential risk to the foetus. Breast feeding should be considered only if the potential benefit of treatment justifies the potential risk to the child. **Interactions:** Caution is advised when combining with alcohol or CNS active medications, and medicines known to cause QT prolongation; P-gp and BCRP inhibitors may increase exposure to lurasidone, lurasidone is an inhibitor of P-gp and BCRP, see SPC for details. Dose adjustment is recommended in combination with CYP3A4 inhibitors and inducers, see SPC for details. Monitoring recommended when lurasidone and CYP3A4 substrates known to have a narrow therapeutic index are coadministered. **Undesirable effects:** In clinical trials, the following adverse drug reactions were reported: very common (≥10%): akathisia, somnolence; common (≥1% to <10%): weight increased, insomnia, agitation, anxiety, restlessness, parkinsonism, dizziness, dystonia, dyskinesia, nausea, vomiting, dyspepsia, salivary hypersecretion, dry mouth, upper abdominal pain, stomach discomfort, musculoskeletal stiffness, blood creatinine phosphokinase increase, serum creatinine increase, fatigue; uncommon (≥ 0.1% to <1%): decreased appetite, blood glucose increased, catatonia, tardive dyskinesia, tachycardia, hypertension, hypotension, alanine aminotransferase increase, blood prolactin increased; rare (≥0.01% to <0.1%): eosinophilia, rhabdomyolysis, neuroleptic malignant syndrome (NMS). This is not a complete list of adverse reactions. Prescribers should consult the SPC in relation to all adverse reactions. **Special precautions for storage:** Store in the original package in order to protect from light. **Special precautions for disposal and other handling:** Any unused medicinal product or waste material should be disposed of in accordance with local requirements. **Legal classification:** Prescription Only Medicine (POM). **Package Quantities and Basic Costs:** Country specific. **Marketing Authorisation Holder:** Sunovion Pharmaceuticals Europe Ltd, Southside, 97 – 105 Victoria Street, London, SW1E 6QT. Latuda is a registered trade mark. **Marketing Authorisation Number(s):** EU/1/14/913/001-021. **Date of Preparation:** February 2016 (MI-LAT-000766).

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions **Adverse reactions should be reported to the Competent Authority in your country. Adverse reactions should also be reported to Sunovion Pharmaceuticals Europe Ltd. on +44207 821 2899**

References: 1. Meltzer HY *et al. Am J Psychiatry* 2011;168:957-967. 2. Loebel A *et al. Schiz Res* 2013;145(1-3):101-109. 3. LATUDA Summary of Product Characteristics. 4. Stahl SM *et al. J Clin Psychiatry* 2013:74;507-51.

sunovion

Job code: LAT553-17. **Date of preparation:** April 2017

and LATUDA are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd.
© 2016 Sunovion Pharmaceuticals Europe Ltd. All rights reserved. 6/16.

13:15–14:45, Tuesday 20 June 2017
Auditorium 12, Bella Center Copenhagen,
Copenhagen, Denmark

SATELLITE SYMPOSIUM

Orchestrating the differential diagnosis of organic psychosis: shining a spotlight on NP-C

Chaired by Hans-Hermann Klünemann
(Regensburg, Germany)

Satellite Symposium
at the 13th World Congress of Biological Psychiatry
Supported by an educational grant
provided by Actelion Pharmaceuticals Ltd

Plan of Bella Center Copenhagen



17007165_WFSBP_2017_ADVERT_06.2017

ACTELION